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Thesis Abstract 
Introduction 
The incidence and nature of toxicity related to tuberculosis (TB) treatment, who is most 
commonly affected and what is the true impact on treatment is predominantly 
characterised through retrospective or observational studies; with varying definitions 
for toxicity and estimates of the incidence or patient groups at highest risk. REMoxTB 
was a randomised, controlled, phase III pulmonary TB clinical trial with stringent 
collection of efficacy and safety data. 
Methods 
A total of 639 patients received standard TB therapy as a control arm for the trial, with 
655 patients and 636 patients allocated to the “isoniazid” and “ethambutol” arms. 
Related grade 3 and 4 adverse events were used to investigate the general toxicity 
observed during treatment and the liver biochemical tests collected were described in 
detail separately. Regression techniques investigated the association between patient 
demographics and toxicity. Lastly, the incidence of adverse events and the longitudinal 
pattern of clinical and laboratory data was described for HIV positive patients. 
Results 
Approximately 10% of patients experienced clinically significant toxicity attributed to 
their drug therapy. Older patients, female patients, those of Asian ethnicity, and HIV 
positive patients were at the greatest risk for toxicity. Significant drug toxicity most 
commonly occurred in the first two months of treatment. Liver dysfunction was the 
most frequent clinically significant toxicity. Patients who experienced one or more 
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episode of clinically significant toxicity were at higher risk of failing treatment. Those 
receiving the experimental moxifloxacin-containing arms experienced lower rates of 
clinically significant toxicity. 
Conclusions 
This work identifies patient groups who are at higher risk of toxicity, when this toxicity 
is likely to occur, and what form it most commonly takes: informing the allocation of 
often limited resources to appropriately monitor those patients who are at greatest risk 
during treatment. Additionally, by demonstrating a higher risk of failing treatment 
associated with drug toxicity, this work also provides further justification for changes 
at the policy level. Finally, the experimental arms could have a place in the 
management of patients at high risk of toxicity but this must be viewed in light of 
uncertainty surrounding the optimal duration of therapy.  
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Impact Statement 
Standard TB therapy, while effective for the majority of patients, is acknowledged as 
potentially toxic and patients must know when to seek medical attention. The analyses 
presented here provide reassurance that many side effects from standard TB therapy 
are not life-threatening; however, there were several cases of extremely high liver 
enzyme elevations with associated symptoms of gastrointestinal upset and abdominal 
pain. It is critical that patients are made aware of the symptoms of hepatotoxicity and 
the importance of prompt medical intervention.  
The information in this thesis will assist clinicians in making informed decisions 
regarding the monitoring of at-risk individuals. The identification of increased risk of 
toxicity among female patients, those with HIV infection, and Asian patients allows TB 
clinicians to target patients at greater risk of a complicated treatment course and take 
appropriate steps (for example, more frequent clinical reviews) to ensure an adequate 
package of care is in place. 
The data presented here demonstrate that the majority of patients with liver enzyme 
elevations of greater than 3x upper limit of normal (ULN), but less than 5xULN, 
completed standard TB therapy and were not withdrawn from the trial. This would 
suggest that a practice of close monitoring but continuing treatment when liver enzyme 
levels are >3xULN but <5xULN would be reasonable in the absence of concerning 
features.  
Episodes of clinically significant toxicity were associated with an increase in the odds 
of a patient failing to achieve a cure. Patients who fail to be cured of their TB can either 
remain infectious or return to an infectious state, are at a higher risk of developing 
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drug-resistant infections, and also are unlikely to remain fit to continue working. The 
first two risks are of public health concern as they will directly work against any efforts 
to curb or eradicate TB, and the third is a well-recognised economic issue associated 
with TB disease. This thesis would support the increased availability of liver function 
testing for all TB programs and regular testing to ensure significant elevations are 
detected early. The incidence of significant liver enzyme elevations in the intensive 
phase will help guide the timing for when these resources should be made available. 
The experimental treatment arms had fewer patients reporting clinically significant 
adverse events compared to the standard TB therapy arm. The main implication of 
this finding would be the potential for the moxifloxacin-containing regimens to be 
adopted as treatment options for patients who are at elevated risk of experiencing 
adverse effects from treatment (for example, those with advanced liver disease, other 
significant pathologies, or an intolerance of isoniazid). However, any possible benefits 
of using these less toxic regimens must be carefully balanced against their failure to 
achieve formal non-inferiority compared to standard TB therapy, and the uncertain 
optimal duration of these experimental arms.
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Chapter One: Introduction 
1 Historical Perspective on Mycobacterium 
tuberculosis 
Pulmonary tuberculosis has claimed the lives of countless individuals since the genus 
Mycobacterium first originated over 150 million years ago (Hayman, 1984). The 
destructive lung disease caused by the infection has gone by many names throughout 
history (White Plague, phthisis, consumption) and in the 18th and 19th centuries it was 
crowned “Captain Among these Men of Death” across Europe and North America 
(Daniel, 2006). Celebrity has afforded no special privileges and tuberculosis has 
claimed the lives of many famous individuals, who in many cases continued to work 
under the burden of the infection that would ultimately kill them, including Emily Brontё, 
John Keats, Frédéric Chopin, and George Orwell. 
On March 24 1882, Herman Heinrich Robert Koch stood at the podium in front of the 
Berlin Physiological Society and delivered his famous presentation Die Aetiologie der 
Tuberculose (Koch, 1932; Daniel, 2005). This was the first time that Mycobacterium 
tuberculosis had been identified as the infectious agent responsible for causing 
tuberculosis and the death of millions across the world. The discovery of the organism 
responsible did not lead directly to an effective cure, but sputum smear microscopy 
(followed by fluorescence microscopy) was then introduced as a test for the diagnosis 
of pulmonary tuberculosis (Hagemann, 1938; Steingart et al., 2006).  
The incidence of tuberculosis began to decline in the middle of the 19th century across 
Europe and North America, despite the lack of a pharmacologic cure for the disease 
(see Figure 1-1). Social conditions began to improve during this period, with the 
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introduction of basic hygiene measures such as sanitary disposal of human waste, 
and this had a significant impact on the transmission of all infectious disease including 
tuberculosis (McKeown and Record, 1962). There was increased access to safe and 
nutritious food sources from the beginning of the 19th century due to improvements in 
the ability to farm, transport and store food. An impaired nutritional status is linked to 
a reduction in the effectiveness of the immune system and an increased risk of active 
tuberculosis in endemic areas; this improvement in nutrition is believed to have been 
another factor in the reducing incidence of the disease (McKeown and Record, 1962; 
Wilson, 1990). Another factor that contributed to the reduction in the burden of TB 
disease in the UK was the improvement in the quality of city housing. An effort was 
made at the level of government to reduce overcrowding in public housing from the 
late 19th century, and this is credited with helping reduce the burden of disease by 
providing better ventilated and more hygienic living spaces for people from lower 
socioeconomic groups, among whom TB wasmost prevalent (McKeown and Record, 
1962; Wilson, 1990). Finally, in the early 20th century it became routine practice to 
segregate patients suffering from active tuberculosis in sanatoria and this later 
intervention will likely have contributed further to the decline in the number of new 
cases by curbing the number of patients actively spreading infection (Vynnycky and 
Fine, 1997). 
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Figure 1-1. Notification rate for tuberculosis affecting any site from 1913 to 2015 in England and Wales. Graph 
obtained from Public Health England Tuberculosis: annual notification and mortality data (1913 onwards) 
[https://www.gov.uk/government/publications/tuberculosis-tb-annual-notifications-1913-onwards] 
 
While the medical community was encouraged by the reduced number of tuberculosis 
cases seen across Europe and North America the fall began from a high incidence 
and pulmonary tuberculosis remained a major public health issue in the first half of the 
20th century (Vynnycky and Fine, 1999). Additionally, while significant progress was 
being made in settings with adequate resources, progress was much slower in other 
parts of the world. By the middle of the 20th century it was becoming clear that 
tuberculosis incidence figures and outcomes were diverging at global economic 
boundaries: the tuberculosis epidemic continued largely unabated in low income 
settings where the available healthcare resources fell far short of what was required 
(Keshavjee and Farmer, 2012). 
2 Tuberculosis Chemotherapy 
The discovery of para-aminosalicylic acid (PAS) in 1943 and the isolation of 
streptomycin a year later brings the narrative into the current era of tuberculosis 
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chemotherapy (Medical Research Council, 1948; Marshall et al., 1950). The next three 
decades would see the development of an effective but lengthy treatment regimen for 
pulmonary tuberculosis (Fox, Ellard and Mitchison, 1999). However, at the time of 
writing it is the most common cause of death from an infectious disease world-wide 
(WHO, 2017) and the End TB Strategy proposed by the World Health Organisation to 
curb the epidemic has continued to fall short of its stated goals (Floyd et al., 2018). 
The road that led to the current standard tuberculosis therapy began with what is 
considered to be the world’s first randomised controlled trial in 1947 (Medical 
Research Council, 1948). The British Medical Research Council (BMRC) recruited 107 
patients with confirmed pulmonary tuberculosis and randomly allocated them to 
receive either regular streptomycin injections or bedrest alone (see Figure 2-1). There 
were only 4 deaths in the group receiving streptomycin and 14 deaths in the control 
group, which represented an unprecedented success in the treatment of tuberculosis. 
However, the majority of the patients treated with streptomycin relapsed (Crofton and 
Mitchison, 1948) and by 1950 it was apparent that single-agent therapy led to the 
development of bacterial resistance, even in patients who were apparently cured at 
the time (Fox, Sutherland and Daniels, 1954). The next two decades were spent in a 
flurry of activity as more drugs with activity against tuberculosis were brought into 
widespread use (isoniazid, rifampicin, and pyrazinamide in particular), the first 
standardised 18 to 24 month regimen for treating tuberculosis was developed, 
management of the disease was brought out of hospital and into the community, and 
treatment was eventually shortened from 18 to 6 months (Fox, Ellard and Mitchison, 
1999; Mitchison and Davies, 2012). 
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Figure 2-1. Chest X-rays for the same patient prior to treatment and after treatment with streptomycin in the 
first British Medical Research Council trial to investigate the effects of treatment in 1948. [British Medical 
Research Council. Streptomycin Treatment of Pulmonary Tuberculosis. Br Med J 1948;30:769-782]  
Following the success in using a combination of rifampicin and pyrazinamide to 
shorten treatment down to 6 months, attempts were made to shorten treatment even 
further. A series of trials in Eastern and Central Africa, Hong Kong, Singapore, Madras, 
and Algeria demonstrated that reducing treatment to less than 6 months resulted in 
an unacceptable rise in the number of relapsed infections (Fox, Ellard and Mitchison, 
1999). These trials also used different combinations of drugs over the course of the 6 
months to identify the most effective therapy, and this was in part driven by a desire 
to reduce the cost of treatment but also to reduce the risk of drug-related toxicity. The 
sterilising activity of rifampicin was identified as persisting through the full 6 months of 
treatment and was therefore essential to treating tuberculosis with a “short course” of 
treatment (East African/British Medical Research Council, 1973). Conversely, 
pyrazinamide’s activity seemed to be confined to the first two months of therapy (East 
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African/British Medical Research Councils Study, 1981; East and Central 
African/British Medical Research Councils, 1986; Fox, Ellard and Mitchison, 1999). 
The increasing availability and use of tuberculosis chemotherapy coincided with the 
ongoing decrease in the number of notified cases of tuberculosis from approximately 
20,000 new cases in 1955 to approximately 5,000 cases in 2015 across England and 
Wales (Figure 1-1). Untreated tuberculosis carries an approximately 70% chance of 
death (Tiemersma et al., 2011) and, while much can (and should) be made of the 
importance of social reform in the eradication of tuberculosis, active treatment has an 
impact at both the individual patient level and from the public health perspective. The 
earliest treatment regimens (although lengthy) did contribute to the fall in case fatality 
from between approximately 40-70% in untreated disease to less than 10% among 
treated patients in both resource-rich and resource poor settings (Hermans, 
Horsburgh and Wood, 2015) (Figure 2-2).  
Current tuberculosis chemotherapy’s public health impact results from over 90% of 
the mycobacteria dying within two weeks of starting treatment (Donald and Diacon, 
2008) as this reduces the ability of the infection to spread through aerosol transmission 
from the host (Brooks, Lassiter and Young, 1973; Fennelly et al., 2004). Although it 
should be noted that there is some challenge to a dogmatic approach to this time 
period, as some patients will become less infectious earlier and later than two weeks 
(Escombe et al., 2007; Fennelly, 2007; Churchyard et al., 2017). The World Health 
Organisation has endorsed the Directly Observed Treatment, Short-course (DOTS) 
approach to administering treatment as part of tuberculosis control strategies since 
the early 1990s (WHO 2011); however, there is evidence that suggests there is no 
significant difference between DOTS and self-administered treatment in terms of 
treatment outcomes (Karumbi & Garner 2015; Pasipanodya & Gumbo 2013). 
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Figure 2-2. Line graphs illustrating the reported TB mortality (Graph A) and case fatality (Graph B) rates over time 
in London, New York and Cape Town from 1910 to 2012. Rates from 1913 to 1965 are for London County Council 
(current Inner London) and thereafter refer to data relating to the Greater London Area (Inner and Outer London). 
[Hermans et al. A Century of Tuberculosis Epidemiology in the Northern and Southern Hemisphere: The 
Differential Impact of Control Interventions.PLoS ONE 2015;10(8):e0135179] 
Standard tuberculosis therapy for drug-sensitive disease now consists of isoniazid (H), 
rifampicin (R), pyrazinamide (Z), and ethambutol (E) for two months followed by 
isoniazid and rifampicin for a further four months (2HRZE/4HR). This regimen has a 
relapse-free cure rate of over 90% in clinical trial conditions (Fox, Ellard and Mitchison, 
1999) and it has been used in an essentially unchanged format for over 25 years. 
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From the early 1980s the prevailing belief was that all the necessary tools were 
available to end the epidemic, and it would not be long before tuberculosis would 
obligingly melt away. 
3 Tuberculosis and the Human Immunodeficiency 
Virus 
It is thought that sometime in the 1930s the Simian Immunodeficiency Virus (SIV) was 
transmitted from its ape hosts to bushmeat hunters in the Democratic Republic of 
Congo (Sharp and Hahn, 2011). This initial transmission would go on to become 
Human Immunodeficiency Virus 1 (HIV-1), and is the most widespread form of the 
virus found today (Maartens, Celum and Lewin, 2014). The infection is most commonly 
spread between humans through sexual contact, and over the first several decades of 
human-to-human transmission it appears to have been relatively contained 
(Hutchinson, 2001). However, genetic analysis of HIV suggests that the virus first 
arrived in the United States of America in the late 1960s and over the course of the 
1970s a global pandemic silently unfolded (Robbins et al., 2003).  
The early 1980s saw a high prevalence of Kaposi’s sarcoma and pneumonia detected 
among men who have sex with men in New York and California (Altman, 1981; Anon, 
1981). In 1982, the Centre for Disease Control in Atlanta established the term 
“Acquired Immune Deficiency Syndrome” (AIDS) and an infectious aetiology was 
assumed despite no organisms having been identified (Merson et al., 2008). Other 
groups at risk were identified, including injecting drug users and haemophiliacs 
(Altman, 1981; Anon, 1982; Merson et al., 2008). By the end of 1982, AIDS had been 
detected on five continents and the scientific community became aware that the so-
called “slim disease” seen on the African continent was, in fact, AIDS as well (Merson 
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et al., 2008). At the close of the decade, it was estimated that up to 10 million people 
could be infected with HIV across the globe and the World Health Organization 
launched its Global Program on AIDS to tackle the pandemic (Mann, 1987). Over the 
next 20 years, efforts toward controlling the HIV epidemic led to the discovery of the 
virus responsible, and the development of effective treatment that can suppress the 
infection and reduce transmission of the virus (Barré-Sinoussi, Ross and Delfraissy, 
2013).  
HIV is one of the main reasons behind our failure to control the global tuberculosis 
epidemic. The virus acts to suppress the host immune system, and therefore leaves 
the patient vulnerable to infection (Deeks et al., 2015). This particularly applies to 
tuberculosis as HIV impairs the activity of several immune cells that are essential for 
the containment of tuberculosis in the lung parenchyma (Bell and Noursadeghi, 2017). 
Groups who are at higher risk of contracting HIV include men who have sex with men, 
sex workers, prisoners, and injecting drug users (Maartens, Celum and Lewin, 2014). 
The HIV epidemic was associated with an increase in the number of cases of both 
pulmonary and extra-pulmonary tuberculosis across Europe and North America in the 
1980s and 1990s, particularly among these higher-risk groups, as at this time there 
was no effective treatment available to suppress HIV (Merson et al., 2008).  
In low- and middle-income countries efforts to control tuberculosis had met with limited 
success before the HIV pandemic, and now they were faced with an even greater 
challenge with the overlap of the two infections (Chaisson and Martinson, 2008). As a 
result of both social and political factors the highest prevalence of people living with 
HIV (PLHIV) can be found in Africa (UNAIDS, 2017) (reported as an estimated 25.6 
million individuals in 2016, see Figure 3-1). In particular, the eastern and southern 
regions of the continent are home to a very large number of PLHIV (UNAIDS, 2017) 
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(estimated at 19.4 million individuals in 2016). This distribution of HIV is reflected in 
the global tuberculosis figures: the WHO Africa region contains the highest number of 
co-infected (TB-HIV) patients and out of approximately 500,000 incident tuberculosis 
cases in South Africa over 50% are also HIV-positive (WHO, 2017). It is estimated that 
10% of the 10.4 million incident tuberculosis cases in 2016 were co-infected with HIV, 
and tuberculosis-related deaths accounted for approximately 340,000 of the 1 million 
deaths among all HIV-infected patients (UNAIDS, 2017; WHO, 2017). Despite a world-
wide decrease in case fatality from HIV-associated tuberculosis (largely attributable to 
the roll-out of ART and earlier identification and treatment of tuberculosis) many PLHIV 
in low- and middle-income countries die from undiagnosed TB (Cohen et al., 2010). 
While anti-retroviral therapy (ART) does lower the risk of developing tuberculosis in 
PLHIV, and there is an association with an overall reduction in the risk of treatment 
failure in retrospective and observational work (Manosuthi et al., 2006; 
Sungkanuparph et al., 2006; Zhou et al., 2009), despite significant gains in the roll-out 
of ART globally there are still many areas where treatment coverage is below 50% of 
PLHIV (UNAIDS, 2017). 
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4 The Current Global Distribution of Tuberculosis 
Approximately 4000 people die every day from active tuberculosis, and there was an 
estimated total of 1.4 million deaths in 2016 across the world (WHO, 2017). There 
were an estimated 10.4 million new cases of active tuberculosis in 2016, an increase 
from the estimated 8.6 million new cases in 2012 and the highest number of people 
with the disease at any point in history (WHO, 2017). However, it must be remembered 
that many cases of tuberculosis still go undiagnosed, untreated, or unreported and 
these figures may be significantly under-estimating the true burden of the disease: the 
upper limit to the estimated incident cases provided by the World Health Organisation 
(WHO) for 2016 was 12.2 million (WHO, 2017). Central and southern Africa were 
reported as having some of the highest incidence rates per 100,000 of the population 
in 2016 (Figure 4-1). 
Figure 3-1. The estimated number of people (all ages) living with HIV in 2016 according to World Health 
Organisation region. [Image sourced from the World Health Organisation website, 
http://www.who.int/gho/hiv/epidemic_status/cases_all/en/] 
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Figure 4-1. Global estimated TB incidence rates for 2016 sourced from the WHO Global Tuberculosis Report 
2017. [WHO. Global Tuberculosis Report. Geneva 2017] 
India, Indonesia, China, the Philippines, and Pakistan are the five countries cited as 
having the highest burden of disease. In 2016, they accounted for an estimated 56% 
of the incident cases across the world, and the WHO African region was thought to 
represent a further 25% of the new presentations (WHO, 2017). India alone was 
estimated to have had 2,790,000 new cases of tuberculosis in 2016 (WHO, 2017) and, 
as is the case for the many of the other countries, this information was calculated using 
case notification data. It should be noted that India’s large population of over 1 billion 
people is a significant factor in its contribution to the number of new tuberculosis cases 
worldwide, as can be seen by comparing the incidence rate per 100,000 of the 
population in Figure 4-1 and the total number of incident cases from 2016 in Figure 
4-2. 
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Figure 4-2. Globally estimated TB incidence in 2016, for countries with at least 100 000 incident cases, 
sourced from the WHO Global Tuberculosis Report 2017. [WHO. Global Tuberculosis Report. Geneva 2017] 
The emergence of drug-resistant tuberculosis (DR-TB) has been identified as a major 
factor continuing to drive the ongoing global epidemic, alongside coinfection with HIV 
(Pawlowski et al., 2012; WHO, 2012; Eldholm et al., 2016; Dheda et al., 2017; Floyd 
et al., 2018). There were over 600,000 new cases of tuberculosis resistant to rifampicin 
in 2016, and this number includes a reported 19% of previously-treated cases 
presenting in 2016 (WHO, 2017). China, India, and the Russian Federation together 
account for 47% of the DR-TB cases world-wide (WHO, 2017). A failure to sufficiently 
address these drivers in the tuberculosis epidemic will in turn lead to a failure to end 
the epidemic in anything approaching the proposed timescale of the World Health 
Organisation’s End TB strategy (WHO, 2017). 
Tuberculosis has always been the hallmark disease of vulnerable and marginalised 
populations, and remains so to this day. Migrant populations, homeless individuals, 
itinerant people, those in lower socio-economic groups and injecting drug users are all 
recognised as at-risk groups. This increased risk is due to one or more factors such 
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as poor nutrition, overcrowding, a lack of adequate sanitation, social deprivation, risk-
taking behaviour, stress, smoking, and poor social capital (Aerts et al., 2006; Fleming 
et al., 2006; WHO, 2017; Aldridge et al., 2018). Sadly, the social circumstances that 
characterise most of these groups can make the implementation of public health 
measures and delivery of tuberculosis treatment challenging (Pablos-Méndez et al., 
1997; Storla, Yimer and Bjune, 2008). These social circumstances are compounded 
by the length of treatment and toxicity associated with standard tuberculosis therapy. 
5 Toxicity and Adverse Events during Standard TB 
Therapy 
Unwanted side-effects of the medication that have a negative physiological impact on 
the patient, hereafter referred to as “toxicity”, are a well-recognised complication of 
standard tuberculosis therapy. Hepatic toxicity, peripheral and optic neuropathies, and 
gastrointestinal disturbance are just some of the acknowledged side-effects 
associated with the medication used to treat drug-sensitive pulmonary TB (Forget and 
Menzies, 2006; Lorent et al., 2011; Zhang et al., 2015; Sarkar, Ganguly and Sunwoo, 
2016). Toxicity during therapy is associated with poor adherence, treatment 
interruptions, and a higher risk of treatment failure (Iseman, 2002; Saukkonen et al., 
2006; WHO, 2017); the fall in cure rates from over 90% in trials to approximately 80% 
in real-world settings (WHO, 2017) is at least partly related to toxicity from standard 
tuberculosis therapy. Rapid identification of adverse reactions to medications has 
been shown to improve outcomes (Gholami et al., 2006; Marra et al., 2007; Lehloenya 
and Dheda, 2012; Michail, 2013; Naik et al., 2015) as the offending agent can be 
withheld and appropriate treatment can be implemented. Therefore, it is crucial that 
tuberculosis services are set up to identify patient groups at the highest risk of a 
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complicated course on treatment and are also aware of the most common patterns of 
toxicity to optimise the management of their patients. 
The majority of the published work on clinical implications of toxicity relating to 
standard tuberculosis therapy is retrospective or observational in nature and involves 
small numbers of patients, and as such suffers from a number of limitations. As is the 
case with retrospective and observational studies, there is a risk of both observed and 
unknown bias and confounding affecting the results through the sampling of the study 
population. There are some studies available, predominantly relating to hepatotoxicity 
(Kumar et al., 2010; Shang et al., 2011; Shu et al., 2013; Yimer et al., 2014), that have 
large numbers of patients involved in the analysis and this may attenuate the risk of 
confounding (although this could actually be accentuated through selection bias), but 
they still rely on passive detection of significant toxicity or a review of patient notes.  
Conclusions drawn from the literature are further impaired by the varying definitions 
employed for “toxicity”; for example, the quoted rates of hepatotoxicity attributed to 
standard TB therapy range from 5-33% (Thompson et al., 1995; Tost et al., 2005; 
Saukkonen et al., 2006; Tostmann et al., 2008; Kumar et al., 2010) in published 
reports. A large part of the explanation for this variation lies in some studies including 
only cases with associated clinical symptoms, varying laboratory thresholds to define 
“hepatotoxicity”, or different periods of observation for patients. The tuberculosis 
community has therefore continued to operate in quite a reactive manner to treatment 
complications, aware of common toxicities but with no clearly defined guidance on 
timing, risk factors, clinical course, or what the best evidence-based approach is to the 
management of side-effects. 
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5.1 Toxicity Associated with Drugs used for Tuberculosis 
Treatment 
The drugs used in the treatment of active tuberculosis are never given in isolation, due 
to the risk of resistance, and therefore it is not easy to make definitive statements 
about their individual side effects. Additionally, there could be differences in the drug 
dynamics in healthy volunteers compared to patients with active TB disease. Isoniazid 
and rifampicin are used in isolation as treatment for latent tuberculosis infection (Akolo 
et al., 2010; Sharma et al., 2014), and moxifloxacin is used alone in the treatment of 
other bacterial infections (Grossman et al., 2014), and this has allowed for the 
collection of some clinical evidence for individual drug toxicity. Data relating to the 
drugs in other diseases, basic science work looking at in vitro activity of the drugs, 
early clinical trials and observational work can be used in combination to gain some 
understanding of the expected toxicity associated with each medication and the 
mechanisms responsible. 
5.1.1 Isoniazid Toxicity 
Isoniazid is a prodrug with an active metabolite (nicotinoyl-NAD) that acts to inhibit 
mycolic acid synthesis, which is an essential component of the mycobacterial cell wall. 
The prodrug is metabolised by a catalase-peroxidase enzyme in M. tuberculosis called 
KatG, and the active metabolite eventually blocks the activity of the protein reductase 
InhA which finally leads to impaired activity of fatty acid synthase(Timmins and Deretic, 
2006). Isoniazid predominantly acts as a bactericidal agent against actively dividing 
mycobacteria, killing almost 90% of mycobacteria in a case of active tuberculosis 
within a matter of days (Donald and Diacon, 2008), but also exerts a bacteriostatic 
effect (as well as bacteriocidal) on dormant organisms (Heifets, Lindholm-Levy and 
Flory, 1991). 
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Hepatotoxicity is a well-recognised side effect of isoniazid use and the quoted rates 
range between approximately 0.1% to 20% (Nolan, Goldberg and Buskin, 1999; Grant 
et al., 2010; Al-Darraji, Kamarulzaman and Altice, 2012; Hassan et al., 2015; Metushi, 
Uetrecht and Phillips, 2016). In the human host, isoniazid is metabolised in the liver 
through acetylation by N-acetyl transferase 2 (NAT2) to produce acetylisoniazid 
(Cordes et al., 2016). Figure 5-1 summarises the metabolic pathway for isoniazid in 
the liver. Polymorphisms of NAT2 are used to categorise patients as either slow- or 
fast-acetylators. The former produces hydrazine predominantly when greater doses of 
isoniazid are administered, while the latter will produce higher levels of 
acetylhydrazine, and these are both toxic metabolites that damage liver tissue through 
oxidative stress (Perwitasari et al., 2015; Metushi, Uetrecht and Phillips, 2016; P. 
Wang et al., 2016). Therefore, the cause of isoniazid-induced hepatotoxicity is thought 
to be slightly different depending on the patient’s acetylator status, although ultimately 
resultant from oxidative stress effects on hepatocytes due to hydrazine generation.  
As can also be seen in Figure 7, CYP2E1 also plays an important role in the generation 
of oxidised hepatotoxic hydrazines. CYP2E1 polymorphisms have been shown to 
influence the risk of tuberculosis treatment-associated liver injury, both in isolation and 
in conjunction with NAT2 genotypes (Vuilleumier et al., 2006; Sheng et al., 2014; 
Singla et al., 2014). In light of this, the optimal dosing strategy is still unclear, whereby 
antimicrobial activity is maximised with minimal risk of hepatotoxic effects based on 
the presence or absence of individual genetic polymorphisms (Huang et al., 2002; 
Azuma, Ohno and Kubota, 2013; Cordes et al., 2016; Toure et al., 2016). 
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Figure 5-1. Flow diagram illustrating hepatic metabolism of isoniazid. Isoniazid is metabolised to 
acetylhydrazine by one of two pathways regulated by the NAT2 enzyme, and “slow” or “fast” acetylators will 
predominantly accumulate the toxic metabolites hydrazine or acetylisoniazid, respectively. Acetylhydrazine is 
converted to the non-toxic diacetylhydrazine by NAT2 in the liver preferentially but it is also oxidised into 
hepatotoxic metabolites. Enzymes involved in the process are included in boxes above the arrows linking 
metabolites and the metabolic process is described in italics. NAT2= N-acetyl transferase 2; CYP2E1=  
Cytochrome P4502E1; GST= Glutathione S-transferase. Imaged reproduced from “Tuberculosis – Current 
Issues in Diagnosis and Management”, Chapter: Tuberculosis Pharmacogenetics: State of the Art, P109 
(Mahboub and Vats, In Tech – Open Science, 2013) 
Peripheral neuropathy affects between 2% and 10% of patients taking isoniazid on 
average(Kass and Shandera, 2010). It is mediated by isoniazid inhibiting the activation 
of pyridoxine to essential co-enzymes for protein metabolism and the production of 
some neurotransmitters. The risk of neuropathy is increased with HIV infection, 
alcohol abuse, diabetes, malnourishment, increasing age, and with concurrent use of 
other medications that antagonise the effects of vitamin B6 (e.g. hydralazine, 
cycloserine) (Desai and Agarwal, 2017). Isoniazid overdose is also associated with 
seizure activity (Kass and Shandera, 2010). 
There are other less common side effects of isoniazid. Rhabdomyolysis can result 
from a direct toxic effect of isoniazid metabolites on skeletal muscle or secondary to 
prolonged seizure activity (Blowey, Johnson and Verjee, 1995; Panganiban, 
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Makalinao and Cortes-Maraba, 2001). Agranulocytosis is a very rare and idiosyncratic 
drug reaction from isoniazid use, and the effect seems to reverse within days of 
stopping the drug (Claiborne and Dutt, 1985; Bidarimath et al., 2016). Isoniazid can 
also cause a pyridoxine-responsive sideroblastic anaemia (Morrow et al., 2006). In 
cases of isoniazid overdose there is infrequently a severe metabolic acidosis caused 
by a combination of increased lactic acid production during seizures, acidic 
metabolites of isoniazid, and a ketoacidosis from enhanced fatty acid oxidation 
(Brown, 1972; Hankins et al., 1987). Finally, there are scattered reports of pancreatitis, 
febrile reactions, and dermatitis associated with isoniazid use (Desai and Agarwal, 
2017). 
5.1.2 Rifampicin Toxicity 
Rifampicin is a bactericidal drug acting on actively dividing mycobacteria, but it also 
exerts a bactericidal effect on mycobacteria in a dormant state (Wehrli, 1983). The 
bactericidal effect of rifampicin is critical to treating pulmonary tuberculosis with six 
months of standard therapy (Grosset, 1978), and the resistance to rifampicin that is 
characteristic of multi-drug resistant tuberculosis is a large part of why that infection is 
so difficult to treat. Rifampicin acts on M. tuberculosis by inhibiting DNA-dependent 
RNA polymerase, interfering with the organism’s gene transcription and the synthesis 
of messenger RNA, and this eventually leads to cell death (Wehrli, 1983).  
Hepatitis presenting with a cholestatic picture on liver biochemical tests occurs in 
approximately 1% to 3% of patients being treated with rifampicin in isolation 
(Lardizabal et al., 2006; Menzies et al., 2008; Fountain et al., 2009; Ziakas and 
Mylonakis, 2009). An asymptomatic elevation in serum bilirubin without hepatic 
enzyme elevation is seen in approximately 5% of patients receiving rifampicin in 
isolation (Grosset and Leventis, 1983; Byrne et al., 2002). Over 80% of the ingested 
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drug is metabolised in the liver through the CYP450 enzymatic system, and the drug 
is excreted via the biliary tract (Acocella, 1983). The hepatic metabolism of rifampicin 
leads to an upregulation of the CYP450 enzymes in the liver, and this induction can 
lead to reduced concentrations of other drugs that are metabolised through the same 
pathway. Drugs that are especially affected are some anti-retroviral therapies, oral 
contraceptives, warfarin, and clarithromycin with a consequent reduction in the 
efficacy (Niemi et al., 2003). 
Rifampicin has a relatively favourable toxicity profile in the existing literature, and other 
side-effects are only infrequently reported. Immunological reactions causing blood 
dyscrasia, autoimmune thrombocytopenia, vasculitis, haemodynamic shock, and 
interstitial nephritis have been identified in less than 0.1% of patients taking rifampicin 
(Mary Aquinas et al., 1972; Girling, 1977; Grosset and Leventis, 1983; Jung et al., 
2007; Mori et al., 2011; Chiba et al., 2013). These immunological reactions, in 
particular interstitial nephritis, have been observed more frequently in patients taking 
rifampicin intermittently compared to those taking the drug on a daily basis (Grosset 
and Leventis, 1983).  Exanthema has been noted due to rifampicin use and generally 
resolves when the drug is withdrawn (Lehloenya and Dheda, 2012). Mild 
gastrointestinal upset can also occur, but this rarely leads to an interruption in therapy 
(Forget and Menzies, 2006). 
5.1.3 Pyrazinamide Toxicity 
Pyrazinamide is a nicotinic acid derivative first synthesised in 1936 and has been used 
as an anti-tuberculosis drug since as early as 1952 (Fox, Ellard and Mitchison, 1999). 
The drug is bactericidal and has a powerful sterilising effect in the treatment of 
tuberculosis infection (Grosset, 1978; Steele and Des Prez, 1988; Zhang and 
Mitchison, 2003). The drug is initially absorbed into the mycobacteria and then 
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subsequently converted to the active metabolite pyrazinoic acid by the enzyme 
pyrazinamidase (encoded by the pncA gene) (Momekov et al., 2014) and is also 
activated by human hepatic amidases (Laine et al., 1989). Pyrazinoic acid then 
diffuses out of the mycobacteria and, in the acidic conditions found in the granuloma, 
is converted to a conjugate acid which then diffuses back into the mycobacteria again 
and accumulates (see Figure 5-2). The precise mechanism by which the pyrazinoic 
acid exerts its bactericidal effect is unknown at the time of writing, and possibly 
involves inhibition of fatty acid synthase (Zhang and Mitchison, 2003; Momekov et al., 
2014).  
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Figure 5-2. Diagrammatic representation of pyrazinamide metabolism within M. tuberculosis. Pyrazinamide 
enters the mycobacteria through passive diffusion and is converted to pyrazinoic acid by pyrazinamidase. 
Pyrazinoic aid is then excreted from the cell via a weak efflux pump and converted to protonated pyrazinoic 
acid by hydrogen-donation from the acidic environment. This protonated pyrazinoic acid is reabsorbed into the 
mycobacteria, where it begins to accumulate due to the inefficiency of the efflux pump and causes cellular 
damage through one or more proposed mechanisms. PZA= Pyrazinamide; POA= Pyrazinoic acid; PZase= 
Pyrazinamidase; HPOA= Protonated POA. Image reproduced from Momekov G, Ferdinandov D, Voynikov Y 
et al. Pyrazinamide – Pharmaceutical, biochemical and pharmacological properties and reappraisal of its role 
in the chemotherapy of tuberculosis. Pharm 2014;61(4):38-67(Figure 2 in article).  
Liver toxicity is an established side effect of pyrazinamide use in tuberculosis 
treatment (Durand et al., 1995; Saukkonen et al., 2006; Chang et al., 2008; Shih et al., 
2013; Jeong et al., 2015). The drug is predominantly metabolised in the liver (Donald 
and McIlleron, 2009), and hepatotoxicity was observed in the early studies where 
patients were treated with pyrazinamide (Angel, Somner and Citron, 1979). The 
hepatotoxicity can be either dose-related, as was seen in the early dosing studies, or 
idiosyncratic at accepted treatment doses (Chang et al., 2008; Pasipanodya and 
Gumbo, 2010; Sahota and Pasqua, 2012). Pyrazinamide-induced hepatotoxicity can 
present in a sub-acute manner and is often severe (Hussaini and Farrington, 2007; 
Yew and Leung, 2007). The mechanism of pyrazinamide-mediated hepatotoxicity is 
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not clear, but the metabolite 5-hydroxypyrazinoic acid has been implicated (Momekov 
et al., 2014). 
The efficacy of pyrazinamide in treating pulmonary tuberculosis is matched by its side-
effect profile, and it is generally considered to be the most toxic of the four drugs used 
in standard tuberculosis therapy. Pyrazinoic acid inhibits the renal secretion of uric 
acid and this causes increased serum uric acid levels (Donald and McIlleron, 2009). 
Acute arthritis can occur in the context of drug-induced hyperuricaemia, and those 
patients with a previous history of gout are at increased risk (Jenner et al., 1981). 
Rhabdomyolysis is a rare but severe complication of pyrazinamide use, possibly due 
to a toxic effect exerted on cell mitochondria, and this can lead to renal impairment in 
some cases (Arbex et al., 2010). Additionally, pyrazinamide can cause a 
photosensitivity dermatitis in some patients that resolves after withdrawal of the 
medication (Bharat et al., 2003).  
5.1.4 Ethambutol Toxicity 
Prevention of the development of resistance is the primary reason for including 
ethambutol in standard tuberculosis therapy (WHO, 2011b; Nahid et al., 2016). It is a 
synthetic compound that has been in use since 1966 for the treatment of TB (Fox, 
Ellard and Mitchison, 1999). Ethambutol works to interfere with mycobacterial cell wall 
synthesis by inhibiting the action of the embB gene which is responsible for the 
polymerisation of arabinose into arabinogalactan within the mycobacteria (Forbes, 
Kuck and Peets, 1962). This is an essential component of the mycobacterial cell wall, 
and ethambutol exerts a bacteriostatic effect on actively dividing mycobacteria through 
the inhibition of this polymerisation reaction. The drug is metabolised in the liver into 
dicarboxylic acid via an intermediate aldehyde but there is no change in the activity of 
the liver enzymes (Forbes, Kuck and Peets, 1962). 
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Ethambutol has the most favourable toxicity profile of the four drugs used in standard 
TB therapy, and side effects are generally dose-related (Sarkar and Ganguly, 2016). 
Bilateral optic neuropathy is a serious toxic effect of ethambutol and most commonly 
presents with a retrobulbar neuritis affecting the axial fibres, likely related to 
mitochondrial dysfunction (Fraunfelder, Sadun and Wood, 2006). The central fibres 
are more often affected than the peripheral fibres and this manifests clinically as 
reduced visual acuity, impaired colour vision, and scotomas (Lim, 2006). The overall 
risk of developing optic neuropathy is thought to be less than 1% at doses less than 
15mg/kg body weight per 24 hours (Ezer et al., 2013; Kim and Park, 2016; Yang et 
al., 2016). The risk is increased in the context of renal disease, due to increased serum 
concentrations, but the effects are generally reversible if the drug is stopped promptly 
(Fraunfelder, Sadun and Wood, 2006).  
Ethambutol can also rarely cause a peripheral neuritis in cases when vitamin B2 levels 
are low (e.g. older age or alcohol excess) (Kass and Shandera, 2010). Other toxic 
effects of the drug are either mild in nature, very rare, or both, and the literature relating 
to them predominantly takes the form of isolated case reports: these include 
gastrointestinal upset, depression, blood dyscrasia, hypersensitivity reactions and 
arthropathy secondary to uric acid retention (Kwon et al., 2004; Lehloenya and Dheda, 
2012; Yen et al., 2015; Kassa et al., 2016). 
5.1.5 Moxifloxacin Toxicity 
Moxifloxacin is an 8-methoxy-fluoroquinolone that was first licenced in 1999 for the 
treatment of a range of bacterial infections including community-acquired pneumonia, 
skin and soft tissue infections, and intra-abdominal infections (Gillespie, 2016). In the 
late 1990s and early 2000s there was increasing interest in the drug’s ability to treat 
tuberculosis, and this led to early-phase clinical studies that demonstrated potent 
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bactericidal activity against M. tuberculosis (Ji et al., 1998; Nuermberger et al., 2004). 
Moxifloxacin is used in cases where patients are unable to tolerate standard 
tuberculosis therapy and in the treatment of drug-resistant tuberculosis (Gillespie, 
2016). It exerts a bactericidal effect by inhibiting the activity of DNA gyrase with a 
consequent disruption of cell replication (Donald and McIlleron, 2009).  
The drug is metabolised in the liver to an N-sulfate conjugate and an acyl glucuronide 
which are then excreted in the urine and faeces, but urinary excretion of unchanged 
drug accounts for approximately 20% of the given dose (Sullivan et al., 1999; Moise, 
Birmingham and Schentag, 2000). Moxifloxacin does not act to alter hepatic enzyme 
activity, but co-administration with rifampicin can lead to reduced plasma 
concentrations of moxifloxacin (Nijland et al., 2007). Approximately 1 – 10% of patients 
may experience an asymptomatic elevation in liver enzymes while taking the drug 
(Bertino and Fish, 2000; Ball et al., 2004), and there are very rare reports of fulminant 
liver failure mediated by a hypersensitivity reaction in hepatic tissue (Soto et al., 2002; 
Nori et al., 2004; Verma et al., 2009).  
Moxifloxacin has a generally favourable side effect profile, but cardiac toxicity and 
tendonitis are the two other rare toxicities that have been reported. Blockade of the 
cardiac potassium channels can cause delayed repolarisation and prolongation of the 
QT interval occurs in 1-10% of cases (Haverkamp et al., 2012; Mehrzad and Barza, 
2015). Cardiac arrest with either unspecified arrhythmias or torsade de pointes is 
thought to affect less than 0.01% of patients, however (Owens and Nolin, 2006; Altin 
et al., 2007; Briasoulis, Agarwal and Pierce W J, 2011). It is estimated that 
approximately 0.01 – 0.1% of patients will experience tendinopathy that is believed to 
be mediated through ischaemia with only a very small proportion rupturing tendons as 
a result (van der Linden et al., 2002; Khaliq and Zhanel, 2003). Other potential side 
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effects with a risk of approximately 0.01 – 0.1% include coagulopathy, 
agranulocytosis, significant electrolyte disturbance, psychiatric symptoms, and drug-
induced nephropathy (Food and Drug Association, 1999; Ball et al., 2004). 
6 Further Work to Shorten Tuberculosis Treatment 
6.1 The Climate in Tuberculosis Research at the end of the 
20th Century 
After decades of active research output, transforming tuberculosis from a largely fatal 
and incurable condition into one with an effective treatment, the BMRC closed its doors 
in 1986. Trial after trial had created a robust framework for TB surveillance, treatment 
regimens, and supervision of therapy and now the bulk of the work rested on the public 
health authorities to implement these in control programmes. However, an inability to 
bring the TB epidemic under control in low and middle income countries made it 
apparent that it was not as simple as that. Among other things the HIV epidemic, living 
conditions associated with poverty, and emerging drug resistant strains all worked 
together to undermine efforts to eradicate tuberculosis in these regions. 
Standard tuberculosis therapy also did not perform as well outside of controlled trial 
conditions and the efficacy of treatment fell from over 90% in the trial setting (Fox, 
Ellard and Mitchison, 1999) to approximately 80-85% in the field (WHO, 2017). Toxic 
side effects, lengthy duration of treatment, limited infrastructure, an improvement in 
symptoms with reduced drive to adhere, chaotic lifestyles, and social stigma relating 
to a tuberculosis diagnosis are just some of the reasons that standard tuberculosis 
therapy becomes less effective in real-world settings. At the end of the 20th century a 
renewed interest started to gather pace towards reducing the treatment duration to 
less than 6 months for drug-sensitive tuberculosis; if the treatment duration could be 
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lessened without compromising efficacy then a major barrier to adherence would be 
removed and real-world cure rates could be brought closer to 90%. 
6.2 The Fluoroquinolone Studies 
At the beginning of this century murine models and early phase clinical studies 
demonstrated potent activity of moxifloxacin against M. tuberculosis (Gosling et al., 
2003; Pletz et al., 2004; Rustomjee et al., 2008). The potential for moxifloxacin to 
shorten the duration of treatment for tuberculosis was reinforced by clinical studies 
investigating the early bactericidal activity at 8 weeks of regimens with 
fluoroquinolones substituted for isoniazid or ethambutol (Burman et al., 2006; 
Rustomjee et al., 2008; Conde, Efron, Loredo, Muzy, et al., 2009; Dorman et al., 2009). 
There was also now more of a willingness on the part of major funding bodies to 
engage with tuberculosis research, and this led to three phase III trials investigating 
the impact of fluoroquinolones on the treatment of pulmonary tuberculosis launching 
in the first decade of the 2000s. All three of these trials sought to investigate the 
efficacy of at least one four-month, fluoroquinolone-containing treatment regimen for 
drug-sensitive pulmonary tuberculosis. 
6.2.1 The OFLOTUB Study 
This study sought to determine if gatifloxacin could be substituted into standard 
tuberculosis therapy to allow the treatment duration to be reduced from 6 to 4 months 
(Gninafon et al., 2014). The experimental arm in the trial consisted of standard 
tuberculosis therapy with gatifloxacin substituted for ethambutol in the intensive 
phase, and then given alongside isoniazid and rifampicin for a further two months for 
a total of 4 months’ treatment. Over 1800 patients were recruited from five sub-
Saharan countries and randomised to receive either standard tuberculosis therapy or 
the experimental regimen between 2005 and 2009. Patients were to be followed for 
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24 months after treatment completion and a non-inferiority design was used to assess 
the primary efficacy endpoint of an unfavourable outcome on treatment (treatment 
failure, recurrence, death, or study dropout during treatment). A non-inferiority margin 
of 6 percentage points at the upper bound of the difference for unfavourable outcomes, 
adjusted for country, was agreed during the design of the study. 
The risk of an unfavourable outcome was 17.2% with standard tuberculosis therapy 
and 21.0% on the experimental arm in the modified intention-to-treat analysis, and the 
adjusted difference was 3.5 percentage points (95% confidence interval [CI], -0.7 to 
7.7). Therefore, non-inferiority was not achieved by the experimental arm based on 
the primary endpoint. In other aspects, standard tuberculosis therapy did not perform 
as well as the gatifloxacin-containing arm with a higher dropout rate during treatment 
(5.0% vs 2.7%) and more treatment failures (2.4% vs 1.7%). Despite this, however, 
there were fewer recurrences on standard tuberculosis therapy (7.1% vs 14.6%).  
There were similar numbers of Serious Adverse Events (SAEs) reported on the control 
(23 events) and experimental (20 events) arms. On the standard tuberculosis therapy 
arm 10 of 23 (43.5%) SAEs were related to respiratory symptoms and 4 of 20 (20.0%) 
SAEs on the experimental arm were related to diabetes or meningitis (grouped under 
“nervous system disorders”). In particular, there was no increased risk of QT interval 
prolongation or dysglycaemia for patients taking the experimental regimen.  
6.2.2 The RIFAQUIN Study 
The RIFAQUIN trial group built on murine models that suggested combining high-dose 
rifapentine with a fluoroquinolone would overcome the heightened risk of relapse or 
acquired resistance seen previously with intermittent dosing (Jindani et al., 2014). This 
non-inferiority study involved two experimental regimens: both replacing isoniazid with 
moxifloxacin given daily during the intensive phase, followed by moxifloxacin and 
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rifapentine administered twice per week for a further two months or in one weekly dose 
for four months. There were 827 patients enrolled from South Africa, Zimbabwe, 
Botswana, and Zambia. A primary end point of treatment failure or relapse was used 
to compare the experimental arms to standard tuberculosis therapy, with non-
inferiority set at a margin of 6 percentage points difference using 90% confidence 
intervals.  
The six-month experimental arm in the trial met the criteria for non-inferiority compared 
to standard tuberculosis therapy. On the control arm, 14.4% of patients had an 
unfavourable outcome, compared to 13.7% on the six-month arm in the modified 
intention-to-treat analysis (adjusted difference 0.4 percentage points; 90% CI, -4.7 to 
5.6). Once more, reducing the treatment duration to four months meant non-inferiority 
was not achieved with 26.9% of patients classed as unfavourable (adjusted difference 
13.1 percentage points; 90% CI, 6.8 to 19.4). 
There were 45 adverse events that were graded as severe or life-threatening during 
the trial. Across the three treatment arms there were 16, 12, and 17 grade 3 or 4 
adverse events reported on the standard tuberculosis therapy, 4-month, and 6-month 
regimens respectively. There were 6, 12, and 7 deaths reported on the standard, 4-
month, and 6-month arms. Among the 25 deaths only 4 were assessed as being 
possibly or probably related to the trial medication, and 8 deaths did not have a clear 
cause reported (all had negative sputum culture prior to death, and 6 were HIV co-
infected).  
6.2.3 The REMoxTB Study 
The Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) study sought to 
evaluate the efficacy and safety profile of two experimental treatment regimens 
compared to standard tuberculosis therapy (Gillespie et al., 2014). Patients were 
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recruited into the randomised, controlled trial over a period of 6 years and allocated to 
one of three treatment arms: standard tuberculosis therapy as a control arm, or a four-
month experimental arm with moxifloxacin substituted for either ethambutol (the 
“isoniazid arm”) or isoniazid (the “ethambutol arm”). The trial used a non-inferiority 
design to assess the efficacy of the two experimental arms compared to standard 
tuberculosis therapy after almost 2000 patients completed 18 months of follow-up. 
Non-inferiority was defined as a between-group difference of less than 6 percentage 
points in the upper boundary of the two-sided 97.5% Wald confidence interval for the 
proportion of patients considered to have an unfavourable outcome. Unfavourable 
outcomes were defined as an extension in treatment beyond that permitted in the 
protocol, failing to achieve sustained sputum culture negative status, or death from 
any cause). The full criteria for favourable and unfavourable outcomes, and for 
inclusion in analysis populations, can be found in Section 1.6, Chapter 2 of the thesis.  
Neither of the experimental arms met the criteria for non-inferiority in the per-protocol 
population. The relapse-free cure rates were 85% and 80% for the isoniazid and 
ethambutol arms, and 92% among patients allocated to standard tuberculosis therapy. 
The adjusted absolute difference in the proportion of patients with an unfavourable 
outcome compared to standard tuberculosis therapy was 6.1 (97.5% CI, 1.7 to 10.5) 
and 11.4 percentage points (97.5% CI, 6.7 to 16.1) for the isoniazid and ethambutol 
arms, respectively.  
There was no significant difference detected for the incidence in grade 3 or 4 adverse 
events across the three treatment arms in the original analysis. There were 123 (19%), 
127 (19%), and 111 (17%) patients affected by one or more grade 3 or 4 adverse 
event on the standard, isoniazid and ethambutol arms. The number of SAEs, type of 
events, and numbers of patients with SAEs were similar in the three trial arms during 
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treatment and follow up. Additionally, there was no difference between the groups for 
incidence of adverse events particularly related to the substitution of fluoroquinolones: 
cardiac toxicity, tendinopathy, seizures, dysglycaemia, or peripheral neuropathy. 
7 Toxicity Related to Tuberculosis Treatment: The 
Aim of the Thesis 
While the REMoxTB study did not result in the adoption of a novel four-month 
treatment for drug-sensitive pulmonary tuberculosis a significant advance that came 
from the trial was the collection of stringent, prospectively-gathered data relating to 
639 patients receiving standard tuberculosis therapy (Gillespie et al., 2014). 
Microbiological, clinical, demographic, and safety data was incorporated into the 
database for every patient randomised into the trial and, where possible, even for 
patients who were withdrawn from treatment and referred to the National Treatment 
Program. The result is a rich database with the potential to provide firm answers to 
clinical questions that previously have been answered through a combination of 
anecdote or retrospective and observational studies prone to bias and confounding. 
There are many reasons why our efforts to control the global tuberculosis epidemic 
have struggled to curb the disease at a rate in line with policy timelines (Floyd et al., 
2018), and the toxicity associated with standard tuberculosis therapy is one of them. 
At this point in time, standard tuberculosis therapy is unlikely to be replaced with a 
novel regimen anytime soon (Laughon and Nacy, 2017) and there is a need to better 
equip tuberculosis physicians with an evidence-based approach to managing 
treatment toxicity. Improved monitoring strategies based on robust data, fuelled by 
increased funding attracted through clearly-defined effects on treatment outcome from 
toxic events, could help move cure rates towards 90% and reduce the disease burden. 
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The effort to shorten tuberculosis treatment to less than 6 months continues despite 
the disappointing results of the fluoroquinolone trials. The drive to shorten therapy is 
based on the logistic difficulties in administering lengthy treatment, poor adherence 
due to treatment duration, and reducing toxicity through reduced exposure (Pai et al., 
2016). Despite failing to achieve the pre-defined non-inferiority criteria in the study, 
both of the experimental arms in REMoxTB demonstrated similar relapse-free 
microbiological cure rates to those seen with standard tuberculosis therapy outside of 
trial settings (Gillespie et al., 2014). Therefore, we have two four-month treatment 
regimens that could be as effective as standard tuberculosis therapy in real world 
settings as they are less complex to administer, and with similar adverse event 
incidence in the original analysis. However, this would need to be confirmed with 
further prospective work as it could be that the experimental arms actually have a 
reduced efficacy in the field compared to their performance in trial conditions (similar 
to existing standard TB therapy). 
The aim of this thesis is to use the data made available through the REMoxTB 
database to address two broad questions. First, how toxic is standard tuberculosis 
therapy? Specifically, to determine which patient groups are at highest risk, when 
toxicity occurs, and what form it most commonly takes. This can be coupled with an 
analysis of the impact on treatment outcome using stringently gathered microbiological 
data to produce recommendations for monitoring practice and build an argument 
supporting the direction of resources towards this program. Second, how does this 
toxicity profile compare to that seen on the four-month treatment arms in REMoxTB? 
An accurate characterisation of the toxicity and adverse events observed with patients 
allocated to the experimental arms may help define a place for them in the 
management of pulmonary tuberculosis. The future of tuberculosis treatment should 
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not be a single new regimen but rather a choice of treatment options that will allow us 
to treat the disease in a tailored way (accounting for patient characteristics such as 
personalised risk of toxicity, environmental factors such as ability to perform safety 
monitoring, and resistance patterns of the mycobacteria causing disease). The goal is 
to minimise duration and toxicity, and maximise efficacy and a detailed analysis of 
these experimental arms could bring us closer to this point.  
Tuberculosis continues to claim thousands of lives every day, and the fight against it 
is far from over. A more informed approach to the management of side-effects from 
standard tuberculosis therapy would help with adherence and more can be made of 
the treatment that we already have available, while work continues on developing 
shorter effective regimens. This thesis will present analyses relating to the general 
pattern of toxicity seen on standard therapy, and in particular hepatotoxicity, and 
compare this to the patterns seen on the experimental arms. Finally, the course over 
treatment and toxicity profile seen among the HIV-positive patients receiving standard 
tuberculosis therapy will be analysed in detail. 
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Chapter Two: Materials and 
Methods 
1 The REMoxTB Study 
The analyses presented in this thesis were all performed using the REMoxTB study 
database (Gillespie et al., 2014) [Clinicaltrials.gov trial number NCT00864383], and 
the original New England Journal of Medicine publication can be found in Appendix 1. 
The Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) study was a 
randomised, blinded, placebo-controlled trial comparing two experimental, 
moxifloxacin-containing four-month treatment arms to standard TB therapy. Human 
immunodeficiency virus (HIV) positive and HIV-negative patients with sputum smear-
positive, drug-sensitive pulmonary TB were recruited between 2007 and 2012.  
The study screened 2763 patients and randomised 1931 patients to receive treatment. 
Patients failed screening most commonly because of sputum smear-negative results, 
a CD4+ count of less than 250 cells/mm3 if HIV-positive, or multidrug resistant TB 
detected using the Hain test. There were 909 patients randomised in South Africa, 376 
in India, 212 in Tanzania, 136 in Kenya, 119 in Thailand, 69 in Malaysia, 66 in Zambia, 
and 22 in both China and Mexico.  
1.1 REMoxTB Hypothesis and Design 
REMoxTB was designed to investigate the hypothesis that replacing either isoniazid 
or ethambutol in standard TB therapy with moxifloxacin and treating for four months 
would result in rates of relapse-free cure that were non-inferior to those seen with six 
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months of treatment with standard TB therapy. The primary outcome was a non-
inferiority comparison of the rates of relapse-free cure between standard TB therapy 
and the experimental arms individually, and efficacy and safety data was collected for 
all patients. The trial schematic can be seen in Figure 1-1. 
 
Figure 1-1. REMoxTB trial schematic describing the regimens and visit schedule.  [Obtained from 
Supplementary Appendix, available at 
https://www.nejm.org/doi/full/10.1056/NEJMoa1407426#article_supplementary_material] 
1.1.1 Treatment Arms in the REMoxTB Study 
The control arm in REMoxTB consisted of six month’s treatment with standard TB 
therapy. Ethambutol (E), isoniazid (H), rifampicin (R), and pyrazinamide (Z) were 
prescribed together for eight weeks as an intensive phase, and then isoniazid and 
rifampicin only for a total of 26 weeks’ treatment (2EHRZ/4HR). The “isoniazid arm” 
replaced ethambutol with moxifloxacin (M) in the intensive phase of treatment followed 
by a continuation phase of moxifloxacin, isoniazid, and rifampicin for a total of 17 
weeks (2MHRZ/2MHR). The “ethambutol arm” replaced isoniazid with moxifloxacin for 
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both the intensive phase and continuation phase of treatment, and the total duration 
was 17 weeks of therapy (2EMRZ/2MR). 
Those patients who were found to be eligible during the screening process were 
randomised to receive either the control, isoniazid, or ethambutol arm. All staff at the 
local sites and centrally were blinded to patient treatment allocations. Placebo drugs 
were used to replace moxifloxacin, ethambutol, isoniazid, and rifampicin if these were 
not contained in the allocated study treatment regimen to maintain blinding. Patients 
allocated to a 17-week regimen received only placebo drugs from week 18 to week 26 
as part of this (see Figure 1-1). Block randomisation according to baseline weight was 
used to ensure equal numbers of patients across the study arms in each weight 
category at each of the sites.  
All regimens involved single daily dosing of trial medication, including placebo 
medication, and study drug dosing was supervised. The different sites were permitted 
to use a method of supervision that was most suitable for them, and included directly 
observed therapy by site staff, supervision by a community engagement worker or 
family member, or supervision by another patient nominated treatment supervisor. 
Medication adherence was recorded from data provided by the patients on questioning 
by site staff, and drug packaging was inspected for remaining medication. The doses 
were calculated based on categorical weight bands and these are detailed in Table 
1-1. 
Patients taking 26-week standard TB therapy in the trial were considered to have taken 
adequate treatment if they had taken a total of at least 42 doses of intensive phase 
treatment within 70 days of starting treatment and at least 84 doses of continuation 
phase treatment within 168 days of completing the intensive phase. Additionally, the 
patient could not have missed more than 42 doses of medication overall in the trial.  
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For patients receiving the 17-week experimental treatment in the study, adequate 
treatment was considered to be at least 42 doses of intensive phase treatment within 
70 days of starting treatment and at least 42 doses of continuation phase treatment 
within 84 days of completing the intensive phase. These patients must not have 
missed no more than 28 doses overall as well. 
Drug Name Weight Banding Drug Dose 
 
 
Ethambutol 
<40kg 15mg/kg daily rounded to 
nearest 100 mg  
40kg to ≤55kg 800mg daily  
>55kg to ≤75kg 1200mg daily 
>75kg 1600mg daily 
Isoniazid All weight ranges 300mg daily 
Rifampicin <45kg 450mg daily 
45kg or higher 600mg daily 
Pyrazinamide <40kg 25 mg/kg rounded to nearest 
500mg (if <40 kg 1000mg used 
instead of 500mg) 
45kg to ≤55kg 1000 mg daily 
>55kg to ≤75kg 1500 mg daily 
>75kg 2000 mg daily 
Moxifloxacin All weight ranges 400mg daily 
Table 1-1. TB medication dosing in the REMoxTB Study based on patient weight. 
 
1.2 Randomised Patients in the REMoxTB Study 
The REMoxTB study aimed to investigate the efficacy and safety of the two 
experimental, moxifloxacin-containing treatment arms in patients with sputum smear-
positive, drug-sensitive pulmonary TB. Patients presenting to the local healthcare 
services with smear-positive pulmonary TB were eligible for screening by the sites in 
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the study and subsequently randomised based on the study inclusion and exclusion 
criteria.  
Signed written consent or witnessed oral consent in the case of insufficient literacy 
was taken before any study-related procedures were undertaken. All randomised 
patients agreed to any data and samples collected as part of the trial being used in 
further studies to improve the diagnosis and treatment of tuberculosis, as stated on 
the informed consent form for the study. All the research activities and data collection 
for the study was compliant with the Helsinki Declaration and the principles of Good 
Clinical Practice.  
Patients aged over 18 years old who had never been treated for TB were eligible for 
participation in the study. Two smear-positive sputum samples positive for tubercle 
bacilli were also required for inclusion in the study, and at least one of these samples 
must have been confirmed by the REMoxTB study laboratory at the local laboratory. 
All patients were tested for HIV at screening, and HIV-positive patients were eligible 
to take part if their CD4+ cell count was greater than or equal to 250 cells/mm3 and 
they were not taking antiretroviral medication. A full medical history was taken with 
clinical examination to ensure there were no pre-existing conditions or contra-
indications to trial medications that would exclude the patient. Pre-menopausal women 
not using an intra-uterine device or surgically sterilised were required to use barrier 
contraception for the duration of the trial. Patients found to be ineligible during 
screening were referred to the National Treatment Program for further management 
of their TB. The inclusion criteria for the trial were: 
• Signed written consent or witnessed oral consent in the case of illiteracy, before 
undertaking a trial related activity  
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• Two sputum specimens positive for tubercle bacilli on direct smear microscopy 
of which one confirmed by the REMoxTB study laboratory at the local laboratory  
• No history of previous anti-tuberculosis chemotherapy  
• Aged 18 years and over  
• A firm home address that is readily accessible for visiting and willingness to 
inform the study team of any change of address and follow-up period  
• Agreement to participate in the study and to give a sample of blood for HIV 
testing  
• Negative pregnancy test (women of childbearing potential)  
• Pre-menopausal women must be using a barrier form of contraception or be 
surgically sterilised or have an IUCD in place  
• Laboratory parameters performed at least 14 days prior to enrolment: 
o Serum AST and ALT less than 3xULN  
o Serum total bilirubin level less than 2.5xULN  
o Creatinine clearance (CrCl) level greater than 30 mL/min 
o Haemoglobin level of at least 7.0 g/dL  
o Platelet count of at least 50x109 cells/L 
o Serum potassium greater than 3.5 mmol/L  
The trial exclusion criteria were: 
• Patients unable to take oral medication 
• Previously enrolled in this study 
• Receiving any investigational drug in the past 3 months or an antibiotic active 
against M. tuberculosis 
• Pregnancy or breast-feeding 
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• Any condition that may prove fatal during the first two months of the study 
period 
• Severe tuberculosis with high risk of a poor outcome (e.g., meningitis) 
• A pre-existing condition likely to prejudice the response to, or assessment of 
treatment, a condition likely to lead to uncooperative behaviour  
• A contraindication to any medications in the study regimens  
• A congenital or sporadic cardiac syndrome or taking medications that could 
result in QTc prolongation  
• Patients already receiving anti-retroviral therapy 
• Weight less than 35kg  
• HIV infection with CD4 count less than 250 cells/μL 
• End stage liver failure (class Child-Pugh C)  
• Patients whose initial isolate was shown to be multiple drug resistant or mono-
resistant to rifampicin, or any fluoroquinolone  
1.3 The Patient Assessment Schedule for REMoxTB 
The visit schedule in relation to all three of the treatment arms in REMoxTB can be 
seen in Figure 1-1. The total period for both treatment and follow up in the trial was 18 
months from the point of randomisation. Patients were assessed weekly for the first 8 
weeks of treatment, monthly until week 26 following the initiation of treatment, and 
then 3-monthly for a further 12 months. Visit windows were ±3 days for weekly visits, 
±14 days for monthly visits, and ±6 weeks for 3 monthly visits. Patients were also 
reviewed with indicated investigations performed at unscheduled visits, at any time 
when thought to be necessary by the treating physician. The patient assessment 
schedule with associated procedures and investigations is shown in Figure 1-2. 
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1.4 Laboratory Methods in the REMoxTB Study 
Standardised laboratory techniques were employed across all the sites in REMoxTB 
following training by the trial staff. Regular laboratory monitoring visits were carried 
out through the trial to ensure that laboratory performance was of an acceptable 
standard and to address any issues or problems. Some site-specific variations in 
practice were agreed to improve operational aspects of the laboratory’s activity while 
minimising the chance of quality being compromised. Full details of the laboratory 
procedures in the REMoxTB study can be found in the Laboratory Manual for the trial, 
and this is available from the UCL Centre for Clinical Microbiology resources website 
(www.ucl.ac.uk/infection-immunity/centre-clinical-microbiology/resources).
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1.5 Data Collection in REMoxTB 
Data relating to efficacy and safety was collected locally at sites using the paper 
Clinical Research Forms (CRFs) presented in the Appendix. The data fields on the 
paper forms were then transcribed into an online database that was managed centrally 
in the MRC CTU at UCL. During the course of the trial, data entry was monitored and 
reviewed regularly with data queries generated for the sites to address missing data 
or inconsistencies identifies by the data scientists. Monitoring visits included checking 
CRFs against the source documentation where available and data entry against the 
CRF entry. 
At the end of the trial, the database underwent a cleaning process involving both data 
scientists and statisticians. The data sets were ordered according to the principles of 
tidy data (Wickham, 2014) and stored at the MRC CTU at UCL.  
1.6 Study Outcomes in REMoxTB 
Patients in the REMoxTB study were considered to be one of unfavourable, 
favourable, or not assessable at the end of their follow up period. In this thesis, unless 
otherwise stated, these outcome measures were not used and instead 
microbiologically-defined outcome measures were employed. The trial outcomes were 
defined as follows: 
• Unfavourable outcome 
o Patients who required an extension of their treatment beyond that 
permitted by the protocol, a re-start or a change of treatment for any 
reason except re-infection or pregnancy. 
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o Patients who had a positive culture when last seen (with the exception 
of patients found to have been re-infected) whether confirmed by a 
second sample or not. 
o Patients dying from any cause during treatment. 
o Patients failing to complete treatment and not assessable at 18 months. 
• Favourable outcome 
o Patients with a negative culture result at 18 months who had not already 
been classified as having an unfavourable outcome. 
• Not assessable 
o Patients who, having completed active treatment, default from follow-up 
and their last culture was negative. 
o Women who became pregnant during the treatment phase and stopped 
their allocated treatment, unless their last culture was positive in which 
case they were classified as having an unfavourable outcome. 
o Patients who died during the follow-up phase with no evidence of failure 
or relapse of their TB. 
o Patients re-infected with a new strain different from that with which they 
were originally infected.  
A per-protocol (PP) and modified intention-to-treat (mITT) analysis was carried out for 
the original publication. The exclusion criteria for the mITT analysis were: 
1. Patients with MDR disease documented from samples taken at enrolment or 
week 1 (late exclusions from the study). 
2. Patients without culture confirmation of tuberculosis at enrolment or weeks 1 or 
2 around enrolment, from screening to week 2 (late exclusions from the study). 
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3. Patients withdrawn from treatment because of a protocol violation at enrolment 
(late exclusions from the study, based on data collected prior to randomisation). 
4. Patients who, having completed the treatment phase at Month 6, are lost to 
follow-up or withdrawn from the study, their last status being culture negative 
and their last positive culture result (“isolated positive culture”) followed by at 
least two negative culture results (without an intervening positive culture). 
5. Women who become pregnant during the 6-month treatment phase and stop 
their allocated treatment. 
6. Patients who died during the treatment phase from violent or accidental cause 
(e.g. road traffic accident). N.B.: This does not include death from suicide, which 
will be considered an unfavourable outcome. 
7. Patients who died during the follow-up phase with no evidence of failure or 
relapse of their TB, their last status being culture negative and their last positive 
culture result (“isolated positive culture”) followed by at least two negative 
culture results, and who have not already been classified as unfavourable. 
8. Patients who, after being classified as having culture negative status, are re-
infected with a new strain different from that with which they were originally 
infected. “Reinfection” will be defined specifically as a patient infected with a 
strain that is different from the initial strain as defined by MIRU and IS6110 
typing. Assessments of relapse vs. reinfection were made before database lock 
and unblinding. 
9. Patients who are able to produce sputum at 18 months, but whose 18-month 
visit sputum samples are all (L-J and MGIT) contaminated or missing, who 
cannot be brought back for repeat cultures, provided they have not already 
been classified as unfavourable and provided their last positive culture was 
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followed by at least two negative cultures. N.B.: This does not apply to patients 
who are unable to produce sputum at 18 months, or to patients who are able to 
be brought back subsequently and produce negative cultures. 
Further exclusion criteria applied to the PP analysis: 
1. Patients not meeting the definition of having received an adequate amount of 
their allocated study regimen, provided they have not already been classified 
as having an unfavourable outcome.  
2. Patients lost to follow-up or withdrawn before the Month 6 visit, unless they 
have already been classified as having an unfavourable outcome. 
3. Patients whose treatment was modified or extended for reasons (e.g. an 
adverse drug reaction or pregnancy) other than an unfavourable therapeutic 
response to treatment, unless they have already been classified as having an 
unfavourable outcome. 
4. Patients who are classified as “major protocol violations”, unless they have 
already been classified as having an unfavourable outcome on the basis of data 
obtained prior to the protocol violation. 
1.7 Withdrawal from the Study and Follow-up 
The Sponsor and the site Investigators had the right to withdraw a patient from 
treatment in the study in the event of a serious or severe adverse event. Patients who 
were withdrawn from study treatment were to be followed up according to the trial 
protocol visit schedule for assessment and investigations including sputum sampling, 
unless the patient also withdrew their consent to follow up. If further treatment for 
tuberculosis was required, patients were referred to the National Treatment Program 
by the site staff.  
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2 Statistical Methods  
The REMoxTB study database was available through the Medical Research Council 
Clinical Trials Unit at University College London (MRC CTU at UCL). All data 
manipulation and statistical analysis was performed using Stata version 14 
(StataCorp, Texas, USA), and statistical significance was set at 5% throughout the 
thesis.  
2.1 Data Distribution 
Continuous variables were assessed for their distribution before any statistical tests 
were performed. The data was visualised as a histogram to determine if the spread 
was unimodal or multi-modal and to detect skewness in the data. Inverse normal 
plotting was used to assess whether the data was normally distributed. If all variables 
been investigated were thought to be approximately normally distributed then 
parametric testing was used, but if any of the variables under investigation were 
thought to be not normally distributed then a non-parametric alternative was used 
instead. Non-parametric methods were also used if one or more of the variables being 
tested had extreme outliers that could influence the mean. 
2.2 Tests for Variable Association or Difference 
The Mann-Whitney U test (Mann and Whitney, 1947) was used to test for significant 
differences in continuous variables between the three treatment arms in the REMoxTB 
study. This test does require an assumption of normality to produce meaningful 
results, and is also robust when used to test differences between normally distributed 
variables. The Chi squared test (Pearson, 1900) was employed to test for significant 
differences in the proportions of patients seen in categorical variables. This test 
assumes the predicted values in each square of a frequency table, showing the 
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numbers belonging to each category, will be greater than 5 and if this was not the case 
then Fisher’s exact test (Fisher, 1922) was used instead. The Kruskal-Wallis test 
(Kruskal and Wallis, 1952) was used in this thesis as a non-parametric alternative to 
an analysis of variance. This test was used in cases when a continuous variable was 
compared across the three study treatment arms to detect statistically significant 
differences, as opposed to the Mann-Whitney test which was used for non-parametric 
pairwise comparisons in this thesis.  
In cases where an association was investigated between a binary outcome variable 
and one or more exposure variables, logistic regression was used to test for significant 
associations. The assumptions that had to be met for this test were that the 
observations were independent of each other, that there was little or no 
multicollinearity among the exposure variables, a linear relationship between the 
exposure variables and the log odds, and lastly that there was a minimum of 10 
patients with the least frequent outcome for each independent variable in the 
regression model. The Hosmer and Lemeshow test (Hosmer and Lemeshow, 1980) 
was used as a regression diagnostic for the models used in the thesis. 
Zellner’s seemingly unrelated regression (Zellner, 1962) was used as a multivariate 
regression test. This multivariate regression uses simultaneous generalised linear 
regression for a number of outcomes of interest in relation to one or more exposure 
variables, but there is an assumption that the covariance for the error terms between 
the individual linear regression models is non-zero. Therefore, a degree of relatedness 
between the outcome variables is assumed and the final regression coefficients for 
each outcome variable can be interpreted as the association with the exposure 
variable of interest, with an accounting for any relatedness between the outcomes. 
Hence, the term “seemingly unrelated”. This is a feasible least squares technique, and 
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there is a lot of overlap with ordinary least squares calculations. The initial step is to 
use ordinary least squares regression for each of the outcome variables against the 
exposure variables as univariable regressions, and the residuals are used to create a 
matrix. Following on from this, a generalised least squares regression is carried out 
using this residual matrix as a variance matrix for each of the outcome variables again 
in univariable regressions against the exposure of interest. As a result, the error 
estimator for the equations uses shared variance from across the univariable linear 
equations and allows for interpretation of each outcome in relationship to the other 
outcomes. When this test was utilised, the assumptions considered were the same as 
for ordinary least squares: that the linear regression model was effectively linear in its 
parameters, there was random sampling of the observations, the conditional mean 
would be zero, and that there was no multicollinearity.  
2.3  Time to Event Analyses 
The stset command in Stata was used for data relating to time-to-event analyses. 
This provides the software with the information it needs to label events in relation to 
the start of treatment in the study, and creates further variables relating to the timing 
of any events of interest for use in further tests and graphs. Kaplan-Meier curves 
(Kaplan and Meier, 1958) were constructed using the sts graph command with risk 
tables added as an argument to the command.  
The logrank test (Mantel, 1966; Peto and Peto, 1972) was used to test for differences 
between study treatment arms. The null hypothesis that there is no difference between 
the two groups for the probability of the event of interest at any time point, and a p 
value is calculated to that effect. The test involves calculating the observed number of 
events in each group at each time point when an event occurs, and the number that 
would be expected if there was no difference between the groups.  
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Cox regression (Cox, 1972; Breslow, 1975) was used to generate hazard ratios for the 
time to the event of interest based on selected exposure variables. This test operates 
under the proportional hazards assumption, meaning the effects of exposure variables 
upon the time to the event are constant over time and proportional across the groups 
being tested (ie the ratio of the hazards for any two individuals is constant over time). 
The proportional hazards assumption was checked using the stphplot command 
to generate log-log plots (ensuring they do not cross) and estat phtest to test the 
assumption using Schoenfeld residuals (Schoenfeld, 1981) after the Cox regression 
model was fitted. 
2.4 User-written Packages 
User-written packages were utilised in the thesis. However, a package must have 
been published in a peer-reviewed journal specialising in statistical analysis or 
software programming (such as the Stata Journal). Where user-written packages have 
been used as part of an analysis, a reference to the publication has been provided 
and the package has been explicitly named with a description of its application.
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Chapter Three: Adverse Events 
and Toxicity Related to 
Tuberculosis Treatment 
1 General Introduction 
The toxicity associated with standard tuberculosis (TB) therapy is poorly characterised 
in the existing literature. Isoniazid (H), rifampicin (R), pyrazinamide (Z), and 
ethambutol (E) have been used in combination to treat TB for several decades and 
there are recognised side effects from these drugs when they are used to treat TB: 
including peripheral neuropathy (Zilber et al., 1963; Schaberg, Rebhan and Lode, 
1996), gastrointestinal upset (Yee et al., 2003), optic neuropathy (Marra et al., 2007), 
and liver injury (Ormerod et al., 1998; Saukkonen et al., 2006). However, the 
interpretation of the existing publications is impaired by varying definitions for reporting 
toxicity (Devarbhavi, 2011; Saukkonen, Powell and Jereb, 2012), and the 
retrospective or observational nature of the majority of studies. There are few 
prospective studies designed to investigate efficacy and safety, largely due to the lack 
of new drugs until recently (Pai et al., 2016). This can lead to clinical practice being 
predominantly guided by personal experience and anecdotal evidence, which results 
in variable approaches to the management of drug side effects and monitoring for 
toxicity. 
The patient characteristics associated with toxicity are also variably reported. Female 
gender, human immunodeficiency virus (HIV) infection, alcohol dependence, and 
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some ethnic groups have been identified as being at higher risk for experiencing 
adverse events (AEs) on TB treatment (Yee et al., 2003; Marra et al., 2007; Pepper et 
al., 2010; Lorent et al., 2011; McIlleron et al., 2015; Sadiq et al., 2015; Vasakova, 
2015). The lack of a consistent approach to defining and reporting across these 
studies results in variable risks being reported. As an example, the rates of 
ethambutol-associated visual impairment range from 0.02% to greater than 35% in the 
literature (Fraunfelder, Sadun and Wood, 2006; Menon et al., 2009; Chen et al., 2012; 
Ezer et al., 2013), despite the importance of this complication and the relative 
simplicity of testing for its presence with little training required.  
Toxicity related to treatment has been associated with poorer outcomes in TB to 
different extents (Lorent et al., 2011; Wohlleben et al., 2017). Side effects such as 
hepatotoxicity have been linked with treatment interruptions (Sharma et al., 2010), and 
increased morbidity and mortality (Saukkonen et al., 2006; Shang et al., 2011). 
Additionally, less severe drug toxicities such as gastrointestinal upset have been 
reported as factors related to patient non-compliance and loss to follow up in TB clinics 
(Chida et al., 2015; Gugssa Boru, Shimels and Bilal, 2016).  
In this chapter, the aim was to investigate the pattern of toxicity associated with 
standard TB therapy using a large prospectively collected database. Specifically, to 
answer the following questions: 
• Who is affected by toxicity? 
• When does it happen and what form does it most commonly take?  
• What is the impact of experiencing toxicity on treatment outcomes?  
• How does the toxicity associated with standard TB therapy compare to the 
toxicity seen in the experimental arms used in REMoxTB? 
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2 Baseline Characteristics for Patients taking 
Standard TB Therapy 
The TB physician needs to be able to identify those patients that are at highest risk for 
experiencing clinically significant toxicity. This has implications on how monitoring 
programs will be set up to ensure that the most vulnerable patient groups are kept 
under close review and any toxicity that could potentially have a negative impact on 
their treatment is acted upon at an early stage. There are also considerations for 
clinical trials where eligible patients need to be identified and patients have to give 
informed consent before participation, and if a patient belongs to a group at higher risk 
of adverse events they should be made aware of this fact. 
This section uses the data relating to patient characteristics to investigate for any 
significant associations between patient characteristics at the beginning of treatment 
and reported adverse events while taking standard TB therapy. 
2.1 Methods 
2.1.1 Adverse Event Definitions 
In REMoxTB adverse events (AEs) were recorded for all randomised patients during 
both the treatment and follow up phases of the trial. AEs were defined as any untoward 
medical occurrence in a patient who has been administered trial medication, with or 
without a causal relationship to the drugs. All AEs were graded in terms of clinical 
severity by the site doctor on a scale from grade 1 (least severe) through to grade 4 
(most severe). The grading system worked to specific criteria depending on the nature 
of the individual event, for example test results could be graded based on numerical 
cut-offs while symptoms were graded based on the reported and observed severity, 
and adhered to the Division of AIDS of the National Institute of Allergy and Infectious 
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Diseases (DAIDS) criteria. To act as an illustration, Table 2-1 demonstrates a sample 
of severity grading criteria using events that are both clinically and numerically graded 
taken from the DAIDS Tables for Grading the Severity of Adult and Paediatric Adverse 
Events Version 2.0 (November 2014). The DAIDS guidelines also state that any AE 
that ends in death should be reported as “grade 5”, but in REMoxTB these events 
were identified when reported as Serious Adverse Events (SAEs). For the purposes 
of this chapter, events that were grade 3 or 4 in severity were considered “clinically 
significant” based on the assumption that these are the events that would generally 
be acted upon in routine clinical practice. AEs were considered “serious” if they fulfilled 
any of the standard criteria, regardless of the severity grading. These criteria were: 
• Death from any cause 
• Hospitalisation for any reason 
• Events that were considered life-threatening by the clinician 
• Congenital abnormalities 
• Persistent or significant disability 
• Medical significance, as judged by the site doctor 
The local clinicians made an assessment for relatedness to the trial medication for 
each AE and this would be based on the timing of the event, known side effects of the 
treatment, and the effects of re-starting medication after a treatment pause. Those 
AEs that were classified as “possibly”, “probably” or “definitely” related to trial 
medication were classed as “related” for this chapter’s analyses. Any AEs that were 
considered “not related” or “unlikely related” by the site doctors were classed as “not 
related” for this chapter. 
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PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-
THREATENING 
Clinical 
adverse event 
NOT identified 
elsewhere in 
the grading 
table  
 
Mild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicated  
 
Moderate 
symptoms 
causing greater 
than minimal 
interference with 
usual social & 
functional 
activities with 
intervention 
indicated  
 
Severe symptoms 
causing inability 
to perform usual 
social & functional 
activities with 
intervention or 
hospitalization 
indicated  
 
Potentially life-
threatening 
symptoms causing 
inability to perform 
basic self-care 
functions with 
intervention 
indicated to prevent 
permanent 
impairment, 
persistent disability, 
or death  
Prolonged 
QTc Interval  
 
0.45 to 0.47 
seconds  
 
> 0.47 to 0.50 
seconds  
 
> 0.50 seconds 
OR 
≥ 0.06 seconds 
above baseline  
 
Life-threatening 
consequences 
(e.g., Torsade de 
pointes, other 
associated serious 
ventricular 
dysrhythmia)  
Vomiting  
 
Transient or 
intermittent AND 
No or minimal 
interference with 
oral intake  
 
Frequent 
episodes with no 
or mild 
dehydration  
 
Persistent 
vomiting resulting 
in orthostatic 
hypotension OR 
Aggressive 
rehydration 
indicated (e.g., IV 
fluids)  
Life-threatening 
consequences 
(e.g., hypotensive 
shock)  
 
Creatinine, 
High  
 
1.1 to  
1.3 x ULN  
 
> 1.3 to 1.8 x 
ULN OR 
Increase of 
> 0.3 mg/dL 
above baseline  
>1.8 to<3.5 
x ULN OR 
Increase of 1.5 to 
< 2.0 x above 
baseline  
≥ 3.5 x ULN OR 
Increase of ≥ 2.0 x 
above baseline  
 
Vertigo  
 
Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities  
Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional 
activities  
Vertigo causing 
inability to 
perform usual 
social & functional 
activities  
 
Disabling vertigo 
causing inability to 
perform basic self-
care functions  
 
Table 2-1. Sample entries from the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and 
Pediatric Adverse Events Version 2.0 (Nov 2014). [Obtained from https://rsc.tech-res.com/docs/default-
source/safety/daids_ae_grading_table_v2_nov2014.pdf] 
The AEs in REMoxTB were coded using the MedDRA coding system and allocated a 
System Organ Class (SOC) and Preferred Term (PT) based on the nature of the event. 
Having reviewed the SOCs and PTs for a sample of the AEs, it was decided that the 
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most clinically relevant approach to analysing this data was to predominantly use the 
SOC as this would give the reader a better grasp of the overall trends in AEs. However, 
as a result of the coding process there were many AEs grouped under the 
“Investigations” SOC because the PT related to the test result rather than the 
pathology underlying it (e.g. “low haemoglobin” as opposed to “anaemia”) and this 
meant that a lot of meaningful information would be lost if the SOCs were used in their 
natural state. Therefore, the majority of the AEs classed as “Investigations” were 
manually recoded into SOCs that better reflected the nature of the event (e.g. “raised 
ALT” was reallocated to “Hepatobiliary Disorders”).  
2.1.2 Baseline Characteristics and Adverse Events 
Baseline characteristics (e.g. sex, weight, age, ethnicity) were available for all the 
patients allocated to the standard therapy arm in REMoxTB. Patients were grouped 
according to whether they experienced no clinically significant AEs (grade 3 or 4 
severity), ≥1 clinically significant AE, or ≥1 clinically significant AE assessed as related 
to treatment. The proportions of patients belonging to each group was tabulated to 
facilitate visual comparison between the group with no events and the group of 
patients with ≥1 (total or related-only) AEs according to individual baseline 
characteristics. Age and weight were both converted from continuous to categorical 
variables for the table and for use in the regression analyses. 
Univariable logistic regression was used to test the relationship between the baseline 
characteristics and the binary outcome variable of ≥1 clinically significant AE. Baseline 
characteristics were used as independent variables and ≥1 grade 3 or 4 AE was used 
as the binary dependent variable to generate odds ratios. Separate univariable logistic 
regression analyses were carried out using the total number of grade 3 or 4 AEs, and 
also in regression analyses using only the grade 3 or 4 AEs judged to be related to 
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trial medication by the site doctor. Ethnicity was considered a factor variable with 
“black” used as the baseline for the variable due to the largest number of patients 
belonging to this group. Time to Mycobacterial Growth Indicator Tube (MGIT) 
positivity, as a marker of bacillary load, was included in the regression analysis as a 
continuous variable. 
Characteristics with a p value of <0.10 in the manual univariable regression were 
chosen for inclusion in a random-effects multivariable logistic regression model. 
Separate regression analyses were carried out using the total grade 3 or 4 AEs, and 
those events thought to be related only. Age, gender, and baseline weight were 
included in the multivariable models looking for association with total and related grade 
3 or 4 AEs regardless of the p value. This was based on the clinical judgement that 
these patient characteristics should be included to weight the model regardless of 
statistical significance, as they would be expected to have an impact on a patient’s 
clinical course. Random-effects multivariable logistic regression was used to test for 
associations between the selected variables and grade 3or 4 AEs with trial centre used 
as the panel variable to account for any effect from the individual sites. 
2.2 Results 
Of the 639 patients taking standard therapy, 128 (20.0%) experienced ³1 grade 3 or 
4 AE during the trial. Table 2-2 describes the baseline characteristics for all patients 
on the standard therapy arm based on whether the patient experienced ³1 grade 3 or 
4 AE. There were higher proportions of females compared to males (25.5% vs 17.7%), 
patients with baseline weight £45kg compared to >45kg (56.8% vs 43.2%), and HIV-
positive versus HIV-negative patients (43.5% vs 18.2%) experiencing ³1 grade 3 or 4 
AE. Cavities on chest X-ray and smoking history did not show higher proportions than 
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the overall proportion of 20.0% for patients experiencing events. The median time-to-
positivity (TTP) in liquid culture was 111 hours and 116 hours among those patients 
who did and did not experience ≥1 grade 3 or 4 AE, respectively. 
 Zero Grade 
3/4 AEs 
≥1 Grade 
3/4 AEs 
Total 
No of subjects (% 
total) 
511 (80.0%) 128 (20.0%) 639 
Gender (%)    
 Male 368 (82.3%) 79 (17.7%) 447 
 Female 143 (74.5%) 49 (25.5%) 192 
Age (%)    
 <25 yrs 150 (80.2%) 37 (19.8%) 187 
 25-35 yrs 155 (84.2%) 29 (15.8%) 184 
 >35 yrs 206 (76.9%) 62 (23.1%) 268 
Baseline Weight (%)    
 <40 kg 45 (71.4%) 18 (28.6%) 63 
 40-45 kg 74 (71.8%) 29 (28.2%) 103 
 >45-55 kg 214 (84.3%) 40 (19.7%) 254 
 >55-75 kg 163 (80.3%) 40 (19.7%) 203 
 >75 kg 15 (93.8%) 1 (6.2%) 16 
Ethnicity (%)    
 Black 237 (80.3%) 58 (19.7%) 295 
 Asian 147 (75.8%) 47 (24.2%) 194 
 Mixed Race 119(85.0%) 21 (15.0%) 140 
 Other 8 (80.0%) 2 (20.0%) 10 
Smoking History (%)    
 Never 235 (78.9%) 63 (21.1%) 298 
 Ex-smoker 126 (81.3%) 29 (18.7%) 155 
 Current 150 (80.7%) 36 (19.3%) 186 
HIV Status (%)    
 Positive  26 (56.5%) 20 (43.5%) 46 
 Negative  485 (81.8%) 108 (18.2%) 593 
Cavities on CXR*    
 Yes (%) 366 (80.3%) 90 (19.7%) 456 
 No (%) 96 (80.7%) 23 (19.3%) 119 
MGIT Median TTP in 
hours (IQR) 
116 
(89 – 154) 
111 
(86 – 163) 
114 
(88-156) 
Table 2-2. Baseline characteristics of patients allocated to standard therapy grouped according to the number of 
grade 3 or 4 AEs experienced during the course of the trial. Row totals provided for patients based on 
characteristic and row percentages given in each cell. Note that population totals vary depending on whether 
timing of event is considered, as there was no start date recorded for some AEs *Note some X-rays were either 
unobtainable or unsuitable for reporting 
Table 2-3 presents the output from univariable and random-effects multivariable 
logistic regression of baseline characteristics against a binary outcome of ≥1 grade 3 
or 4 AE. HIV infection (adjOR 3.43, 95% CI 1.82 – 6.49) was the only baseline 
characteristic found to be significantly related to grade 3 or 4 AEs in the multivariable 
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model. While female sex (OR 1.60, 95% CI 1.06 – 2.39) and baseline weight (OR 0.79, 
95% CI 0.65 – 0.97) were significantly associated with experiencing an event in the 
univariable analysis, these characteristics failed to maintain their significance in the 
multivariable model. Age, ethnicity, smoking history and measures of bacillary burden 
(cavitation on chest X-ray and MGIT time-to-positivity) were not significantly 
associated with increased odds of experiencing ³1 grade 3 or 4 AE. 
Baseline 
Characteristic 
OR 95% CI P value adjOR 95% CI P value 
Female 
Gender 
1.60 1.06 – 
2.39 
0.02 1.36 0.87 – 
2.13 
0.18 
Age* 1.13 0.90 – 
1.43 
0.30 1.15 0.90 – 
1.47 
0.25 
Baseline 
Weight* 
0.79 0.65 – 
0.97 
0.02 0.79 0.63 – 
1.03 
0.08 
Ethnicity       
 Black BASELINE --- --- --- --- --- 
 Asian 1.31 0.84 – 
2.02 
0.23 --- --- --- 
 Mix Race 0.72 0.42 – 
1.24 
0.24 --- --- --- 
Smoking Hist.       
 Never BASELINE --- --- --- --- --- 
 Ex-smoker 0.86 0.53 – 
1.40 
0.54 --- --- --- 
 Current 0.90 0.57 – 
1.42 
0.64 --- --- --- 
HIV Positive 3.45 1.86 – 
6.42 
<0.001 3.43 1.82 – 
6.49 
<0.001 
Cavities on 
CXR 
1.03 0.62 – 
1.71 
0.92 --- --- --- 
Baseline TTP 1.00 1.00 – 
1.00 
0.46 --- --- --- 
Table 2-3. Output from univariable and random-effects multivariable logistic regression with ³1 grade 3 or 4 AE 
as outcome. OR= Odds ratio, adjOR= Adjusted OR, 95% CI=95% confidence intervals *Age and baseline weight 
were categorised as presented in Table 3 of this chapter 
There were 57 of the 639 (8.9%) standard therapy arm patients who reported ³1 grade 
3 or 4 AE thought to be related to standard TB therapy. Table 2-4 shows the baseline 
characteristics for all the patients taking standard TB therapy, with numbers grouped 
according to the number of related grade 3 or 4 AEs experienced. HIV positive patients 
(23.9%), patients with a baseline weight 45kg or less (13.3%), and female patients 
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(13.5%) had higher proportions with ³1 related grade 3 or 4 AE compare to the overall 
proportion of 8.9%. While patients who were labelled “Other” ethnicity had the highest 
proportion of the different ethnic groups at 20%, this was based on a total number of 
ten patients. 
 Zero Related 
Grade 3/4 AEs 
≥1 Related Grade 
3/4 AEs 
Total 
No of subjects (% 
total) 
582 (91.1%) 57 (8.9%) 639 
Gender (%)    
 Male  416 (93.1%) 31 (6.9%) 447 
 Female  166 (86.5%) 26 (13.5%) 192 
Age (%)    
 <25 yrs 176 (94.1%) 11 (5.9%) 187 
 25-35 yrs 164 (89.1%) 20 (10.9%) 184 
 >35 yrs 242 (90.3%) 26 (9.7%) 268 
Baseline Weight 
(%) 
   
 <40 kg 55 (87.3%) 8 (12.7%) 63 
 40-45 kg 89 (86.4%) 14 (13.6%) 103 
 >45-55 kg 241 (94.9%) 13 (5.1%) 254 
 >55-75 kg 181 (89.2%) 22 (10.8%) 203 
 >75 kg 16 (100%) 0 (0.0%) 16 
Ethnicity(%)    
 Black 269 (91.2%) 26 (8.8%) 295 
 Asian 174 (89.7%) 20 (10.3%) 194 
 Mixed Race 131 (93.6%) 9 (6.4%) 140 
 Other 8 (80.0%) 2 (20.0%) 10 
Smoking History 
(%) 
   
 Never 271 (90.9%) 27 (9.1%) 298 
 Ex-smoker 139 (89.7%) 16 (10.3%) 155 
 Current 172 (92.5%) 57 (7.5%) 186 
HIV Status (%)    
 Positive  35 (76.1%) 11 (23.9%) 46 
 Negative  547 (92.2%) 46(7.8%) 593 
Cavities on CXR    
 Yes (%) 424 (93.0%) 32 (7.0%) 456 
 No (%) 106 (89.1%) 13 (10.9%) 119 
MGIT Median TTP 
(IQR) 
114 
(88 – 155) 
118 
(95 – 173) 
114 
(88-156) 
Table 2-4. Baseline characteristics of patients allocated to standard therapy grouped according to the number of 
related grade 3 or 4 AEs experienced during the course of the trial. Row totals provided for patients based on 
characteristic and row percentages given in each cell. Note that population totals vary depending on whether 
timing of event is considered, as there was no start date recorded for some AEs 
Female gender (adjOR 1.97, 95% CI 0.91 – 1.83) and HIV-positive status (adjOR 3.33, 
95% CI 1.55 – 7.14) were both found to be significantly associated with experiencing 
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³1 related grade 3 or 4 AE in the random-effects multivariable regression model shown 
in Table 2-5. Baseline weight was not found to be significant in either the univariable 
or multivariable regression. Similar to the total events, none of the other characteristics 
were found to be significant when analysed as an univariable exposure in logistic 
regression with the outcome of ≥1 related grade 3 or 4 AE. 
Baseline 
Characteristic 
OR 95% CI P value adjOR 95% CI P value 
Female 
Gender 
2.10 1.21 – 
3.65 
0.01 1.96 1.08 – 
3.56 
0.03 
Age* 1.25 0.89 – 
1.74 
0.20 1.29 0.91 – 
1.83 
0.16 
Baseline 
Weight* 
0.86 0.65 – 
1.14 
0.30 0.90 0.67 – 
1.21 
0.49 
Ethnicity       
 Black BASELINE --- --- --- --- --- 
 Asian 1.19 0.64 – 
2.20 
0.58 --- --- --- 
 Mix Race 0.71 0.32 – 
1.56 
0.40 --- --- --- 
Smoking Hist.       
 Never BASELINE --- --- --- --- --- 
 Ex-smoker 1.16 0.60 – 
2.22 
0.66 --- --- --- 
 Current 0.82 0.42 – 
1.60 
0.56 --- --- --- 
HIV Positive 3.74 1.78 – 
7.84 
<0.001 3.33 1.55 – 
7.14 
0.002 
Cavities on 
CXR 
0.62 0.31 – 
1.21 
0.16 --- --- --- 
Baseline TTP 1.00 1.00 – 
1.00 
0.05 1.00 1.00 – 
1.01 
0.06 
Table 2-5. Output from univariable and random-effects multivariable logistic regression with ³1 related grade 3 or 
4 AE as outcome. OR= Odds ratio, adjOR= Adjusted OR, 95% CI=95% confidence intervals. *Age and baseline 
weight were categorised as presented in Table 3 of this chapter 
3 Incidence of Adverse Events while taking 
Standard TB Therapy 
Doctors managing patients with TB disease are frequently working in resource-
constrained settings and it is critical that these resources are directed towards the 
patients with the greatest need. It is clear that appropriate allocation of resources is 
key to ensuring safe monitoring for patients taking TB treatment. An accurate 
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description of the timings when complications are most likely, and what form these 
complications take, would assist in the allocation of these limited resources.  
The section is focused on the issue of providing evidence for guidance for physicians 
developing monitoring schedules by elucidating the time periods during treatment 
where the risk of adverse events is greatest. The focus is on standard therapy and its 
toxicity profile for this section to allow for greater detail, given that this is the regimen 
that is currently in widespread use for TB treatment. 
3.1 Methods 
Grade 3 and 4 AEs were categorised according to the treatment phase in which they 
occurred. The start date for the event was used to categorise events as occurring in 
either intensive (0-8 weeks), continuation (9-26 weeks), or follow up (26 weeks to 18 
months) phases for patients on the standard therapy arm. The difference in weeks 
between the first dose of medication and the start date of the event was calculated, 
and the resulting number used to allocate the AE into a treatment phase. The total 
number of grade 3 and 4 AEs in each phase was counted separately and the 
proportions of these events that were considered related were calculated. The number 
of patients who experienced 0, 1, 2 or ≥3 related grade 3 or 4 AEs in each of the 
treatment phases was tabulated. The number of patients who experienced ≥1 SAE in 
each treatment phase was also included in the table. 
The stset command was used to create a survival-time dataset relating to the time 
to first grade 3 or 4 AE.  The start date for each event was converted to the day of 
treatment by creating a new variable containing the time difference in days between 
the patient’s first dose of drug and the event start date. Any events that occurred up 
to seven days before the first drug dose were considered to have happened on day 
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“zero”, and events that started earlier than this were excluded. This was to ensure that 
adverse events occurring close to the time of treatment initiation were included, to 
attempt to characterise the clinical picture for patients initiating treatment and also to 
include them as part of the analysis looking at the impact on treatment outcomes. A 
hazard curve was constructed to illustrate the probability of experiencing a clinically 
significant episode of drug toxicity at different time points after starting treatment. The 
hazard argument was used with the sts graph command to construct a smoothed 
hazard function with 95% confidence intervals using the weighted kernel smoothed 
hazard estimate to obtain an instantaneous rate of occurrence for the grade 3 and 4 
AEs.  
Deaths from any cause and withdrawals from treatment for any reason were also 
categorised according to the treatment phase in which they occurred. All deaths in the 
standard arm had a date of death recorded, and the difference between this date and 
the patient’s first dose of trial drug was used to calculate the time variable. Withdrawals 
in the REMoxTB database were flagged as either “treatment phase” or “follow up”, 
depending on whether the patient was still taking medication at the time of their 
withdrawal. This analysis included only withdrawals from the treatment phase for two 
reasons. First, the majority of withdrawals were in the patient’s treatment phase, and 
secondly my main interest in this thesis was to explore the effects of drug toxicity. As 
with other events, the treatment phase was determined by calculating the difference 
between the withdrawal date and the first dose date. 
3.2 Results 
The majority of grade 3 and 4 AEs occurred in the intensive phase of treatment, as 
Table 3-1 demonstrates. This was the case regardless of the relatedness assessment 
by the site doctor, with 135 of 250 (54.0%) grade 3 or 4 AEs and 80 of 113 (70.8%) 
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related grade 3 or 4 AEs reported in the first eight weeks of treatment. Four grade 3 
or 4 AEs occurred in follow up that were assessed as “possibly” related to treatment. 
These occurred between 31 and 61 weeks after starting treatment and related to poor 
diabetic control, diabetic ketoacidosis, spontaneous abortion, and anaemia. There 
was only one report of clinically significant deterioration in visual acuity on the standard 
arm, assessed as probably related to treatment. 
The hazard curve in Figure 3-1 demonstrates the adjusted risk for the occurrence of a 
related grade 3 or 4 AE in weeks since the first dose of standard TB therapy. The 
curve is non-linear and illustrates that the time period of highest risk for experiencing 
one of these events lies within the first two months after starting therapy, before rapidly 
falling in the intensive phase of treatment.  
 
Figure 3-1. Hazard Curve for Grade 3 or 4 Related Adverse Events According to Number of Weeks Since 
First Dose of Standard Therapy. Hazard function for the occurrence of a grade 3 or 4 related adverse event 
(with 95% confidence intervals) is plotted on the y axis, with the number of weeks following the first dose of 
standard tuberculosis therapy on the x axis. The rise in the hazard function after week 25 is accounted for by 2 
events reported as “possibly” related to study drug 
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 Intensive 
Phase 
(Weeks 0 – 8) 
 
n= 639 
Continuation 
Phase 
(Weeks 9 – 
26) 
n= 596 
Follow-up 
Phase 
(Month 7 – 
18) 
n= 569 
Total Grade 3 & 4 AEs  
Reported 
135 62 53 
 Related 
(% Total in Treat Phase) 
80 
(59.3%) 
29 
(46.8%) 
4 
(7.5%) 
No of Grade 3 AEs  
Reported 
100 48 33 
 Related  
(%Grade3 in Treat 
Phase) 
50 
(50.0%) 
23 
(57.5%) 
3 
(9.1%) 
No. Grade 4 AEs  
Reported 
35 14 20 
 Related  
(%Grade4 in Treat 
Phase) 
30 
(85.7%) 
6 
(42.9%) 
1 
(5.0%) 
System Organ Class of  
Related Events (% of Total 
G3 or G4 AEs in Treat Phase) 
   
 Hepatobiliary 25 (18.5%) 13 (21.0%) 0 (0.0%) 
 Musculoskeletal 15(11.1%) 7 (11.3%) 0 (0.0%) 
 Metabolism & Nutrition 9 (6.7%) 1 (1.6%) 2 (3.8%) 
 Blood & Lymphatic 5 (3.7%) 2 (3.2%) 1 (1.9%) 
No of Related Grade 3 or 4 
AEs per Patient (%n) 
   
 0 592 (92.6%) 581 (97.5%) 566 (99.5%) 
 1 33 (5.2%) 12 (2.0%) 2 (0.4%) 
 2 10 (1.6%) 1 (0.2%) 1 (0.2%) 
 ≥3 4 (1.0%) 2 (0.3%) 0 (0.0%) 
No of Patients  
with ≥1 SAE (% n) 
32 
(5.0%) 
18 
(3.0%) 
20 
(3.5%) 
 No of Patients with ≥1 
Related SAE (%n) 
17 
(2.7%) 
3 
(0.5%) 
2 
(0.4%) 
Mean No of SAEs  
per Patient  
1.78 1.39 1.60 
No of Withdrawals  
(%n) 
38 
(5.9%) 
26 
(4.4%) 
1 
(0.2%) 
No of Deaths 
(%n) 
5 
(0.8%) 
1 
(0.2%) 
10 
(1.8%) 
Table 3-1. Adverse events in standard arm by treatment phase. The number of grade 3 and 4 AEs are shown 
according to treatment phase along with the most common SOC for related events and the number of grade 3 or 
4 AEs experienced by patients in each treatment phase. Serious adverse events are shown in in each treatment 
phase regardless of severity grading. The treatment phases were not independent and the same patient could 
appear in more than one phase 
The related grade 3 or 4 AEs were most commonly hepatobiliary disorders, 
musculoskeletal disorders, and related to metabolism or nutrition. Figure 3-2 illustrates 
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the SOC assignment for all related grade 3 or 4 AEs reported on the standard therapy 
arm. Hepatobiliary disorders were most commonly “Hepatic enzyme increased” 
(47.3%), “Gamma-glutamyltransferase increased” (13.2%), and “Alanine 
aminotransferase increased” (10.5%). Musculoskeletal disorders were predominantly 
“Arthralgia” (31.8%), “Pain in extremity” (27.3%), or “Joint range of motion decreased” 
(13.6%). Lastly, metabolism and nutrition disorders most frequently referred to 
“Hyponatraemia” (33.3%), “Decreased appetite” (25.0%), or 
“Diabetes/hyperglycaemia/diabetic ketoacidosis” (24.9%). The breakdown of related 
grade 3 or 4 AEs according to treatment phase can be seen in Table 3-2. 
 
Figure 3-2. System Organ Class (SOCs) for all related grade 3 or 4 AEs reported for patients taking standard 
TB therapy. SOCs are arranged by descending frequency and bar chart values correspond to the percentage 
of the total number of events that fall into the SOC 
The SOCs for the 137 unrelated grade 3 or 4 AEs on standard therapy were most 
commonly respiratory, thoracic and mediastinal disorders (21.2%), blood and 
lymphatic disorders (18.3%), or metabolism and nutrition disorders (12.4%). 
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Hepatobiliary disorders accounted for 8 of 137 events (5.8%). “Haemoptysis” (31.0%), 
“Dyspnoea” (20.7%), and “Respiratory disorder” (13.8%) were the most commonly 
reported PTs among the 29 respiratory, thoracic and mediastinal disorders. The 
majority of the 25 blood and lymphatic disorders were “Haemoglobin decreased” 
(32.0%), “Anaemia” (20.0%), or “Prothrombin time prolonged” (20.0%). The highest 
number of reported PTs were “Weight decreased” (41.2%), and 
“Diabetes/hyperglycaemia” (35.3%) among the 17 Metabolism and Nutrition SOC 
events.  
SYSTEM ORGAN 
CLASS 
TREATMENT PHASE TOTAL 
 INTENSIVE CONTINUATION FOLLOW UP  
Hepatobiliary 
Disorders 
25 
(65.8%) 
13 
(34.2%) 
0 
(0.0%) 
38 
Musculoskeletal 
and Connective 
Tissue 
15 
(68.2%) 
7 
(31.8%) 
0 
(0.0%) 
22 
Metabolism and 
Nutrition 
9 
(75.0%) 
1 
(8.3%) 
2 
(16.7%) 
12 
Blood and 
Lymphatic 
System 
5 
(62.5%) 
2 
(25.0%) 
1 
(12.5%) 
8 
Skin and Subcut. 
Tissue 
6 
(75.0%) 
2 
(25.0%) 
0 
(0.0%) 
8 
Gastrointesinal 
Disorders 
6 
(85.7%) 
1 
(14.3%) 
0 
(0.0%) 
7 
Eye Disorders 
 
3 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
3 
Vascular 
Disorders 
 
3 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
3 
General 
Disorders 
 
1 
(50.0%) 
1 
(50.0%) 
0 
(0.0%) 
2 
Nervous System 
Disorders 
2 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
Table 3-2. System Organ Class (SOC) of grade 3 or 4 AEs assessed as related to standard TB therapy 
according to treatment phase, based on the start date of the event 
While the majority of withdrawals from treatment occurred in the intensive phase, the 
highest number of deaths in the standard treatment arm occurred in follow-up after 
patients completed their treatment (see Table 3-1). 38 of the 65 (58.5%) withdrawals 
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from treatment on the standard arm took place during the intensive phase and were 
most frequently due to “adverse drug reactions/toxicity” (24 of 65, 36.9%) or 
“withdrawal of consent” (13 of 65, 20.0%). 10 of the 16 (62.5%) deaths among patients 
taking standard therapy were after the patient had finished taking treatment and none 
of the 16 deaths were assessed as related to therapy. 8 (50%) of the deaths were 
reported as due to trauma, suicide, or unknown cause but possibly violent. Only 4 of 
the 16 (25.0%) deaths were due to TB disease. None of the deaths were assessed as 
related to standard therapy. 
The incidence of related SAEs followed a similar pattern to grade 3 or 4 AEs. Table 
3-1 demonstrates that the majority of patients who experienced ³1 SAE assessed as 
related to treatment did so in the intensive phase. In comparison, patients who 
experienced ³1 SAE (related or unrelated) were more evenly distributed across the 
phases of treatment. 
4 Outcomes from Treatment and the Impact of 
Toxicity 
While the aim in the previous two sections was to identify how best to implement 
change, in this section the goal was to investigate the association between the 
incidence of adverse events and outcomes on treatment with standard TB therapy. In 
order to create impetus for change there must be a demonstration of negative 
consequences if no action is taken. Policy makers must be convinced to distribute 
funding and this is achieved by demonstrating the potential for tangible positive impact 
from change in that area. A well-defined and robust description of the consequences 
from drug toxicity would help build the case for improving TB services.  
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This section focusses on the associations between drug toxicity and negative 
outcomes on treatment with standard TB therapy in the form of treatment failure, 
withdrawal from the REMoxTB trial, and death from any cause.  
4.1 Methods 
The reported outcomes for all AEs recorded on standard therapy were collected to 
investigate how the proportions of events with different outcomes differed according 
to severity grading and the relatedness assessment. The site doctor provided an 
outcome for each AE, which would be one of five options: “improved”, “ongoing”, 
“recovered”, “worsened”, or “death”. AEs were tabulated from the standard therapy 
arm according to their severity and outcome, with the exception of any events with 
“death” as an outcome as these events would be grade 4 by necessity. The Chi square 
test for significance was employed to detect differences in the proportions of events 
with different outcomes according to severity grading. Following this, the same 
tabulation and analysis was carried out using the related AEs only. The experimental 
arms were excluded from the analysis of outcomes as they failed to achieve non-
inferiority compared to standard therapy in the original REMoxTB publication. 
4.1.1 Defining Treatment Outcomes 
Data relating to culture status at eighteen months after randomisation on both 
Lowenstein-Jensen (LJ) slopes and Mycobacterial Growth Indicator Tube (MGIT) 
culture were available for the majority of patients randomised into the trial, including 
most of the patients who were withdrawn from treatment in the trial and referred on to 
the National Treatment Program. For the purposes of this analysis, patients who were 
culture negative at eighteen months were labelled as “cured”. If a patient was lost to 
follow up, or died before eighteen months in the trial, then they were considered cured 
if they had completed their treatment and had two or more consecutive negative 
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cultures (at different visits) prior to the date that they were last seen. Patients were 
considered as not having achieved cure if they were culture positive at eighteen 
months, were lost to follow up, or died with less than two consecutive negative cultures 
immediately prior.  
To generate more detailed treatment outcome groups the patients on standard therapy 
were further classified into one of three groups relating to treatment completion in the 
trial and death from any cause. Within these three categories patients were then 
labelled as either “cured” or “not cured” based on the definition above. This resulted 
in six different outcomes: 
1. Completed trial treatment and cured 
2. Completed trial treatment and not cured 
3. Early withdrawal from treatment in the trial and cured 
4. Early withdrawal from treatment and not cured 
5. Death from any cause and cured 
6. Death from any cause and not cured 
4.1.2 Adverse Events and Treatment Outcomes 
All patients taking standard TB therapy were grouped according to whether they had 
achieved microbiological cure as defined above and whether they had experienced ≥1 
(total or related-only) grade 3 or 4 AE. These data were tabulated and a Chi square 
test was used to investigate for statistical significance in the difference in proportions 
of cure between those patient groups with and without AEs. Binary logistic regression 
tested the relationship between experiencing ≥1 related grade 3 or 4 AE and achieving 
eventual cure. This analysis was performed as a univariable regression, and then 
subsequently as a multivariable model. The multivariable model included sex, age, 
baseline weight (clinical significance for these three), ethnicity (due to univariable 
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model significance) and HIV status (due to earlier reported association with AE 
incidence). 
Patients were then categorised as having experienced 0, 1, 2, or ≥3 related grade 3 
or 4 AEs on standard therapy. The number of patients in each of these categories was 
tabulated against the more detailed treatment outcomes to allow for comparison.  
4.2 Results 
Out of the total 230 grade 3 or 4 AEs reported on the standard arm, 200 (87.0%) were 
considered to have either improved or recovered (see Table 4-1). This was also the 
case for events thought to be related to treatment, where 104 of 111 (93.7%) events 
were classed as recovered or improved by the site doctors. Those events that ended 
in the patient’s death were not included in this count. 
 AE OUTCOME 
TOTAL IMPROVED ONGOING RECOVERED WORSENED TOTAL 
GRADE 3  57 
(32.0%) 
21 
(11.8%) 
98 
(55.1%) 
2 
(1.1%) 
178 
GRADE 4 23 
(44.2%) 
7 
(13.4%) 
22 
(42.3%) 
0 
(0.0%) 
52 
RELATED IMPROVED ONGOING RECOVERED WORSENED TOTAL 
GRADE 3 
 
33 
(44.0%) 
4 
(5.3%) 
36 
(48.0%) 
2 
(2.7%) 
75 
GRADE 4 
 
19 
(52.8%) 
1 
(2.8%) 
16 
(44.4%) 
0 
(0.0%) 
36 
Table 4-1. Reported outcomes for grade 3 or 4 AEs on the standard arm. Total and related-only events are 
shown, and row percentages included in each cell 
 While the majority of patients who experienced ³1 related grade 3 or 4 AEs achieved 
a microbiological cure this proportion was smaller than seen in the group of patients 
with no related grade 3 or 4 AEs. 523 of the 582 (89.9%) patients who did not 
experience a related grade 3 or 4 AE achieved microbiological cure as defined in 
Section 4.1.1. In comparison 42 of 57 patients (73.7%) who experienced ³1 related 
grade 3 or 4 AE achieved cure, as shown in Table 4-2. 
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 No. of 
Grade 3/4 
AEs 
Microbiological 
Cure 
No 
Microbiological 
Cure 
Total 
 
TOTAL 
0 464 
(90.8%) 
47 
(9.2%) 
511 
≥1 101 
(78.9%) 
27 
(21.1%) 
128 
 
RELATED 
ONLY 
0 523 
(89.9%) 
59 
(10.1%) 
582 
≥1 42 
(73.7%) 
15 
(26.3%) 
57 
Table 4-2. Rates of Microbiological Cure According to Number of Grade 3 or 4 Adverse Events Experienced by 
Patients Taking Standard TB Therapy. Patients are grouped by the number of AEs they experienced in the trial. 
The number of patients who were either cured or not cured of their TB are displayed with row percentages (Chi 
square test p value <0.001) 
Patients who experienced ³1 grade 3 or 4 AE were at significantly higher odds of 
failing to be cured by their treatment with standard TB therapy. Table 4-3 demonstrates 
that experiencing ≥1 grade 3 or 4 AE was significantly associated with not being cured 
of TB in a multivariable logistic regression model (adjOR 2.37, 95% CI 1.37 – 4.14, 
p<0.01). Table 4-4 also shows a comparable relationship was seen between ≥1 
related grade 3/4 AE and an outcome of not cured (adjOR 3.11, 95% CI 1.59 – 6.10, 
p<0.01). 
 
 
 
 
 
 
 
 
 
 84 
 
Baseline 
Characteristic 
OR 95% CI P value adjOR 95% CI P value 
³1 Grade 3 or 
4 AE 
2.64 1.57 – 
4.44 
<0.01 2.37 1.36 – 
4.14 
<0.01 
Female 
Gender 
1.13 0.67 – 
1.91 
0.63 0.97 0.54 – 
1.75 
0.93 
Age* 1.43 1.05 – 
1.95 
0.02 1.42 1.03 – 
1.95 
0.03 
Baseline 
Weight* 
0.85 0.66 - 
1.09 
0.20 0.96 0.72 – 
1.28 
0.76 
Ethnicity       
 Black BASELINE --- --- --- --- --- 
 Asian 1.82 1.03 – 
3.19 
0.04 1.66 0.88 – 
3.13 
0.12 
 Mix Race 1.33 0.69 – 
2.58 
 1.36 0.68 – 
2.69 
0.38 
Smoking Hist.       
 Never BASELINE --- --- --- --- --- 
 Ex-smoker 1.42 0.79 – 
2.56 
0.24 --- --- --- 
 Current 1.10 0.61 – 
1.97 
0.76 --- --- --- 
HIV Positive 0.93 0.35 – 
2.42 
0.88 0.85 0.01 – 
0.14 
0.76 
Cavities on 
CXR 
1.17 0.60 – 
2.27 
0.64 --- --- --- 
Baseline TTP 1.34 0.50 – 
3.57 
0.56    
Table 4-3. Output from univariable and multivariable logistic regression with failure to achieve microbiological 
cure as outcome, with all grade 3 or 4 adverse events included. OR= Odds ratio, adjOR= Adjusted OR, 95% 
CI=95% confidence intervals. *Age and baseline weight were categorised as presented in Table 3 of this chapter 
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Baseline 
Characteristic 
OR 95% CI P value adjOR 95% CI P value 
³1 Grade 3 or 
4 AE 
3.16 1.66 – 
6.05 
<0.01 2.63 1.30 – 
5.35 
<0.01 
Female 
Gender 
1.13 0.67 – 
1.91 
0.63 1.00 0.56 – 
1.80 
0.99 
Age* 1.43 1.05 – 
1.95 
0.02 1.42 1.03 – 
1.96 
0.03 
Baseline 
Weight* 
0.85 0.66 – 
1.09 
0.20 0.93 0.70 – 
1.24 
0.61 
Ethnicity       
 Black BASELINE --- --- --- --- --- 
 Asian 1.82 1.03 – 
3.20 
0.04 1.67 0.89 – 
3.14 
0.11 
 Mix Race 1.33 0.69 – 
2.58 
0.39 1.31 0.67 – 
2.61 
0.43 
Smoking Hist.       
 Never BASELINE --- --- --- --- --- 
 Ex-smoker 1.42 0.79 – 
2.56 
0.24 --- --- --- 
 Current 1.10 0.61 – 
1.97 
0.76 --- --- --- 
HIV Positive 0.93 0.35 – 
2.42 
0.88 0.90 0.32 – 
2.55 
0.85 
Cavities on 
CXR 
1.17 0.60 – 
2.27 
0.64 --- --- --- 
Baseline TTP 1.34 0.50 – 
3.57 
0.56 --- --- --- 
Table 4-4. Output from univariable and multivariable logistic regression with failure to achieve microbiological 
cure as outcome, with only grade 3 or 4 adverse events assessed as related to treatment included. AE= Adverse 
events, OR= Odds ratio, adjOR= Adjusted OR, 95% CI=95% confidence intervals. *Age and baseline weight 
were categorised as presented in Table 3 of this chapter 
 
Table 4-5 displays microbiological outcomes in the trial according to the patient’s 
status, based on whether they completed their treatment without an early withdrawal 
or died from any cause and the number of related grade 3 or 4 AEs they experienced 
during the trial. The proportion of patients who completed standard therapy and were 
cured of their disease can be seen to decrease between the patient group with no 
events reported (86.6%) down to those patients with ³3 grade 3 or 4 related AEs 
(25.0%). However among those patients with ³1 related grade 3 or 4 AE the majority 
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(39 of 57, 68.4%) still ultimately reached a microbiological cure, including those 
patients who were withdrawn early and referred on to the National Treatment Program. 
The majority of patients taking standard therapy who died in the trial did not experience 
any grade 3 or 4 AEs that were thought to be related to therapy. Ten of the sixteen 
patients did not experience any related event; while only 4 patients and 2 patients 
experienced 1 and 2 grade 3 or 4 AEs respectively. None of the patients who died 
experienced ³3 related grade 3 or 4 AEs, and 9 of the 16 (56.3%) had completed 
therapy and achieved microbiological cure before dying. 
Number 
Related 
G3/4 
AEs 
Completed 
Treatment 
Early Withdrawal 
from Treatment 
Death 
(Any Cause) 
 
 
TOTAL 
 Cured Not 
Cured 
Cured Not 
Cured 
Cured Not 
Cured 
0 504 
(86.6%) 
27 
(4.6%) 
13 
(2.2%) 
28 
(4.8%) 
6 
(1.0%) 
4 
(0.7%) 
582 
(91.1%) 
1 19 
(54.3%) 
2 
(5.7%) 
6 
(17.1%) 
4 
(11.4%) 
3 
(8.6%) 
1 
(2.9%) 
35 
(5.5%) 
2 4 
(28.6%) 
1 
(7.1%) 
4 
(28.6%) 
3 
(21.4%) 
0 
(0.0%) 
2 
(14.3%) 
14 
(2.2%) 
≥3 2 
(25.0%) 
0 
(0.0%) 
4 
(50.0%) 
2 
(25.0%) 
0 
(0.0%) 
0 
(0.0%) 
8 
(1.3%) 
TOTAL 529 
(82.8%) 
30 
(4.7%) 
27 
(4.2%) 
37 
(5.8%) 
9 
(1.4%) 
7 
(1.1%) 
639 
(100.0%) 
Table 4-5. Microbiological outcomes in the trial according to patient status. Patients are grouped according to the 
number of related grade 3 or 4 AEs experienced during the trial and whether treatment was completed in the trial 
or if the patient died at any time from any cause. Row percentages are demonstrated in the cells 
5 Incidence of Adverse Events across the three 
Treatment Arms 
The development of new TB drugs will require a balance between efficacy and the 
safety profile of any regimen to treat the disease in less than six months. In REMoxTB, 
the isoniazid and ethambutol arms demonstrated a cure rate of approximately 85% 
and 80% respectively. These are cure rates in keeping with those for some cancers 
that are now considered “curable”, and in a meta-analysis of the three randomised 
trials investigating four-month fluoroquinolone-containing regimens patients with a 
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lower bacillary burden receiving the shorter experimental regimens were found to have 
non-inferior outcomes compared to the same patients receiving standard TB therapy 
(Imperial et al., 2018). The safety profile of these experimental regimens could help to 
further clarify what, if any, role they have in the treatment of TB.  
While the experimental arms were not non-inferior to standard therapy, this section 
characterises the reported toxicity in the experimental arms according to treatment 
phase and compares this to the standard therapy arm. The intention was to investigate 
their potential for use in patients at higher risk of side effects from treatment. 
5.1 Methods 
The number of patients and the total number of grade 3 or 4 AEs in the experimental 
arms was collected and assigned to different treatment phases based on their start 
date. The start date of the AEs was used to calculate the number of days after the first 
drug dose, and the AEs in all three treatment arms were then assigned to one of three 
time windows: intensive phase (0 – 8 weeks), continuation phase (9 – 17 weeks), or 
continuation/placebo (17 – 26 weeks). The number of patients reporting ≥1 grade 3 or 
4 AE (either total or related-only) in each of the treatment phases was obtained for the 
three arms. The Chi square test was used to test for significant differences in the 
proportion of patients reporting ≥1 grade 3 or 4 AE between the treatment arms in 
each treatment phase.  
The time to first related grade 3 or 4 AE was calculated for each patient in the treatment 
arms, using the stset command, and Kaplan Meier curves constructed with risk 
tables. A variable containing the time in weeks since first medication dose was created 
for each AE using the event start date and the first dose date. The earliest grade 3 or 
4 related AE was considered a failure event for each patient. The difference in time to 
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first AE was tested using the logrank test instead of Cox regression, as visual 
assessment showed the survival curves crossed and the proportional hazards 
assumption was violated. 
The related grade 3 and 4 AEs were labelled according to their SOC, and totals 
calculated for each treatment arm. As before, preferred terms were used to group 
events from the “Investigations” SOC into more clinically relevant SOCs. The events 
were tallied based on their treatment arm and presented as a bar chart with the SOCs 
in descending order of frequency. 
Finally, the numbers of patients who were withdrawn from treatment or died was 
investigated in the different arms. All the patients across the treatment arms who were 
early withdrawals from treatment or deaths from any cause were selected out, and 
then assigned the event of withdrawal or death to one of the three treatment phases 
in the treatment arm using its start date. The Kruskal-Wallis test was used to test the 
variation in timing of withdrawal and timing of death between the three arms as a non-
parametric alternative to analysis of variance testing because of a non-normal 
distribution of the timing data.  
5.2 Results 
A higher number of grade 3 or 4 AEs occurred in the standard therapy arm compared 
to the two experimental arms. Patients on the standard therapy arm reported 113 
related grade 3 or 4 AEs, compared to 63 & 65 related events in the isoniazid and 
ethambutol arms respectively. The total number of grade 3 or 4 AEs was similar 
irrespective of treatment with 250, 217, and 209 events reported across the standard, 
isoniazid and ethambutol arms as shown in Table 5-1. The number of patients 
experiencing ≥1 related grade 3 or 3 AE was found to be significantly different in the 
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intensive phase, with the highest number of patients experiencing events receiving 
standard therapy, and this phase was when the majority of related grade 3 or 4 AEs 
occurred in all three treatment arms. 
There was no significant difference in the number of grade 3 or 4 AEs occurring 
between the three treatment arms during Months 5 and 6. There were 2 events 
reported in the standard and ethambutol arms, and 3 events from the isoniazid arm in 
this time window. The number of patients mirrored these values; with each patient 
experiencing only one related grade 3 or 4 AE. 12, 13, and 17 patients reported ≥1 
grade 3 or 4 AE in Months 5 and 6 on the standard, isoniazid and ethambutol arms 
respectively (p=0.57). There was no significant difference in the number of patients 
reporting ≥1 grade 3 or 4 AE (p=0.81) or related AE (p=0.32) during Months 3 and 4, 
when all three arms were receiving active treatment (see Table 5-1). 
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  Standard 
Arm 
(2EHRZ/ 
4HR) 
n=639 
Isoniazid 
Arm 
(2MHRZ/ 
2MHR) 
n=655 
Ethambutol 
Arm 
(2EMRZ/ 
2MR) 
n=636 
P value 
 
 
Intensive 
Phase 
 
(M0-M2) 
Patients 
with ≥1 
G3/4 AEs 
(Tot No 
AEs) 
 
85 
(135) 
 
83 
(119) 
 
66 
(114) 
 
0.24 
 
Patients 
with ≥1 
Related 
G3/4 AEs 
(Tot No 
AEs) 
 
47 
(80) 
 
36 
(51) 
 
25 
(44) 
 
0.03 
 
 
 
Continuation 
Phase 
 
(M3-M4) 
Patients 
with ≥1 
G3/4 AEs 
(Tot No 
AEs) 
 
29 
(47) 
 
25 
(32) 
 
26 
(37) 
 
0.81 
 
Patients 
with ≥1 
Related 
G3/4 AEs 
(Tot No 
AEs) 
 
14 
(27) 
 
9 
(9) 
 
16 
(19) 
 
0.32 
 
 
 
Cont/Placebo 
Phase 
 
(M5-M6) 
Patients 
with ≥1 
G3/4 AEs 
(Tot No 
AEs) 
 
12 
(15) 
 
13 
(17) 
 
17 
(21) 
 
0.57 
 
Patients 
with ≥1 
Related 
G3/4 AEs 
(Tot No 
AEs) 
 
2 
(2) 
 
3 
(3) 
 
2 
(2) 
 
0.88 
 
TOTAL* Total 
G3/4 AEs 
(Related 
G3/4 AEs 
only) 
 
 
250 
(113) 
 
 
217 
(64) 
 
 
209 
(66) 
 
 
N/A 
Table 5-1. Comparing Adverse Events in Treatment Arms. The number of patients experiencing one or more 
grade 3 or 4 adverse event, and those who experienced events considered related to treatment only, are shown 
according to the treatment phase and study arm in the trial. The numbers of events are shown in brackets. The 
Chi square test was used to test for significant differences between the treatment arms for the proportions of 
patients who experienced ≥1 event in each treatment phase, for both total and related-only grade 3 or 4 AEs. 
Number of patients shown is number for that treatment window: 4 patients with ≥1 related AE appear in more 
than one time window on standard therapy, and 3 patients in both the isoniazid and ethambutol arms. 
Additionally, two patients excluded from the total count on the standard arm as no start date for AEs recorded * 
AEs that occurred in the follow-up phase (months 7-18) included in total 
The time to first related grade 3 or 4 AE was similar in all three treatment arms, with 
no statistically significant difference detected. The Kaplan Meier curves in Figure 13 
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illustrate the majority of events occurring in the intensive phase followed by a plateau 
from approximately 9 weeks after starting treatment (log rank p=0.19 for comparing 
standard therapy and isoniazid arm; p=0.07 for standard therapy and ethambutol arm). 
The drop seen at 8 weeks of treatment in the number of patients at risk is driven by 
one site reporting 40 grade 3/4 AEs (30 considered related) from all treatment arms in 
a 30-week time window of the trial (the site reported a total of 146 grade 3/4 AEs). 
90% (36 of 40) of these events were reported in the intensive phase of the patient’s 
treatment. 
 
Figure 5-1. Kaplan Meier Curves for time to First Event for Related Grade 3 or 4 Adverse Events in the 
Treatment Arms. The time to first event is plotted for all the patients at risk in the standard (blue), isoniazid (red) 
and ethambutol (green) arms 
Hepatobiliary disorders were the most common SOC reported for related grade 3 or 4 
AEs across all the treatment arms (see Figure 5-2). Within the SOC, the three most 
common PTs were “Hepatic enzyme increased” (48.1%), “AST increased” (13.5%), 
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and “ALT increased” (12.5%). Musculoskeletal and connective tissue disorders were 
the second most common SOC and the two most frequent PTs reported were 
“Arthralgia” (30.3%) and “Pain in extremity” (21.2%). Standard therapy patients 
experienced more grade 3 or 4 related AEs than patients allocated to the experimental 
arms in the five most common SOCs, with the exception of blood and lymphatic 
disorders. Patients receiving the ethambutol arm experienced the highest number of 
these events and they were most commonly “Haemoglobin decreased/anaemia” 
(50.0%) and “Prothrombin time prolonged” (25.0%).  
 
Figure 5-2. Bar chart to illustrate the System Organ Class (SOC) for related grade 3 or 4 AEs in the three 
treatment arms used for REMoxTB. SOCs are presented in descending order based on the total number of 
events across the three treatment arms, and then individual counts for the SOC by treatment arm are 
presented using a colour-coded scheme (as per legend) 
The majority of early withdrawals from treatment occurred in the intensive phase for 
all three treatment arms. Table 5-2 shows that 59.4%, 69.6%, and 50.9% of the 
withdrawals from the standard, isoniazid and ethambutol arms occurred in the 
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intensive phase. “Withdrew consent” (25.0%), “Adverse reaction/toxicity” (21.3%), and 
“MDR/Drug resistance” (15.0%) were the three most common reasons for withdrawal 
from treatment on the isoniazid arm. On the ethambutol arm, “Protocol violation” 
(22.4%), “Adverse reaction/toxicity” (20.7%), and “Withdrew consent” (20.7%) were 
the most frequently reported reasons for withdrawal from treatment. The median 
timing for withdrawal from treatment was 40 days (IQR 21.0 - 98.5), 34 days (IQR 11.5 
– 87.0), and 52 days (IQR 27.0 – 118.0) on the standard, isoniazid and ethambutol 
arms (p value 0.14 by Kruskal-Wallis with ties). 
  2EHRZ/4HR 2MHRZ/2MHR 2EMRZ/2MR 
 
 
WITHDRAWAL 
FROM 
TREATMENT 
Intensive 
(M0-M2) 
38 
(59.4%) 
55 
(69.6%) 
28 
(50.9%) 
Continuation 
(M3-M4) 
13 
(20.3%) 
12 
(15.2%) 
14 
(25.5%) 
Cont/Placebo 
(M5-M6) 
13 
(20.3%) 
12 
(15.2%) 
13 
(23.6%) 
TOTAL 64 79 55 
 
 
 
 
DEATH 
Intensive 
(M0-M2) 
5 
(31.2%) 
5 
(33.3%) 
3 
(25.0%) 
Continuation 
(M3-M4) 
0 
(0.0%) 
2 
(13.3%) 
2 
(16.7%) 
Cont/Placebo 
(M5-M6) 
1 
(6.3%) 
2 
(13.3%) 
3 
(25.0%) 
Follow-up 
(M7-M18) 
10 
(62.5%) 
6 
(40.0%) 
4 
(33.3%) 
TOTAL 16 15 12 
Table 5-2. Early withdrawals from treatment and deaths from any cause at any time in each of the three 
treatment arms. The number of withdrawals in follow up are not shown in this table. Cell percentages refer to 
proportion of column total 
There were fewer deaths reported on both experimental arms compared to the 
standard therapy arm. On the isoniazid and ethambutol arms there were 15 and 12 
deaths, respectively, compared to 16 on standard therapy. There were 6 of 15 (40%) 
deaths on the isoniazid arm that were due to trauma/violence or unknown cause (but 
possibly violent) and 4 of 15 (26.7%) deaths related to TB. 5 of 12 (41.7%) deaths on 
the ethambutol arm were related to TB and only one death was traumatic (a road traffic 
accident) with no deaths reported as even possibly due to violence. Across the three 
treatment arms 15 of 43 (34.9%) of deaths were at least possibly due to 
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violence/trauma, 13 of 43 (30.2%) were due to TB disease, and 15 of 43 (34.9%) were 
due to other causes (e.g. renal failure, other infections etc). One death on the isoniazid 
arm was considered possibly related to treatment (“Guillan Barre Syndrome”) and 2 
were considered possibly related (“hepatitis of unknown cause” and “renal failure”) on 
the ethambutol arm.  The median time of death was 35.6 weeks (IQR 5.0 – 45.2), 21.9 
weeks (IQR 6.4 – 40.1), and 21.2 weeks (IQR 8.0 – 55.6) on the standard, isoniazid 
and ethambutol arms (p=0.23 by Kruskal-Wallis with ties). 
6 Discussion 
This chapter demonstrates that approximately 10% of patients experienced toxicity 
assessed as being related to standard TB therapy by the treating physician in the 
REMoxTB trial. This toxicity most commonly took the form of hepatotoxicity, and 
females and HIV positive patients were significantly more likely to experience clinically 
significant adverse events while taking treatment. The two experimental arms in the 
trial reported lower numbers of adverse events, suggesting they are less toxic 
treatment options, but this must be balanced against their failure to achieve non-
inferiority when compared to standard therapy treatment outcomes.  
The existing literature quotes rates of approximately 1 - 40% for patients experiencing 
toxicity related to therapy (Saukkonen et al., 2006; Marra et al., 2007; Kumar et al., 
2010; Devarbhavi, 2011; Lorent et al., 2011; Zhang et al., 2015; Njuguna et al., 2016; 
Yang et al., 2016; Sekaggya-Wiltshire et al., 2017), however most commonly these 
publications are observational or retrospective and related to hepatotoxicity. The 
estimate of approximately 10% of patients experiencing toxicity related to treatment is 
the product of detailed safety reporting in a large, prospective trial and while some 
confidence can be drawn from the data collection methods it still needs to be 
remembered that this is essentially a cohort study and can therefore still be subject to 
 95 
bias. Two further caveats are that the proportion of patients experiencing any 
significant AE was 20%, closer to the upper limit to the range in the existing literature, 
and that the relatedness assessment is of course subject to bias on the part of the 
physician carrying out the assessment (Hillman et al., 2017).  
The majority of clinically significant adverse events occurred in the intensive phase of 
treatment with implications for the routine monitoring of patients taking standard TB 
therapy. Pyrazinamide could account for most of the related grade 3 or 4 AEs in 
standard therapy occurring in the intensive phase, although this is far from certain. 
Pyrazinamide is a drug with a well-recognised toxicity profile (Horsfall et al., 1979; 
Jenner et al., 1981; Steele and Des Prez, 1988; Schaberg, Rebhan and Lode, 1996; 
Jasmer et al., 2002; Lee et al., 2002; Yee et al., 2003), while ethambutol (the other 
drug only present for the intensive phase) is recognised as having fewer side effects. 
Additionally, hepatotoxicity and arthralgia were among the most common events and 
these are frequently reported side effects of pyrazinamide. The sterilising activity of 
pyrazinamide makes it an essential component of standard therapy (British Medical 
Research Council, 1974; Grosset, 1978; Association, 1982; Snider et al., 1984), but 
there is still some uncertainty surrounding its ideal dosing schedule (British Medical 
Research Council, 1981; Hong Kong Chest Service/Tuberculosis Research Centre, 
1989; Jindani, Nunn and Enarson, 2004; Chang et al., 2007) and there is evidence of 
both a dose-response relationship with toxicity (Service, 1959) and also idiosyncratic 
drug-induced liver injury (Pasipanodya and Gumbo, 2010). There is a need to direct 
more research to optimise the most effective and least toxic dose alongside the other 
components of the standard regimen. 
HIV positive patients, female patients, and patients with a lower weight at baseline 
were shown to be at risk for related clinically significant adverse events, and this 
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should be reflected in clinical practice. While existing guidelines acknowledge the 
issues surrounding the management of TB-HIV co-infection (Saukkonen et al., 2006; 
World Health Organization, 2010; Nahid et al., 2016), there is no reference to female 
gender as a risk factor for a more complicated treatment course (outside of 
pregnancy). There is some evidence in the literature regarding higher observed rates 
of toxicity for both males and females (Marra et al., 2007; Pettit et al., 2013; Sadiq et 
al., 2015; Zhang et al., 2015), and subsequent work on treatment outcomes by gender 
has shown that males with cavitation on the ethambutol arm in REMoxTB had 
especially poor outcomes (Murphy ME et al, in review). However, it is unclear if 
reporting bias has played a role in AE recording for the trial (McGauran et al., 2010) 
and the likelihood for patients themselves to attribute any symptoms to the medication: 
previous work has identified discrepancies between males and females in regards to 
healthcare-seeking behaviour (Samal, 2016; Thompson et al., 2016; Hawkins et al., 
2017). Nonetheless, clinicians should have a low threshold for closer monitoring of 
female patients, those with a low weight at baseline, and HIV positive patients taking 
standard TB therapy. 
Diabetes and its complications accounted for a large proportion of the adverse events 
classed as “Metabolism and Nutrition Disorders” in this analysis. It is projected that by 
2040 there will be approximately 640 million people with either diagnosed or 
undiagnosed diabetes (International Diabetes Federation, 2017), and the majority of 
these will be found in low- and middle-income countries (Dooley and Chaisson, 2009; 
International Diabetes Federation, 2017). In light of this, there has been growing 
interest in the influence of diabetes on TB over the past decade (Dooley and Chaisson, 
2009). Meta-analyses of existing publications relating to TB and diabetes have shown 
a relative risk of 3.1 for developing TB in diabetic patients (Jeon and Murray, 2008) 
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and also an odds ratio of 1.69 for an unfavourable treatment outcome (treatment 
failure or death) in diabetic patients compared to non-diabetic patients(Baker et al., 
2011). As well as diabetes leading to increased risk of active TB disease, there is an 
effect of active TB on glucose homeostasis. Several studies have demonstrated 
impaired glucose tolerance among patients with TB (Nichols, 1957; Zack, Fulkerson 
and Stein, 1973), but this most commonly returns to normal within 3 months of 
completing treatment (Zack, Fulkerson and Stein, 1973; Oluboyo and Erasmus, 1990). 
Whether the patients reported as diabetic in REMoxTB had a true diagnosis or a 
transient loss of blood glucose control which then normalised is unclear, yet the 
prevalence of AEs in this chapter that are related to glucose dysregulation reinforces 
the need for coordinated care between physicians specialising in TB and diabetes. 
The best approach to screening patients with diabetes for the presence of either latent 
or active TB remains uncertain (World Health Organization and the International Union 
Against Tuberculosis and Lung Disease., 2011); however, the fact that 35% of the 
“Metabolism and Nutrition” adverse events (the third most common SOC among 
patients on standard TB therapy) involved diabetes or dysglycaemia lends weight to 
the argument that a co-ordinated approach between between TB physicians and 
diabetologists to screening and management is a area that merits further attention. 
This chapter has shown that patients who experienced one or more clinically 
significant adverse event were more likely to fail their TB treatment, compared to 
patients who did not experience a clinically significant event. The reasons for this 
association are not clear and should prompt further investigation. It may be that this is 
due to other underlying conditions that also contribute to a poor outcome or the effect 
of toxicity on adherence to therapy. Patients in REMoxTB were managed under clinical 
trial conditions with approximately 90% of patients achieving cure (Gillespie et al., 
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2014), however it is recognised that the cure rate with HRZE for drug-sensitive disease 
can fall to approximately 80% in real-world settings (WHO, 2017) and the relationship 
demonstrated here may help explain this finding. 
Treatment interruption is another possible explanation for the association between 
grade 3 and 4 AEs and the increased odds of failing treatment. Most of the clinically 
significant AEs were reported as either resolved or improved as their outcome, 
suggesting that the event did not have persisting sequelae that directly led to a poor 
treatment outcome. However, treatment interruptions have a recognised association 
with poor outcomes for TB patients (Ormerod and Prescott, 1991; Pablos-Méndez et 
al., 1997; Chee et al., 2000) and it is conceivable that medication would have been 
withheld in the context of events that were thought to be either related or unrelated to 
the treatment due to symptoms. Unfortunately, the medication adherence data was 
not adequately recorded by the sites during the trial to allow it to be used in this 
analysis: despite adherence data being available for over 90% of randomised study 
participants, there were inconsistent entries in many cases and the trial data scientists 
used either simple deduction after manual review or automated imputation methods 
to complete the dataset (exact number of participants data affected was unavailable). 
Additionally, there were concerns raised at several sites regarding the source 
documentation for medication adherence (although not for other source 
documentation). Following internal discussion, it was felt that the dataset could be 
used to assess whether participants overall adherence was greater than the threshold 
of 80% adherence but it could not be relied upon to accurately relate discrete episodes 
of toxicity to medication interruptions. 
There is some indication that the experimental regimens in REMoxTB could have a 
role as less toxic treatment options for use in patient groups deemed to be “high-risk” 
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by the treating clinician. The evidence presented in this section demonstrates a lower 
rate of adverse events in the two experimental arms, but this needs to be balanced 
against their failure to achieve non-inferiority compared to standard TB therapy for 
treatment outcome (Gillespie et al., 2014). While the experimental arms failed to 
achieve non-inferiority compared to standard TB therapy in trial conditions, the cure 
rates achieved with standard TB therapy in the field are closer to 80% (WHO, 2017) 
and this is very similar to the cure rates seen in the isoniazid and ethambutol arms. 
Furthermore, the optimal duration of the experimental regimens is not clear and they 
could perhaps show improved rates of cure if carried on to six months with lower rates 
of toxicity than standard therapy. This is plausible given that the majority of AEs 
occurred in the first two months on all three treatment arms. 
There was little difference in the number of related AEs in months 5 and 6 between 
those receiving active treatment and those on placebo.  This does, perhaps, 
emphasise the importance of TB induced pathology on the presence and reporting of 
significant medical events. Reducing toxicity associated with medication is one of the 
factors driving the development of shorter treatment regimens for TB (Zumla et al., 
2014); however, this finding suggests that concerns about toxicity may not be as 
important as previously thought. Again, it should be highlighted that while the 
experimental arms were less toxic, they were also less effective. Whether there is a 
causal relationship between these observations is not known. This could mean that 
the motivation for shortening treatment needs to focus around patient acceptability 
and logistical benefits of few doses, a reduced number of clinic appointments, and 
enhanced adherence.  
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6.1 Limitations 
This study is limited by innate reporting bias and reliance on a subjective assessment 
of severity in many cases (for example, pain scores).  An example of this is the 
reporting activity at one site in the trial. After a trial pause this site reported almost one 
third of its total grade 3/4 AEs, and assessed 75% of them as being related to 
treatment in a 30-week period. Attributing causality to AEs has been shown to produce 
unreliable and subjective data (Hillman et al., 2017) and caution has been advised 
when using trial data to evaluate drug safety profiles (Hammad, Pinheiro and 
Neyarapally, 2011). Given the proximity of the recent pause in trial recruitment it could 
be that there was concern over the safety of the experimental regimens and that in a 
double-blind trial this translated into a lower threshold to both report events and to 
attribute causality to the drugs.  
While there is still merit in using AEs to investigate drug safety profiles, the often 
subjective nature of the reporting is a limitation. This analysis focusses on clinically 
significant adverse events (grade 3 or 4 severity) associated with tuberculosis therapy 
as symptoms were not captured. There are also the potential dangers of drawing 
conclusions based on relatedness assessments for AEs (Darssan, Thompson and 
Pettitt, 2014; Hillman et al., 2017) and to this end both total and related AEs in the 
analysis have been presented.  
6.2 Conclusion 
The work presented in this chapter has shown that most adverse events occur during 
the intensive phase of treatment with female patients, those patients with a lower 
baseline weight and those who are HIV positive constituting a demographic that is 
most at risk of adverse events.  Additionally, those who experienced clinically 
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significant drug related-toxicity while taking standard TB therapy were at greater risk 
of failing treatment. From this it can be seen that there is a need to improve our 
methods of detecting and managing patients experiencing toxicity, and that there is 
real need for novel drugs with more favourable toxicity profiles and preserved efficacy 
in treating active pulmonary TB. These data provide an evidence base to plan future 
research and to support improved treatment guidelines. Tuberculosis remains a global 
health threat, predominantly affecting a vulnerable and disadvantaged population, and 
this chapter illustrates the need for clinicians to be quick to respond to side effects 
from treatment to ensure their patients have the best chance of achieving a cure. 
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Chapter Four: Liver Toxicity during 
Tuberculosis Treatment 
1 General Introduction 
Hepatotoxicity was shown in the previous chapter to be the most common form of 
toxicity during treatment with standard tuberculosis (TB) therapy, and this chapter will 
characterise the pattern of liver enzyme elevations on treatment in more detail. Liver 
enzyme elevations and drug-induced liver injury (DILI) are recognised side effects of 
standard TB therapy. The reported rates of hepatotoxicity on standard therapy vary 
between 5-30% (Thompson et al., 1995; Tost et al., 2005; Saukkonen et al., 2006; 
Shu et al., 2013), and this range is related to the variable definitions used in the 
literature (Devarbhavi, 2012; Saukkonen, Powell and Jereb, 2012). For example, pre-
existing liver disease may be defined as  elevated liver enzyme levels at baseline 
(Ormerod et al., 1998; Saukkonen et al., 2006), previous hepatitis B or C infection 
(Ungo et al., 1998; Kwon et al., 2007; De Castro et al., 2010; N.-T. Wang et al., 2016), 
or established cirrhosis. 
Hepatotoxicity has been associated with treatment interruptions, increased patient 
morbidity, and poorer treatment outcomes to greater or lesser degrees (Shang et al., 
2011; Pandit, Sachdeva and Bafna, 2012; Seaworth, Armitige and Griffith, 2013; Chou 
et al., 2014). Current guidelines for the monitoring of patients taking standard TB 
therapy and the management of liver enzyme elevations on treatment are largely 
based on expert opinion. The British Thoracic Society (BTS) guidelines recommend 
treatment interruption when ALT or AST are elevated to five times the upper limit of 
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normal or when bilirubin rises above the upper limit of normal (Ormerod et al., 1998). 
The American Thoracic Society (ATS), in contrast, recommends interruption when 
hepatic enzymes are greater than three times the upper limit of normal with symptoms 
or jaundice, or more than five times the upper limit of normal in asymptomatic patients 
(Saukkonen et al., 2006). Furthermore, the European Respiratory Society (ERS) 
recommends withholding potentially hepatotoxic medications (H, R, and Z) if 
transaminases are greater than five times the upper limit of normal (Migliori et al., 
1999). However, the timing and magnitude of elevations in the serum transaminases 
over the course of treatment in the entire patient population, with and without 
symptoms, and the outcome of treatment-related enzyme changes, remain unclear. 
This makes the appropriate management of liver toxicity, including timing of treatment 
interruption and re-introduction uncertain (Saukkonen, 2010).  
In 2011 the DILI Expert Working Group published a consensus statement to define 
criteria for use in the diagnosis of “true” DILI (Aithal et al., 2011). Their motivation was 
to produce guidance that could be applied in both routine clinical practice and in trial 
settings to increase the chance of a drug’s hepatotoxic potential being identified early, 
prevent unnecessary treatment interruptions, and avoid delays in reaching the correct 
diagnosis where liver enzyme elevations could potentially distract from the actual 
underlying pathology. In this document DILI is defined as any of the following: alanine 
aminotransferase (ALT) ³5x the upper limit of normal (ULN), alkaline phosphatase 
levels ³2xULN, or ALT ³3xULN with simultaneous bilirubin >2xULN. 
Pre-existing liver disease, HIV infection, female gender, increasing age, and alcohol 
excess have previously been linked with an increased risk of clinically significant 
hepatotoxicity during treatment (Teleman et al., 2002; Yee et al., 2003; Fauzi et al., 
2004; Fernández-Villar et al., 2004; Chou et al., 2014; Hosford et al., 2014; Yimer et 
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al., 2014). Whether a patient is considered to be a “slow acetylator” based on their 
NAT2 genotype has also been linked to a higher risk of hepatotoxicity when taking 
regimens containing isoniazid (Huang et al., 2002; Ng et al., 2014).  
In the REMoxTB trial (Gillespie et al., 2014) liver biochemical tests were performed at 
regular intervals throughout treatment irrespective of the clinical picture. This presents 
an opportunity to accurately characterise the patterns of enzyme elevations seen in a 
complete population of patients taking standard TB therapy. This chapter will 
investigate these patterns with the following research questions: 
• What was the distribution of peak liver enzyme results for all patients taking 
standard TB therapy? 
• What was the timing of peak liver enzyme results on standard TB therapy? 
• Which patient groups were at greater risk of clinically significant elevations? 
• What is the association between significant liver elevations and treatment 
outcome? 
• What was the pattern of peak liver enzyme results on the experimental 
regimens? 
• What was the effect of individual drugs in the regimen on peak enzyme results? 
2 Magnitude of Peak Liver Enzyme Elevations on 
Standard TB Therapy 
The pattern of peak liver enzyme elevations, with and without symptoms, experienced 
by patients taking standard TB therapy is not accurately known. The majority of studies 
available are retrospective and observational, and relate to clinically apparent 
episodes of hepatotoxicity that are then confirmed with biochemical tests (Shang et 
al., 2011; Wu et al., 2012; Chou et al., 2014; Abbara et al., 2017). Knowledge of the 
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pattern of liver enzyme elevations in asymptomatic patients would provide clinicians 
with an evidence-based framework to guide decisions to withhold treatment and 
hopefully reduce the number of unnecessary interruptions to TB treatment. 
This section addresses the magnitude of enzyme elevations detected for all patients 
taking standard TB therapy in REMoxTB. Total bilirubin and international normalised 
ratio (INR) results, and cases of DILI are also described along with the symptom profile 
for those patients with clinically significant elevations.  
2.1 Methods 
Patients were included in the analysis reported in this chapter if they had received at 
least one dose of TB treatment and had liver biochemical tests (LBT) measured two 
times or more, with at least one measurement after the first dose of medication. LBT 
results from between fourteen days before the first dose of medication and up to seven 
days after the last dose of trial medication were eligible for the analysis. All LBT results 
are presented as multiples of the ULN to account for variations in the normal range for 
the tests at the local laboratories. 
2.1.1 Peak ALT and AST Results for all Patients 
The peak ALT and AST values for all patients suitable for inclusion in the analysis 
were obtained from the dataset. The distribution was assessed using histograms and 
inverse normal plotting, and the median values for the peak ALT and AST for all 
patients taking standard TB therapy was determined. 
2.1.2 Drug-induced Liver Injury and Clinically Significant Liver 
Enzyme Elevations  
In this analysis DILI was defined as either ALT ≥5xULN or ALT ≥3xULN with total 
bilirubin >2xULN, based on the 2011 international DILI Expert Working Group 
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consensus statement (Aithal et al., 2011). All ALT elevations ≥3xULN (with or without 
elevated bilirubin or INR) were considered “clinically significant” based on the 
thresholds used by both the BTS and ATS guidance (Ormerod et al., 1998; Saukkonen 
et al., 2006). Patients were then categorised according to their peak ALT result based 
on these definitions. 
Data relating to symptoms were obtained from the trial adverse event reporting 
system. All events recorded within a time window of seven days before until seven 
days after the peak ALT result were collected and reviewed for patients who 
experienced either DILI or clinically significant ALT elevations. Those events 
belonging to gastrointestinal or hepatobiliary System Organ Classes were then 
manually reviewed and any containing information on symptoms were flagged and 
totalled.  
2.1.3 Additional Hepatotoxic Factors and Causality Assessment for 
Liver Enzyme Elevations  
The Serious Adverse Event (SAE) narratives for the REMoxTB trial for all patients with 
a peak ALT ≥3xULN who had experienced one or more SAE were reviewed for 
information regarding treatment interruptions, herbal medications, alcohol use and 
additional tests that were carried out. Additionally, where sufficient information was 
available, the Roussel-Uclaf Causality Assessment Method (RUCAM) (Benichou, 
Danan and Flahault, 1993; Danan and Benichou, 1993) was applied to test for 
evidence of a causal relationship between standard TB therapy and a peak ALT 
≥3xULN.  
A table detailing the criteria used to apply the score can be found in Appendix 2. The 
calculated score can range from -9 to +14 and a score of 0 or less indicates that the 
drug is “excluded”, scores of 1-2 means it is “unlikely” to be the cause, 3-5 that it is 
 107 
“possible” it is the cause, 6-8 that is “probable”, and finally scores of greater than 8 
mean the drug is considered as “highly probable” in terms of a causal relationship to 
any liver dysfunction 
2.1.4 Baseline Liver Disease and Liver Enzyme Elevations 
Baseline liver disease and its relationship to liver elevations on treatment was explored 
by identifying patients with evidence of Child-Pugh disease A or B (Cholongitas et al., 
2005), and those patients with baseline ALT >1xULN. A regular expression search 
was carried out for the terms “ascites”, “cirrhosis”, “child”, “hepatic”, and “liver” in the 
adverse event records. The Child-Pugh scoring criteria, as detailed in Appendix 2, was 
applied to those patients with evidence of chronic liver disease within one month of 
their first dose of trial medication to categorise those with stage A or B liver disease. 
2.2 Results 
A total of 639 patients from the standard therapy arm were eligible for inclusion in this 
analysis. There were 640 patients initially randomised into the standard therapy arm 
but one patient did not receive any medication. 
2.2.1 Peak ALT and AST Results for all Patients Receiving Standard 
TB Therapy 
The median peak ALT value was 0.83xULN (IQR 0.56 – 1.35) and the median peak 
AST value was 1.02 (IQR 0.73 – 1.48) for all patients taking standard TB therapy. The 
histograms in Figure 2-1 show the distribution of the peak liver enzyme results and 
these were not normally distributed on the inverse normal plots.  
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Figure 2-1. Histograms and inverse normal plots for the peak ALT and AST values for patients receiving 
standard TB therapy 
The median value for both ALT and AST at protocol scheduled visits is shown in Figure 
2-2, where it can be seen that the median AST result had a slight upward trend (from 
a median value of approximately 0.6xULN to 0.7xULN) during treatment and was 
consistently higher than the median ALT at every visit. 
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Figure 2-2. Median peak ALT and AST results at protocol scheduled visits as xULN 
2.2.2 Drug-induced Liver Injury and Clinically Significant Liver 
Enzyme Elevations  
There were 22 of 639 (3.4%) patients taking standard TB therapy who met the criteria 
for DILI as defined in Section 2.1.2. Among these 22 patients, 8 patients reported 
diarrhoea and/or vomiting, 10 reported nausea, and 3 reported abdominal pain within 
two weeks of their peak ALT value.  
In total, 41 of 639 (6.4%) patients experienced clinically significant peak ALT 
elevations during treatment with standard TB therapy. There were 4 patients who 
developed diarrhoea and/or vomiting, and 5 who reported nausea around the time of 
their peak ALT. 
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2.2.3 Additional Hepatotoxic Factors and Causality Assessment for 
Liver Enzyme Elevations on Standard TB Therapy 
Viral hepatitis serology indicating acute hepatitis B infection was detected in one case 
of DILI on the standard arm. Excess alcohol use was reported in 3 patients with 
clinically significant peak ALT results. There were no reported cases of herbal 
medication use among patients receiving standard TB therapy. The RUCAM scoring 
system was applied to 7 of the 22 (31.8%) patients who experienced DILI and had 
sufficient information available from their SAE narrative with a median result of 8 (IQR 
3-8).  
2.2.4 Baseline Liver Disease and Liver Enzyme Elevations 
At the time of randomisation there were 65 of 639 (10.2%) patients with a measured 
ALT result >1xULN and <3xULN. 4 of the 65 (6.2%) patients with baseline elevation 
went on the experience DILI during treatment, as compared to 22 of 639 (3.4%) in the 
treatment arm overall. There were no patients receiving standard TB therapy who had 
evidence of chronic liver disease at enrolment based on the applied search criteria in 
Section 2.1.4. 
3 Timing of Peak Liver Enzyme Elevations on 
Standard TB Therapy 
Just as the magnitude of enzyme elevations on standard TB therapy is not accurately 
known, neither is the timing of peak enzyme elevations. While clinically significant 
episodes of hepatotoxicity have been predominantly described early in treatment 
(Singanayagam et al., 2012; Abbara et al., 2017), it is unclear when peak liver enzyme 
elevations are to be expected in all patients regardless of the clinical picture. Such 
information, together with the expected pattern of the elevations would be helpful for 
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the development of monitoring programs designed to detect significant liver enzyme 
elevations.  
This is particularly true in resource-limited settings where it is critical that services are 
used cost-effectively. In this section the timing of the peak enzyme elevations for all 
patients, and those with DILI or clinically significant elevations will be described. The 
aim is to characterise when elevations are most commonly seen to identify the 
optimum time windows to be included in patient monitoring programmes. 
3.1 Methods 
The time in days from first dose of medication to peak ALT result was calculated for 
each patient receiving standard TB therapy. Peak liver enzyme results that occurred 
before the first dose of medication were considered to have occurred at day zero. The 
time to return to within the normal range from peak value was calculated for patients 
with a peak ALT and/or AST >1xULN and ≥3xULN.   
3.2 Results 
The median time to reach the peak ALT value was 28 days (IQR 14 – 84) among all 
patients taking standard TB therapy. The median time to reach the peak AST value 
was 53 days (IQR 14 – 84). The peak ALT result was reached at a median of 21 days 
(IQR 14 – 56) for those patients who met the criteria for DILI, and 28 days (IQR 14 – 
56) in those patients with a clinically significant peak ALT.  
The median time to return to within normal range was 20.5 days (IQR 14.5 – 38.5) for 
patients with DILI. Those patients with clinically significant peak ALT results (but less 
than 5xULN) returned to within the normal range at a median of 28 days (IQR 14 – 
42). Patients with a peak ALT result >1xULN and <3xULN took a median of 28 days 
(IQR 15.5 – 35) to return to within normal range from their peak value. Table 3-1 
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summarises the time to peak ALT and time to normalisation for patients taking 
standard TB therapy based on their peak ALT result.  
 Peak ALT >1xULN 
& <3xULN 
Peak ALT ³3xULN 
& <5xULN 
DILI (ALT >5xULN 
or ALT ³3xULN & 
Bilirubin >2xULN) 
Median Time to 
Peak ALT in Days 
(IQR) 
25 
(10 – 56) 
28 
(14 – 56) 
21 
(14 – 56) 
Median Time to 
ALT <1xULN in 
Days (IQR) 
28 
(15.5 – 35) 
28 
(14 – 42) 
20.5 
(14.5 – 38.5) 
Table 3-1. Time to peak ALT value and time to return to within normal range from peak ALT value displayed 
according to the magnitude of the peak ALT result. Time given as median number of days with interquartile range 
(IQR) included in the cells 
4 Patient Characteristics and Liver Enzyme 
Elevations on Standard TB Therapy 
There is a lack of clarity in the existing literature as to the true extent of the risk for 
hepatic dysfunction according to patient characteristics. This can be attributed to a 
combination of varying definitions of hepatotoxicity, different monitoring approaches, 
and a sometimes unclear prevalence of risk factors in largely observational studies. 
The extent of this risk has been poorly quantified due to the limitations of the study 
design even among those patient populations with clearly increased risk of 
hepatotoxicity. 
The identification of those patients at greatest risk of significant hepatotoxicity would 
allow clinicians to channel their resources and ensure that these vulnerable patients 
are managed appropriately according to a clear idea of the true extent of this risk. 
Baseline characteristics for patients in the REMoxTB trial were used in regression 
analysis to identify which patient groups were at significantly higher risk of liver 
enzyme elevations while taking standard TB therapy. 
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4.1 Methods 
Patients receiving standard TB therapy were grouped based on their peak ALT or AST 
result, into either a peak liver enzyme value of <3xULN or ≥3xULN, and the results 
tabulated according to the baseline characteristics to allow for visual comparison. 
Logistic regression was used to test for a significant association between baseline 
characteristics and binary outcomes of clinically significant peak ALT or DILI 
separately. Univariable regression was manually performed for each of the baseline 
characteristics against the binary outcome variables of DILI or clinically significant ALT 
elevation. Variables with a univariable p value of <0.10 were selected for inclusion in 
the multivariable model along with sex, age, and ethnicity as these were thought to be 
clinically significant regardless of their p value.  
Patients with “extreme” ALT elevations (>10xULN) were selected and more detailed 
scrutiny of the clinical picture at the time of the elevation was carried out using SAE 
narratives and adverse events within two weeks before or after the elevation. The site 
doctor was required to submit a narrative to accompany a SAE at the time of reporting 
the event. This narrative would include the clinical history of the event including the 
timelines for symptoms or key aspects of the SAE (as judged by the site doctor), 
results for any investigations carried out as part of the SAE that were not recorded in 
the trial database (e.g. additional virology screening or abdominal ultrasound), and 
any additional background history (such as alcohol excess). These were manually 
reviewed to gain an understanding of the clinical presentation, contributing factors 
identified, and any other information thought to be of relevance. While there were 
mandatory fields (including time of onset, severity grading, relatedness etc), the free 
text of the narrative was largely left to the site doctor to complete and therefore subject 
to their bias towards what constituted an important element of the history. 
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4.2 Results 
4.2.1 Clinically Significant Liver Enzyme Elevations on Standard TB 
Therapy 
On standard TB therapy the three categories of patients with the highest proportion of 
clinically significant peak liver enzyme results were those with a baseline weight less 
than 40kg, patients of Asian ethnicity, and patients aged 55 years or older at baseline 
(see Table 4-1). Of these categories, those aged 55 or over at baseline contained the 
highest proportion of patients reaching a peak liver enzyme result of ³3xULN (21.1% 
vs 2.3% to 11.4% in the other categories). Patients who were HIV positive also had a 
higher proportion of peak ALT and/or AST results ³3xULN compared to patients who 
were HIV negative (15.2% vs 8.9%).  
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 Peak ALT/AST 
<3xULN 
Peak ALT/AST 
³3xULN 
TOTAL  
 
n (%) 579 (90.6%) 60 (9.4%) 639 
Male Gender (%) 407 (91.1%) 40 (9.0%) 447 
Female Gender 
(%) 
172 (89.6%) 20 (10.4%) 192 
Age in Years (%)    
 18-24 173 (93.0%) 13 (7.0%) 186 
 25-34 163 (88.6%) 21 (11.4%) 184 
 35-44 126 (88.7%) 16 (11.3%) 142 
 45-54 86 (97.7%) 2 (2.3%) 88 
 ≥55 30 (78.9%) 8 (21.1%) 38 
Baseline Weight 
in Kg (%) 
   
 <40 52 (82.5%) 11 (17.5%) 63 
 40-49 196 (89.9%) 22 (10.1%) 218 
 50-59 226 (93.4%) 16 (6.6%) 242 
 60-69 80 (90.9%) 8 (9.1%) 88 
 ≥70 25 (89.3%) 3 (10.7%) 28 
Ethnicity (%)    
 Black 275 (93.2%) 20 (6.8%) 295 
 Asian 160 (82.5%) 34 (17.5%) 194 
 Mix. Race 143 (96.0%) 6 (4.0%) 149 
 Other 1 (100.0%) 0 (0.0%) 1 
HIV Status (%)    
 Positive  39 (84.8%) 7 (15.2%) 46 
 Negative  540 (91.1%) 53 (8.9%) 593 
Cavities on CXR 
(%) 
422 (92.5%) 34 (7.5%) 456 
Smoking History 
(%) 
   
 Never 267 (89.6%) 31 (10.4%) 298 
 Previous 144 (92.9%) 11 (7.1%) 155 
 Current 168 (90.3%) 18 (9.7%) 186 
Table 4-1. Patient baseline characteristics categorised to display proportions with a peak ALT and/or AST 
<3xULN and ³3xULN. Row percentages included in each cell with row totals provided in far-right column. Data 
was not available for all patients regarding their date of birth (approximate age used where possible) or for 
cavitation on chest X-ray 
4.2.2 Baseline Characteristics and Liver Enzyme Elevations  
Asian ethnicity was the only baseline characteristic found to be significantly associated 
with the onset of DILI during treatment. This demographic was significantly associated 
with DILI in both univariable logistic regression (crude OR 4.86, 95% CI 1.74 – 13.60) 
and when included in a multivariable model controlling for age and gender (adjOR 
4.82, 95% CI 1.72 – 13.51). Female gender and HIV positive status were not 
significantly associated with DILI in this model. Table 4-2 details the output from both 
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univariable and multivariable logistic regression of baseline characteristics against the 
outcome of DILI, and it can be seen that no other characteristics were found to have 
a significant relationship to DILI during treatment with standard TB therapy. 
 Crude OR P value 95% CI Adj OR P value 95% CI 
Age (Years)† 1.01 0.70 0.97 – 1.04 1.00 0.82 0.97 – 1.04 
Gender       
 Male BASELINE --- --- BASELINE --- --- 
 Female 1.09 0.85 0.44 – 2.72 1.09 0.85 0.43 – 2.80 
Baseline 
Weight† 0.77 0.26 0.49 – 1.21 --- --- --- 
Ethnicity       
 Black BASELINE --- --- BASELINE --- --- 
 Asian 4.86 <0.01 1.74 – 13.60 4.82 <0.01 1.72 – 13.51 
 Mixed 0.84 0.84 0.16 – 4.39 0.84 0.83 0.16 – 4.36 
HIV Status       
 Negative BASELINE --- --- --- --- --- 
 Positive 1.30 0.73 0.29 – 5.75 --- --- --- 
XR Cavities       
 None BASELINE --- --- --- --- --- 
 Present 0.51 0.19 0.19 – 1.39 --- --- --- 
Smoking       
 Never BASELINE --- --- --- --- --- 
 Previous 0.96 0.94 0.32 – 2.86 --- --- --- 
 Current 1.13 0.81 0.42 – 3.01 --- --- --- 
Table 4-2. Logistic regression of baseline characteristics as exposure variables against an outcome of DILI 
during treatment. Univariable odds ratios (crude) and multivariable odds ratios (adjusted) shown, with a 
univariable p value <0.10 as inclusion criteria for multivariable model. †Analysed as categorical variable 
Similarly to the findings for DILI, Asian ethnicity was also associated with clinically 
significant peak ALT results while undergoing treatment with standard TB therapy 
(adjOR 3.89, 95% CI 1.68 – 9.04, p value <0.01). Cavitation on chest X-ray was 
associated with reduced odds of experiencing a clinically significant peak ALT result 
in a univariable analysis (crude OR 0.45, 95% CI 0.22 – 0.94), and this effect persisted 
into the multivariable model although the p value fell just below the threshold for 
significance (adjOR 0.50, 95% CI 0.23 – 1.06). Female gender and HIV infection again 
failed to achieve statistical significance, at the 5% level cut-off specified in Section 2 
of the Methods chapter, in either a univariable or multivariable analysis. Table 4-3 
contains the results from both the univariable and multivariable logistic regression of 
baseline characteristics against the binary outcome of a clinically significant peak ALT. 
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 Crude OR P value 95% CI Adj OR P value 95% CI 
Age (Years)† 1.01 0.34 0.99 – 1.04 1.00 0.73 0.98 – 1.03 
Gender       
 Male BASELINE --- --- BASELINE --- --- 
 Female 1.37 0.35 0.71 – 2.65 0.95 0.90 0.43 – 2.09 
Baseline 
Weight† 0.82 0.24 0.58 – 1.14 --- --- --- 
Ethnicity       
 Black BASELINE --- --- BASELINE --- --- 
 Asian 3.82 <0.01 1.83 – 7.98 3.89 <0.01 1.68 – 9.04 
 Mixed 0.96 0.94 0.33 – 2.81 1.29 0.66 0.41 – 4.06 
HIV Status       
 Negative BASELINE --- --- --- --- --- 
 Positive 1.43 0.52 0.49 – 4.21 --- --- --- 
XR Cavities       
 None BASELINE --- --- BASELINE --- --- 
 Present 0.45 0.03 0.22 – 0.94 0.50 0.07 0.23 – 1.06 
Smoking       
 Never BASELINE --- --- --- --- --- 
 Previous 0.81 0.62 0.36 – 1.82 --- --- --- 
 Current 0.83 0.63 0.39 – 1.76 --- --- --- 
Table 4-3. Logistic regression of baseline characteristics as exposure variables against an outcome of clinically 
significant (≥3xULN) peak ALT during treatment. Univariable odds ratios (crude) and multivariable odds ratios 
(adjusted) shown, with a univariable p value <0.10 as inclusion criteria for multivariable model. †Analysed as 
categorical variable 
4.2.3 Extreme Liver Enzyme Elevations 
On standard therapy 7 of 639 (1.1%) patients exhibited a peak ALT result of ≥10xULN 
(range 10.1 – 19.1xULN), and among these patients the median time to peak ALT was 
29 days of therapy (IQR 7-52). 6 of these patients were male, the median age was 
33.3 years (IQR 28.5-40.9 years), and 2 patients were HIV positive. Alcohol use was 
confirmed as an underlying feature in 2 cases, and one of these patients had positive 
serology for acute hepatitis B. Most (5 of 7 patients) reported nausea or vomiting, and 
one reported abdominal pain within two weeks of the peak elevation. 
5 Clinical Outcomes and Liver Enzyme Elevations 
on Standard TB Therapy 
The precise impact of different levels of liver enzyme elevations on treatment 
outcomes has not previously been fully elucidated. In the previous chapter, there was 
an association between experiencing one or more clinically significant episodes of any 
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toxicity and an increased risk of failing to achieve microbiological cure. An awareness 
of the significance that should be attached to different levels of liver enzyme elevations 
would also inform monitoring practice and act as a motivating factor to drive policy 
changes that will improve patient care in a meaningful way. 
The REMoxTB trial database contains information relating to early withdrawals, deaths 
and mycobacterial culture data up to 18 months after randomisation. The intention of 
this section was to investigate the number of patients who were withdrawn from 
standard TB therapy in the trial for liver-related reasons, and to use regression 
techniques to test the association between liver enzyme elevations and eventual 
microbiological cure. 
5.1 Methods 
“Liver-related withdrawals” were defined as patients withdrawn from treatment 
following a peak ALT or AST result ≥3xULN with no Adverse Events (either clinical or 
relating to biochemical tests) other than liver events recorded between their peak 
elevation and the time of withdrawal.  
Patients were categorised according to their peak ALT value and an association with 
microbiological cure was assessed using logistic regression. Microbiological cure was 
defined as culture negative status at eighteen months (as in Section 4.1.1, Chapter 3). 
An ordered categorical variable was created for peak ALT in incremental steps of 
1xULN, along with the binary exposure variables for clinically significant peak ALT 
(≥3xULN) and DILI, and these three exposure variables were independently regressed 
against the binary outcome variable for microbiological cure. Regression was 
controlled for age, sex, baseline weight, ethnicity, HIV status, and cavitation on chest 
X- ray. 
 119 
5.2 Results 
Only 11 patients were withdrawn from the standard therapy arm in the trial due to liver 
related events, and all of these patients survived to the end of the study. Their mean 
age was 37 years (±13.96 years) and 73% were male. The median ALT peak value in 
this group was 7.09xULN (IQR 2.83 – 10.05) occurring at 34.5 days, and the median 
peak AST was 5.99xULN (IQR 3.03 – 11.03) at 28.5 days.  4 of 11 (36.4%) patients 
had symptoms recorded; 4 with diarrhoea and/or vomiting and 3 also reported nausea. 
10 of the 11 (90.9%) patients had achieved a microbiological cure at 18 months, after 
onward referral to the National Treatment Program. There was no culture data 
available after withdrawal for the final patient. 
None of the exposure variables of peak ALT magnitude, clinically significant peak ALT, 
or DILI showed any statistically significant association with microbiological cure at 18 
months (p value >0.10 for all three exposures, see Table 5-1). The 639 eligible patients 
taking standard therapy were included in the analysis. The model was controlled for 
age, gender, baseline weight, ethnicity, HIV status and cavitation on chest X-ray. 
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 Adj OR 95% CI P value 
Peak ALT 
Value 
1.24 0.92 – 1.65 0.15 
Age in years* 0.80 0.64 – 0.99 0.04 
Female 
gender 
1.06 0.57 – 1.97 0.87 
Baseline 
Weight* 
1.03 0.77 – 1.39 0.65 
Ethnicity    
 Black BASELINE --- --- 
 Asian 0.49 0.25 – 0.94 0.03 
 Mixed 
Race 
0.74 0.35 – 1.54 0.42 
HIV-positive 0.78 0.25 – 2.42 0.67 
Cavitation on 
CXR 
0.85 0.43 – 1.70 0.65 
Clinically 
Significant 
ALT Peak 
1.55 0.45 – 5.38 0.487 
Age in years* 0.79 0.64 – 0.99 0.04 
Female 
gender 
1.04 0.56 – 1.94 0.89 
Baseline 
Weight* 
1.03 0.77 – 1.39 0.83 
Ethnicity    
 Black BASELINE --- --- 
 Asian 0.50 0.25 – 0.97 0.04 
 Mixed 
Race 
0.72 0.34 – 1.50 0.38 
HIV-positive 0.81 0.26 – 2.47 0.71 
Cavitation on 
CXR 
0.83 0.42 – 1.65 0.60 
DILI 
 
2.35 0.30 – 18.32 0.42 
Age in years* 0.79 0.64 – 0.99 0.04 
Female 
gender 
1.05 0.56 – 1.95 0.88 
Baseline 
Weight* 
1.03 0.77 – 1.39 0.83 
Ethnicity    
 Black BASELINE --- --- 
 Asian 0.50 0.26 – 0.97 0.04 
 Mixed 
Race 
0.72 0.34 – 1.51 0.38 
HIV-positive 0.79 0.26 – 2.44 0.69 
Cavitation on 
CXR 
0.83 0.42 – 1.65 0.59 
Table 5-1. Odds ratio for achieving microbiological cure at 18 months after randomisation based on peak liver 
enzyme elevations during treatment in multivariable models. Peak ALT value is an ordered categorical variable 
grouping peak ALT results as increments of 1xULN, and all variables were investigated in a multivariable model 
controlling for age, gender, baseline weight, ethnicity, HIV status, and chest X-ray cavitation. *Age and baseline 
weight were categorised as presented in Table 4-1 of this chapter 
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6 Liver Enzyme Elevations in the Moxifloxacin-
Containing Treatment Arms Compared to 
Standard TB Therapy 
While they did not achieve non-inferiority, the more favourable toxicity profile 
demonstrated by the experimental arms in the previous chapter raises the question of 
whether they would still have a place in the management of TB if an optimal duration 
of treatment could be defined. Hepatotoxicity was the most prevalent form of toxicity 
in the experimental arms as well as in the standard TB therapy arm, but the magnitude 
of liver enzyme elevations and the incidence of DILI was not quantified in the previous 
chapter. A quantification of the differences seen between the standard TB therapy arm 
and the two experimental arms would help in understanding what, if any, role these 
regimens have in TB treatment. Whether they are potentially more suitable for use 
with patients who are more at risk of liver toxicity is of particular interest. 
The main research questions to be addressed were determining the differences in 
timing and magnitude of liver enzyme elevations between the standard and 
experimental arms, and to identify any differences in the patient groups that 
experienced liver enzyme elevations on the different treatment arms. 
6.1 Methods 
6.1.1 Magnitude and Timing of Liver Enzyme Elevations 
The peak liver enzyme values and timing in days since first dose of trial medication 
were calculated for all eligible patients on all three of the treatment arms, and the 
median value for ALT or AST calculated at each scheduled visit according to treatment 
arm. Depending on the number of patients in each group, the Chi squared or Fisher’s 
exact test (if n ≤5 in any cell) was used to investigate the differences in peak ALT 
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values when grouped as ≥3xULN and <5xULN, ≥5xULN and <10xULN, and ≥10xULN.  
Comparisons made were pairwise comparing each experimental arm to standard TB 
therapy. 
Kaplan-Meier curves were constructed for the time taken to reach the peak value in 
ALT and AST from first dose of medication for all patients in the trial. Kaplan-Meier 
curves were also constructed for the time taken to return to within the normal range 
from the peak value for patients with a peak ALT or AST value of >1xULN in all 
treatment arms. The logrank test was used to test for differences between the 
experimental and standard treatment arms for the events of interest (time to peak and 
time to normalise) occurring at any time point. Scatter plots were constructed to show 
the value and timing of elevations in ALT and AST in each treatment arm for patients 
with a peak value ≥3xULN. 
6.1.2 Baseline Characteristics and Liver Enzyme Elevations 
Baseline characteristics were tabulated for patients with peak ALT and/or AST 
≥3xULN according to the treatment arm. The Chi square test was used to investigate 
for significant differences in the proportion of patients with clinically significant 
elevations according to baseline characteristics by treatment arm. Logistic regression 
was then used to explore the relationship between baseline characteristics for patients 
on each of the experimental arms and the binary outcomes of clinically significant peak 
ALT or DILI separately. 
6.2 Results 
6.2.1 Magnitude and Timing of Liver Enzyme Elevations 
The median peak ALT result for all patients allocated to the isoniazid and ethambutol 
arms was 0.78 (IQR 0.53-1.23) and 0.73 (IQR 0.51-1.09), respectively. Figure 6-1 
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contains line graphs displaying the median value for the peak ALT and AST (as xULN) 
at scheduled visits during treatment, shown as weeks of treatment. 
Patients receiving treatment on the isoniazid arm reached their peak ALT value at a 
median of 28 days (IQR 14-84), and at a median of 55 days (IQR 14-84) for those 
allocated to the ethambutol arm.  
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Figure 6-1. Line graphs displaying the median peak ALT and AST value at scheduled visits for patients on 
all three treatment arms in the REMoxTB trial. ALT and AST both calculated as xULN 
Figure 6-2 contains Kaplan Meier curves for time to peak in all patients, and 
normalisation of elevated ALT and AST results for patients with peak result ≥1xULN. 
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The log rank test detected a significant difference (p value <0.001) for the time to peak 
ALT value between the standard (median time 28 days) and ethambutol (median time 
55 days) arms with p value <0.001. The time for patients with peak ALT & AST values 
>1xULN to return to within the normal range from this peak value is also illustrated, 
with no significant difference detected between the treatment arms (p value >0.10). 
There were 22 of 654 (3.4%) patients from the isoniazid arm who met the criteria for 
DILI. Out of these 22 patients, 5 patients reported diarrhoea and/or vomiting and 5 
patients complained of nausea. The median RUCAM score for DILI patients was 10.5 
(IQR 3.5 – 13). On the isoniazid arm 35 of 654 (5.4%) patients had recorded clinically 
significant peak ALT results.  
14 of 634 (2.2%) patients on the ethambutol arm experienced liver enzyme elevations 
in keeping with DILI. From among the DILI patients, there were 2 patients who reported 
diarrhoea and/or vomiting, 1 patient who experienced nausea, and 2 patients who 
complained of abdominal pain. RUCAM scoring gave a median value of 7 (IQR 4.5 – 
8.5) for those patients who experienced DILI. 25 of 634 (3.9%) patients on the 
treatment arm had peak ALT results that were clinically significant. Table 6-1 shows 
the frequency of peak ALT elevations and the timing for reaching a peak value and 
returning to within the normal range for patients on all three treatment arms. 
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Figure 6-2. Kaplan Meier curves showing the time to peak ALT and AST value for all patients on each of the 
treatment arms in the trial. The time to fall back into the normal range of ALT and AST is also shown for all 
patients with a peak ALT or AST result >1xULN 
The median time to reach peak ALT result was 23.5 days (IQR 14 – 55) for patients 
who developed DILI on the isoniazid arm. On the ethambutol arm, patients with DILI 
reached their peak ALT at 36.5 days (IQR 28 – 56). As shown in Table 6-1, the median 
time to peak ALT for clinically significant elevations was 18 days (IQR 14 – 84) and 55 
days (14 – 84) on the isoniazid and ethambutol arms respectively. The scatter plots in 
Figure 6-3 illustrate the interquartile range for the magnitude of peak ALT and AST for 
patients with a peak value ³3xULN on the three treatment arms, and also the 
interquartile range for the timing of the peak liver enzyme value. The wider interval for 
magnitude and timing of peak AST as compared to that for the peak ALT can be seen 
in all three treatment arms. 
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 Standard 
Arm 
(2EHRZ/4HR) 
 
Isoniazid 
Arm 
(2MHRZ/2MHR) 
Ethambutol 
Arm 
(2EMRZ/2MR) 
 
p value 
n1 
 
634 649 634 N/A 
Median peak 
ALT value as 
xULN (IQR) 
0.83 
(0.56-1.35) 
0.78 
(0.53-1.23) 
0.73 
(0.51-1.09) 
0.0465 
 
<0.0016 
Median time to 
peak ALT 
value in arm 
(days) 
28 
(14-84) 
28 
(14-84) 
55 
(14-84) 
0.9725 
 
0.0176 
Median time to 
peak ALT 
(days) if 
≥3xULN 
28 
(14-56) 
18 
(14-56) 
28 
(27-56) 
0.7555 
 
0.6056 
Median time to 
ALT <1xULN2 
(days) 
26 
(15-42) 
28 
(19-42) 
39 
(30-61) 
0.5605 
 
0.2706 
No. with 
peak ALT 
≥3xULN & 
<5xULN(%n3) 
 
21 
(3.3%) 
 
17 
(2.6%) 
 
11 
(1.7%) 
0.2047 
 Bilirubin 
>2xULN 
2 
(0.3%) 
4 
(0.6%) 
0 
(0.0%) 
0.1427 
 INR4 
>1.5 
0 
(0.0%) 
3 
(0.5%) 
1 
(0.2%) 
0.0987 
No. with 
peak ALT 
≥5xULN & 
<10xULN (%n3) 
 
13 
(2.0%) 
 
16 
(2.4%) 
 
11 
(1.7%) 
0.6567 
 Bilirubin 
>2xULN 
1 
(0.2%) 
2 
(0.3%) 
1 
(0.2%) 
0.7927 
 INR4 
>1.5 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
N/A 
No. with 
peak ALT 
≥10xULN (%n3) 
7 
(1.1%) 
 
2 
(0.3%) 
3 
(0.5%) 
0.1647 
 Bilirubin 
>2xULN 
2 
(0.3%) 
0 
(0.0%) 
1 
(0.2%) 
0.3607 
 INR4 
>1.5 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
N/A 
No of liver-
related 
withdrawals 
11 
(1.7%) 
7 
(1.1%) 
4 
(0.6%) 
 
0.178 
Table 6-1. Summary of the numbers of patients with significant elevations in liver enzyme 
concentration (≥3xULN, ≥5xULN, and ≥10xULN) by treatment arm.  Median days from the start of 
treatment to reach individual patient peak concentrations and the number of patients withdrawing from 
treatment for liver-related reasons are reported. 1Some patients not included because of missing ALT 
results, 2If peak ALT ³3xULN, 3%n refers to percent of total patients in treatment arm, 4Patients with 
known anticoagulant use were excluded, 5Isoniazid arm against standard TB therapy, 6Ethambutol 
arm against standard therapy, 7Chi square (Fisher’s exact if n<5) 
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Figure 6-3. Scatter Plots Illustrating Peak Values for ALT and AST in Patients When Peak Value ≥3xULN. The 
timing in days since first dose of treatment (x axis) and value of peak ALT & AST (y axis) is illustrated for each 
treatment arm for those patients with a peak value of ≥3xULN. The lines on the graphs indicate the interquartile 
ranges for the peak ALT/AST values and the timing of the peak values in this sub-group, with shaded area 
corresponding to the interquartile range for both time and elevation result 
6.2.2 Baseline Characteristics and Liver Enzyme Elevations 
Table 6-2 reports the baseline characteristics for those patients on the experimental 
arms, and standard TB therapy for visual comparison, with a peak ALT and/or AST 
³3xULN. Significantly more Asian patients experienced ALT/AST ³3xULN compared 
to other ethnic groups (11.4% (Asian) vs 6.7% (Black) vs 5.5% (Mixed), p value 
<0.001).   
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Applying the DILI criteria from Section 2.1.2, a significantly higher proportion of Asian 
patients in the trial experienced DILI (28 of 560, 4.8%) compared to the other ethnic 
groups (2.0% Black, 0% Caucasian, and 2.7% Mixed Race/Other [p=0.02]). Of the 67 
Asian patients with a peak ALT/AST ≥3xULN, 57 of 67 (85.1%) were taking isoniazid-
containing regimens and 10 of 67 (14.9%) were allocated to the ethambutol arm 
(p=0.008).   
There were 2 patients in the isoniazid arm with a peak ALT ≥10xULN (39.6xULN with 
Bilirubin 1.7xULN & 11.9xULN at 17 & 56 days respectively). Both of them were male, 
HIV negative, and aged 21 and 28 years. No symptoms were recorded for either of 
these patients. 
On the ethambutol arm, 3 patients developed peak ALT elevations of ≥10xULN (range 
11.0 – 38.8xULN) in a range of 27-56 days. One of the three patients was male, the 
median age was 42.5 years (IQR 39.5-49.5 years), and one female patient who was 
HIV positive. This patient, for whom no predisposing conditions were identified 
suffered a severe and fatal course.  Evidence of DILI arose after two weeks of 
treatment and she exhibited haemodynamic compromise, maculopapular rash, and 
symptoms of gastroenteritis. ALT peaked at 38.8xULN and total bilirubin 6.2xULN. No 
post-mortem was performed, with cause of death pronounced as “hepatitis of unknown 
cause”. 
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 Peak ALT or AST  
≥3xULN1 
 Standard Arm 
(2EHRZ/4HR) 
Isoniazid Arm 
(2MHRZ/2MHR) 
Ethambutol Arm 
(2EMRZ/2MR) 
n (%) 60 / 639 (9.4%) 52 / 654 (8.0%) 38 / 634 (6.0%) 
Male Gender 
(%) 
40 / 447 (9.0%) 38 / 449 (8.5%) 24 / 447 (5.4%) 
Female 
Gender (%) 
20 / 192 (10.4%) 14 / 205 (6.8%) 14 / 188 (7.5%) 
Age in Years2 
(%) 
   
 18-24 13 / 186 (7.0%) 17 / 203 (8.4%) 11 / 172 (6.4%) 
 25-34 21 / 184 (11.4%) 11 / 213 (5.2%) 9 / 210 (4.3%) 
 35-44 16 / 142 (11.3%) 11 / 115 (9.6%) 8 / 122 (6.6%) 
 45-54 2 / 88 (2.3%) 6 / 81 (7.4%) 8 / 86 (9.3%) 
 ≥55 8 / 38 (21.1%) 7 / 41 (17.1%) 2 / 44 (4.6%) 
Baseline 
Weight in Kg 
(%) 
   
 <40 11 /63 (17.5%) 6 / 56 (10.7%) 5 / 56 (8.9%) 
 40-49 22 / 218 (10.1%) 20 / 243 (8.2%) 11 / 224 (4.9%) 
 50-59 16 / 242 (6.6%) 19 / 231 (8.2%) 12 / 236 (5.1%) 
 60-69 8 / 88 (9.1%) 5 / 88 (5.7%) 8 / 86 (9.3%) 
 ≥70 3 / 28 (10.7%) 2 / 36 (5.6%) 2 / 33 (6.1%) 
Ethnicity (%)    
 Black 20 / 295 (6.8%) 21 / 277 (7.6%) 17 / 290 (5.9%) 
 Asian 34 / 194 (17.5%) 23 / 201 (11.4%) 10 / 193 (5.18%) 
 Mix. Race 6 /149 (4.0%) 8 / 174 (4.6%) 11 / 151 (7.3%) 
 Other 0 / 1 (0.0%) 0 / 2 (0.0%) 0 / 0 (0.0%) 
HIV Pos (%) 7 / 46 (15.2%) 3 / 46 (6.5%) 4 / 48 (8.3%) 
HIV Neg (%) 53 / 593 (8.9%) 49 / 608 (8.1%) 34 / 586 (5.8%) 
Smoking 
History (%) 
   
 Never 31 / 298 (10.4%) 23 / 291 (7.9%) 16 / 279 (5.7%) 
 Previous 11 / 155 (7.1%) 17 / 155 (11.0%) 9 / 166 (5.4%) 
 Current 18 / 186 (9.7%) 12 / 208 (5.8%) 13 / 190 (6.8%) 
Table 6-2. Relationship between elevation in liver enzyme concentration and patient characteristics at baseline 
reported by treatment regimen. Characteristics for patients across all treatment arms are shown according to 
peak ALT and/or AST result while taking treatment. 
7 The Impact of Individual Drugs on Liver Enzyme 
Elevations 
The effect on liver enzyme elevations from individual TB drugs is generally not well 
understood (with the notable exception of isoniazid (Nolan, Goldberg and Buskin, 
1999; Jasmer et al., 2002; Al-Darraji, Kamarulzaman and Altice, 2012)) owing to the 
fact that pulmonary TB is always treated with drugs in combination. “Liver-sparing” 
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regimens to treat TB are therefore normally the product of informed opinion guiding 
practice, with the exclusion of isoniazid and the inclusion of a fluoroquinolone a 
common practice; moxifloxacin has been shown to have a good safety profile overall, 
with a low risk of hepatotoxicity (Gosling et al., 2003; Conde, Efron, Loredo, De, et al., 
2009; Dorman et al., 2009).  
A more detailed understanding of the hepatotoxic risk associated with individual drugs 
could allow for the creation of a selection of standardised “liver-sparing” regimens. 
This section utilised the design of REMoxTB to create three new treatment groups 
according to the presence or absence of isoniazid, moxifloxacin, and ethambutol in 
each of the trial treatment arms. The difference between these groups in terms of 
timing and magnitude of liver enzyme elevations was then described in an attempt to 
gain insight into the influence of these three drugs. 
7.1 Methods 
Patients were flagged as belonging to one of two “virtual” treatment arms from three 
different groups. This assignment was based on their treatment allocation in the trial 
to reflect the presence or absence of isoniazid, moxifloxacin and ethambutol. The 
three groups are shown in Table 7-1. 
Drug of Interest Virtual Treatment Arm Study Regimens Included 
 
ISONIAZID 
Isoniazid-containing Standard & Isoniazid Arm 
No-isoniazid Ethambutol Arm 
 
MOXIFLOXACIN 
Moxifloxacin-containing Isoniazid & Ethambutol Arm 
No-moxifloxacin Standard Arm 
 
ETHAMBUTOL 
Ethambutol-containing Standard & Ethambutol Arm 
No-ethambutol Isoniazid Arm 
Table 7-1. “Virtual” treatment arms used to investigate the impact of individual drugs on liver enzyme patterns. 
Patients were allocated to the “virtual” arm based on the regimen they received in REMoxTB according to the 
presence or absence of the three drugs of interest. 
The median peak ALT value and time to reach the peak from first dose of medication 
was calculated for each of the “treatment arms” in the three groups. The values were 
compared using the Mann-Whitney U test to compare the mean time to peak value to 
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account for the skewed distribution of time to peak ALT & AST (histograms and inverse 
normal plots not shown). Box plots were created to display the data relating to time to 
peak ALT between “arms” in the groups. The number of patients experiencing DILI 
and clinically significant elevations was ascertained for each one of the “treatment 
arms” and a Chi square test applied to look for significant difference in the proportion 
of patients between the “arms”. 
7.2 Results 
Table 7-2 demonstrates that the proportion of patients with ALT and/or AST ≥3xULN 
was significantly higher in isoniazid containing arms (112 of 1,181, 8.7%) than the 
ethambutol arm (38 of 597, 6.0% [p value 0.039]). Similar percentages of patients had 
a peak ALT result of ≥5xULN: 3% in both the standard and isoniazid arms and 2% in 
the ethambutol arm. The results for the peak ALT/AST and timing of peak values for 
the groups divided according to the drugs present in the regimen can also be seen in 
Table 7-2. The patients receiving isoniazid as part of their treatment for TB reached 
their peak ALT at a median time of 28 days compared to 55 days in the no-isoniazid 
group (p value <0.01), and patients on the ethambutol arm reached a peak ALT result 
of ≥3xULN 9.5 days later than patients receiving the isoniazid-containing regimens 
combined (median timing 28 vs 18.5 days, p value 0.07). 
There was a small but statistically significant difference for peak ALT value (0.78 & 
0.73 vs 0.83xULN) and AST (0.93 & 0.90 vs 1.02xULN) in the moxifloxacin-containing 
arms when compared to the standard therapy group (p value <0.05). The median 
timing of the peak ALT was 29 days and 28 days in the moxifloxacin-containing and 
the no-moxifloxacin groups respectively (p value 0.137). While the median time to 
reach the peak AST in these two groups was 30 days and 50 days this was not found 
to be a significant difference with p value 0.351.  
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 ISONIAZID MOXIFLOXACIN ETHAMBUTOL 
Group INH No-INH P value* MXF No-MXF P value* ETH No-ETH P value* 
Patients 
ALT/AST 
≥3xULN  
112/ 
1,181 
(8.7%) 
38/ 
597 
(6.0%) 
 
0.039 
90/ 
1,199 
(7.0%) 
60/ 
579 
(9.4%) 
 
0.063 
98/ 
1,176 
(7.7%) 
52/ 
602 
(8.0%) 
 
0.841 
Med. 
Peak 
ALT 
Value 
(IQR) 
 
0.80 
(0.55-
1.30) 
 
0.73 
(0.51-
1.09) 
 
0.001 
 
0.75 
(0.52-
1.15) 
 
0.83 
(0.58-
1.35) 
 
0.001 
 
0.78 
(0.54-
1.18) 
 
0.78 
(0.53-
1.23) 
 
0.942 
Med. 
Time to 
Peak 
ALT 
(IQR) 
 
28 
(14-84) 
 
55 
(14-85) 
 
0.005 
 
29 
(14-84) 
 
28 
(14-84) 
 
0.137 
 
28 
(14-84) 
 
28 
(14-84) 
 
0.196 
Med. 
Peak 
AST 
Value 
(IQR) 
 
0.95 
(0.70-
1.46) 
 
0.90 
(0.68-
1.28) 
 
0.002 
 
0.91 
(0.68-
1.36) 
 
1.02 
(0.73-
1.48) 
 
<0.001 
 
0.94 
(0.70-
1.38) 
 
0.93 
(0.67-
1.45) 
 
0.627 
Med. 
Time to 
Peak 
AST 
(IQR) 
 
30 
(14-84) 
 
54 
(13-84) 
 
0.728 
 
30 
(14-84) 
 
50 
(14-84) 
 
0.351 
 
52 
(14-84) 
 
28 
(14-84) 
 
0.203 
Table 7-2. Peak ALT & AST values and timing presented in groups divided according to the presence of 
individual drugs. *Mann Whitney U test 
 
Figure 7-1. Boxplots demonstrating the time to reach a peak ALT and AST in groups based on the 
presence or absence of a specific drug in the treatment regimen 
There were no significant differences detected using the Mann-Whitney U test in terms 
of magnitude or timing of peak ALT and AST results between the group receiving 
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ethambutol and the group that was not receiving it. The median values for the peak 
ALT/AST result and the time taken to reach a peak ALT were similar between the two 
groups. The median value for time to reach the peak AST was 52 days in the 
ethambutol-containing regimens but 28 days in the regimen with no ethambutol. 
However, the interquartile range was the same in both groups at 14-84 days, and the 
p value was not significant at 0.203. The median time to reach peak ALT according to 
the drugs present in the treatment regimen are visualised in the box plots of Figure 
7-1. 
8 Discussion 
In this chapter it was demonstrated that almost 10% of patients taking standard TB 
therapy demonstrate ALT elevations ≥3xULN, however only a minority reported 
symptoms and approximately 3% of patients met the criteria for DILI. The majority of 
clinically significant elevations occurred within the first two months of standard TB 
therapy, and those patients whose peak ALT was greater than the upper limit of normal 
took approximately one month to return to within the normal range. Asian ethnicity was 
shown to be a significant risk factor for DILI associated with standard TB therapy, but 
female sex and HIV infection did not have a significant association with liver injury. 
DILI and clinically significant ALT elevations on treatment were not associated with 
worse treatment outcomes in this analysis. Of the three treatment arms, the 
ethambutol arm had the lowest incidence of DILI; the majority of clinically significant 
liver enzyme elevations occurred within the first two months of therapy on both 
experimental arms. There was a significant association with receiving isoniazid as part 
of a TB treatment regimen and increased risk of clinically significant liver enzyme 
elevations, and a shorter time to reach peak ALT elevation.  
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The data presented in this chapter provides a more definitive estimate of the incidence 
of TB therapy-related hepatic dysfunction due to the protocol-mandated sampling 
schedule and prospective collection of samples regardless of the clinical picture. The 
majority of published data has been retrospectively collected and the definition most 
frequently used for “hepatotoxicity” relates to patients who have developed symptoms 
and signs that have alerted a clinician to the need for blood tests to be performed 
(Fauzi et al., 2004; Shang et al., 2011; Chou et al., 2014; Shin et al., 2014; Yimer et 
al., 2014; Bright-Thomas et al., 2016; Chang et al., 2018), and therefore the frequency 
of asymptomatic elevations and their significance in terms of management remained 
uncertain. This data would complement some of the largest datasets already 
published that quote rates of significant TB therapy-related hepatotoxicity of 
approximately 3-6% on standard TB therapy (Shang et al., 2011; Shu et al., 2013; 
Bright-Thomas et al., 2016; Abbara et al., 2017), as the proportion of patients seen to 
experience DILI on standard therapy was 3.4% in REMoxTB.  
There has been an assumption that the majority of LBT elevations during TB treatment 
will occur within the first two to four weeks of therapy. The British and American 
Thoracic societies both recommend pre-treatment baseline blood tests followed by 
clinical assessment in all patients (Ormerod et al., 1998; Saukkonen et al., 2006). In 
patients deemed by the physician to be at higher risk of DILI or with existing liver 
disease or age >35 years old the ATS would recommend a further blood test between 
two to four weeks after initiating therapy (Saukkonen et al., 2006). The BTS advises a 
policy of further weekly blood tests for two weeks and two weekly blood tests for the 
first two months for patients with known liver dysfunction (Ormerod et al., 1998). 
Current guidance from the World Health Organisation does not include regular 
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monitoring for hepatotoxicity and instead symptoms would be the method of detecting 
liver dysfunction (World Health Organization, 2010).  
In REMoxTB, the interquartile range for the time to reach a peak ALT ≥3xULN was 14-
56 days for patients taking standard TB therapy, suggesting that 75% of these patients 
would have been detected by regular liver biochemical testing during the first 60 days 
of treatment. Based on the pattern of elevations observed, a monitoring schedule 
consisting of LBTs at baseline, 1 week (to identify early “elevators”), 2 weeks (lower 
end of the interquartile range), 4 weeks (median timing for elevations) and 8 weeks 
(upper end of interquartile range) would be possible, even in resource-poor settings. 
However, these findings suggest diminishing return for LBTs after 8 weeks of therapy 
in the absence of symptoms and, particularly in the absence of reliable data relating 
to treatment interruptions around enzyme elevations, it is not possible to make a 
definitive statement regarding the appropriate use of this suggested monitoring 
schedule in the field. 
There are unanswered questions surrounding the significance of isolated ALT 
elevations: how best to evaluate these patients, and which are the most appropriate 
biochemical markers to be included in the evaluation of ALT elevations? (Saukkonen, 
Powell and Jereb, 2012) Isolated liver enzymes on treatment could reflect “hepatic 
adaptation” to the medication, wherein a transient liver biochemical test abnormalities 
resolve even with continued exposure to the drug and the patient remains clinically 
well throughout (Dara, Liu and Kaplowitz, 2016). One large cohort study of over 11,000 
patients receiving isoniazid preventive therapy observed symptoms and signs of 
hepatotoxicity in only 0.15% of patients completing therapy (Nolan, Goldberg and 
Buskin, 1999), suggesting that the rates of DILI/enzyme elevations requiring 
intervention are actually very low with monotherapy and, by extension, with standard 
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TB therapy as well. Certainly, in this analysis a minority of patients with DILI or 
clinically significant elevations had recorded symptoms or bilirubin elevations and in 
the trial the majority of patients who experienced liver enzyme elevations went on to 
be cured of their disease.  
A prospective series of 1223 patients with drug-induced liver failure demonstrated TB 
therapy-induced liver failure can often have a hyper-acute presentation and was 
associated with 67% mortality (Kumar et al., 2010). The fatality seen on the ethambutol 
arm involving an ALT rise of 38xULN acts to highlight the risk of mortality for patients 
presenting with hyperbilirubinaemia and elevated liver enzymes. While the local 
physician evaluated this as “hepatitis of unknown cause”, it would seem reasonable to 
consider this as DILI. By comparison, the mortality associated with acute viral hepatitis 
is low and the majority of deaths are accounted for by the chronic sequealae of the 
disease (World Health Organization, 2017).  
Despite most patients being clinically unaffected by ALT elevations on treatment, there 
was still an overall risk of 3.4% for DILI on standard TB therapy and higher rates of 
DILI among those patients with enzyme elevations at randomisation compared with 
the overall trial population. Given the challenging circumstances surrounding TB 
treatment (with much higher levels of HIV co-infection than seen in REMoxTB) we 
would still recommend the conservative monitoring schedule presented above to allow 
for the early detection of at risk patients. Given that the majority of patients with liver 
enzyme elevations were not withdrawn, there is some evidence in favour of attempting 
to re-introduce the same regimen following a treatment interruption as opposed to 
immediately changing to a more “liver-sparing” regimen that will potentially be less 
efficacious. 
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The application of the RUCAM scoring system to cases of DILI in REMoxTB showed 
a median score of 8 which indicates a “probable” causal relationship between standard 
TB therapy and liver enzyme elevations consistent with DILI. The RUCAM system for 
attributing causality for liver dysfunction to any medication being taken at the time was 
first published in 1993 (Benichou, Danan and Flahault, 1993; Danan and Benichou, 
1993), and since that time has become an accepted tool for use in routine clinical 
practice, in research settings, and in support of regulatory decisions (Hayashi, 2016; 
Shahbaz, Mahajan and Lewis, 2017; Danan and Teschke, 2018). The main 
reservation in terms of using this score relate to the possibility of inter-observer 
variability and differing attributions of causality. However, in the original publication 
there was no disagreement in 84% of 50 DILI cases reviewed by four assessors 
(Danan and Benichou, 1993), and the RUCAM score has performed well in 
subsequent studies (Björnsson and Olsson, 2005; Danan and Teschke, 2015). 
Increased risk of hepatotoxicity in certain ethnic groups has been variably 
demonstrated (Chamorro et al., 2013; Du et al., 2013; Lee et al., 2014; Bright-Thomas 
et al., 2016), and in this analysis there is evidence to support a higher risk of liver 
enzyme elevations in Asian patients. NAT2 is related to the metabolism of isoniazid, 
and polymorphisms affecting the cytochrome P450, CYP2E1, and NAT2 liver 
enzymes are associated with an increased risk of hepatotoxicity (Deng et al., 2012; 
Chamorro et al., 2013; Singla et al., 2014). Certainly, the effect appeared to persist 
when patients were split into virtual treatment arms based on the presence or absence 
of isoniazid with the majority of Asian patients with a clinically significant peak ALT in 
the isoniazid-containing treatment arms. However, it needs to be remembered that 
there may be unmeasured factors unique to individual sites that confound the 
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relationship between ethnicity and liver function changes, such as alcohol use and 
viral hepatitis.  
A higher proportion of older patients experienced enzyme elevations when taking 
standard TB therapy and this has been shown to be a risk factor for hepatotoxicity 
previously (Yee et al., 2003; Shu et al., 2013; Hosford et al., 2014; Bright-Thomas et 
al., 2016; Ortega-Alonso et al., 2016). The proportion of patients in each age group 
with clinically significant peak ALT results was found to be statistically significant, but 
this effect was not seen in the regression analysis testing the relationship between 
patient age and DILI or clinically significant peak ALT. A probable explanation for this 
finding would lie in the small numbers in the highest age category that could create a 
false association, and therefore a tentative recommendation can be made to ensure 
that older patients are monitored more closely during treatment. 
An association between significant hepatic events secondary to TB treatment and HIV 
positive status has been reported previously (Ungo et al., 1998; Breen et al., 2006; 
Saukkonen et al., 2006; Hassen Ali et al., 2013), however the precise magnitude of 
this risk is not clear.  The observed higher rate of ALT/AST elevations in HIV positive 
individuals in this study is similar to other reports (Ungo et al., 1998; Breen et al., 2006; 
Hassen Ali et al., 2013), although this did not achieve statistical significance in this 
analysis.  Lower CD4+ counts have been significantly associated with risk for sub-
clinical hepatotoxicity in HIV positive individuals on TB therapy (Yimer et al., 2014). 
Exclusion of patients with CD4< 250cells/uL from the trial may have reduced the rates 
of hepatotoxicity. Also, none of the patients were enrolled on ART (as it was an 
exclusion criteria) and the vast majority did not receive ART during their TB treatment, 
reducing the impact of drug interactions on the incidence of toxicity. 
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Hepatotoxicity has previously been linked to a higher risk of poor treatment outcomes 
(Iseman, 2002; Shang et al., 2011; WHO, 2017), often attributed to morbidity from liver 
dysfunction and the effect of treatment interruptions. There was a 92% rate of cure on 
the standard arm in REMoxTB (Gillespie et al., 2014) and an interrogation of the 
outcome data in relation to liver enzyme elevations did not detect a significant 
association with higher peak ALT results, clinically significant peak ALT levels or DILI. 
This analysis used end points relating to microbiological cure (as treatment outcome) 
and withdrawal from treatment in the trial (as a surrogate for a more complicated 
course of treatment) to draw conclusions about the most appropriate response to liver 
enzyme elevations in clinical practice. The results presented give the clinician 
managing TB patients confirmation that, even in cases with clinically significant 
enzyme elevations or DILI, cure is still likely. However, an implication for policy from 
these findings is that patients participating in the trial were being closely monitored in 
the context of any liver enzyme elevations and this standard of care will likely have 
played a role in the outcome from treatment. The positive results seen among these 
patients should act as a strong motivator for policymakers to ensure that TB services 
are adequately funded to avoid unnecessarily unsatisfactory treatment outcomes 
which have implications at both the economic and public health level. 
After observing unacceptably high rates of significant hepatotoxicity associated with 
the use of rifampicin and pyrazinamide to treat latent TB infection (Jasmer et al., 2002; 
Stout et al., 2003), a protective effect of isoniazid on the liver was hypothesised by 
some as a possible explanation (Lee et al., 2002; Hest et al., 2004) although drug 
dynamics in healthy individuals compared to unwell patients could also provide an 
explanation. In REMoxTB those patients taking isoniazid-containing regimens exhibit 
significantly higher and earlier peak ALT and AST values on treatment. Combined with 
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the significantly lower peak values seen in the moxifloxacin-containing arms (lowest 
in the ethambutol arm), this supports the use of moxifloxacin in liver-sparing regimens. 
Specifically, the low rate of enzyme elevations in the ethambutol arm could suggest a 
role for this as a liver sparing regimen but more work would be needed to investigate 
the ideal duration (Gillespie et al., 2014). 
8.1 Limitations 
There are limitations to the work presented in this chapter. The patient population in 
the REMoxTB study was not fully representative of the diversity of tuberculosis 
patients, as CD4 and liver enzyme criteria were set for admission.  Early in the 
REMoxTB study only AST was measured, and not ALT, which led to absent ALT 
results for some patients. The study protocol did not call for alkaline phosphate 
measurements and it was therefore not possible to apply Hy’s Law criteria (Senior, 
2006; Shen et al., 2014) to clinically significant enzyme elevations (ALT >3xULN and 
Total Bilirubin >2xULN with normal alkanine phosphatase).  The timings of temporary 
medication pauses were also not recorded with sufficient accuracy in the database, 
and there is also an inherent interval censoring in the data due to the scheduled 
sampling times that could reduce the precision of time-to-event analyses. Finally, the 
RUCAM scores were calculated by only one individual as part of this work, and a more 
robust method would have been to obtain scores from two separate individuals and 
ensure that there was sufficient agreement between them. 
8.2 Conclusions 
The work in this chapter constitutes one of the most detailed investigations of liver 
enzyme patterns during standard TB therapy available, based on prospective data 
collected according to prescribed schedule for all enrolled patients in the REMoxTB 
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study. Clinically significant ALT elevations predominantly occurred in the first two 
months of therapy, and a pragmatic monitoring schedule has been suggested that 
may increase the chances of identifying hepatotoxicity early. Older age (on standard 
therapy), Asian ethnicity and the presence of isoniazid in a treatment regimen have 
been shown as significantly associated with liver enzyme elevations during treatment. 
Closer monitoring of these patients during treatment may be beneficial. The analysis 
of the impact of individual drugs has provided reassurance for the inclusion of 
moxifloxacin in liver-sparing regimens and justification for the exclusion of isoniazid.  
Despite relatively high rates of liver enzyme elevations the majority of patients 
completed the course of their treatment with a high cure rate in the standard therapy, 
but questions still remain regarding the optimal approach to treatment interruptions.  
Standard TB therapy is lengthy and toxic, and this work further emphasises the need 
to develop a shorter, effective, and better-tolerated treatment to combat the ongoing 
global epidemic of tuberculosis. 
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Chapter Five: Toxicity and Adverse 
Events in HIV-positive, Anti-
Retroviral Naïve Patients with High 
CD4+ Counts Treated for 
Pulmonary Tuberculosis 
1 General Introduction 
Infection with the human immunodeficiency virus (HIV) continues to act as a major 
driver of the global tuberculosis (TB) epidemic (Montales et al., 2015; WHO, 2017), 
along with the development of drug resistance by the mycobacteria (Dheda et al., 
2017). There were an estimated 1.8 million new infections with HIV in 2016, and an 
estimated 36.7 million people living with HIV (PLHIV) in the same year (UNAIDS, 
2017). The highest incidence (960 000) and prevalence (19.1 million) was seen in 
Eastern and Southern Africa (UNAIDS, 2017).  
HIV infection results in greater chance of developing active TB by causing a 
widespread impairment of the body’s immune system through an initial infection of 
CD4+ T helper cells, which then progresses to a reduced function of other T cell 
classes, B cells and dendritic cells (Pawlowski et al., 2012; Maartens, Celum and 
Lewin, 2014; Bell and Noursadeghi, 2017). In keeping with this, the World Health 
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Organization (WHO) reported the African Region as having the highest proportion of 
HIV-positive cases in 2017, with 34% of reported TB patients that were tested for HIV 
demonstrating a positive result (WHO, 2017). However, it also needs to be 
remembered that the number of TB cases notified as having HIV co-infection only 
represents 46% of the estimated global burden of TB-HIV co-infection across the world 
according to the same WHO Global TB Report (WHO, 2017), and therefore the real 
scale of the problem is likely being underestimated in these figures. 
The clinical presentation of TB-HIV co-infected patients has been reported as differing 
from that seen in HIV-negative patients with active TB disease and related to the 
degree of immunosuppression. HIV-positive patients have been shown as more likely 
to be sputum smear negative at presentation (Cattamanchi et al., 2009; Kwan and 
Ernst, 2011; Gupta et al., 2013), and either have fewer cavities or no cavitation seen 
on chest X-ray (Pitchenik 1985; Pedro-Botet et al. 1992; Post et al. 1995; Perlman et 
al. 1997). This is thought to reflect the frequently lower bacillary burden in co-infected 
individuals (Getahun et al., 2007), translating into a delay in the diagnosis of TB in 
HIV-positive patients (Pablos Méndez & Frieden 1996; Palmieri et al. 2002), and 
consequently worse treatment outcomes (Githui et al. 1993; Banda et al. 2000; 
Hargreaves et al. 2001). There is also a higher risk of developing extra-pulmonary TB 
in patients infected with HIV (Sterling, Pham and Chaisson, 2010) and this can 
complicate the matter further.  
There is an increased risk of toxicity in HIV-positive patients being treated for active 
TB noted in the existing literature (Yee et al., 2003; Dworkin et al., 2005; Lorent et al., 
2011; Tesfahuneygn, Medhin and Legesse, 2015), and as shown in the two previous 
chapters of the thesis. The reasons for increased toxicity are likely multifactorial 
relating to the chronic disease state brought about by HIV infection. HIV-positive 
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patients are known to have higher levels of resting inflammation (Sereti et al., 2017; 
W. Yew et al., 2018), and increased risk of cardiovascular, liver and kidney disease 
as a consequence of the infection (Triant, 2013; Cerrato et al., 2015; Freiberg and So-
Armah, 2015). Following from this primed state there is a higher risk of complications 
during standard TB therapy, especially hepatotoxicity (Saukkonen et al., 2006; Yimer 
et al., 2008; Lorent et al., 2011). Additionally, approximately 15% of HIV-positive 
patients receiving ART will develop tuberculosis-immune reconstitution syndrome (TB-
IRIS) with an attributed mortality of 1-3% (Lawn, Bekker and Miller, 2005; Burman et 
al., 2007; Meintjes et al., 2008). Rifampicin also induces the cytochrome enzymes in 
the liver and this can lead to reduced serum concentrations of ART, most notably the 
protease inhibitors (La Porte et al., 2004; Maartens, Decloedt and Cohen, 2009), and 
there is the risk of overlapping toxicities (for example skin rashes and hepatotoxicity 
with nevirapine and efavirenz) (van Leth et al., 2004; Shipton, Wester and Stock, 2009; 
Lehloenya and Dheda, 2012; Bonnet et al., 2013). Unfortunately, the majority of the 
published work relating to HIV-TB infection is retrospective or observational in nature, 
often involves small numbers of patients, and uses variable definitions for toxicity 
(Blanc et al., 2011; Maartens, Celum and Lewin, 2014; Mfinanga et al., 2014; 
Pasipanodya and Gumbo, 2018; Walker et al., 2018). This makes it difficult to reach 
an accurate estimate of the incidence of toxicity and the form it takes. 
The impaired immune system in HIV-positive patients translates into a reduced ability 
of the host to clear the infection during the course of treatment (Shankar et al., 2014; 
Bell and Noursadeghi, 2017), and consequently higher rates of treatment failure and 
relapse (or possibly re-infection) have been described in ART-naïve HIV-positive 
patients being treated for active TB (Zhou et al., 2009; Getahun et al., 2010; Ismail 
and Bulgiba, 2013). Furthermore, there are associations with a HIV-positive status and 
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increased rates of TB treatment default and loss to follow up; often related to the 
stigma associated with both infections, increased pill burden, and structural factors 
such as transport costs (Munro et al., 2007; Gebremariam, Bjune and Frich, 2010; 
Legido-Quigley et al., 2013; Tesfahuneygn, Medhin and Legesse, 2015). The overall 
risk of treatment failure is reduced in the context of adherence to ART (Manosuthi et 
al., 2006; Sungkanuparph et al., 2006; Zhou et al., 2009), but despite significant gains 
in the roll-out of ART globally there are still many areas where treatment coverage is 
well-below 50% and there were an estimated 1.0 million AIDS-related deaths in 2016 
(UNAIDS, 2017).  
In Chapter 3 and 4 of this thesis, HIV-positive patients were identified as being at 
significantly higher risk of adverse events and toxicity during treatment with standard 
TB therapy, despite only patients with a CD4+ count of 250 cells/mm3 or higher being 
eligible. In this chapter a matched sample of HIV-positive cases and HIV-negative 
controls selected from the REMoxTB database is compared using the detailed 
information collected for these patients over the course of the trial. The research 
questions proposed for the analysis of this matched sample were: 
• What were the differences in the clinical characteristics of HIV-positive and 
HIV-negative patients with pulmonary TB at their presentation? 
• How did the incidence of toxicity and change in measured physiological 
parameters compare between HIV-positive and HIV-negative patients in a 
sample matched for selected baseline characteristics? 
• What differences were seen in terms of treatment outcomes between these 
ART-naïve, HIV-positive patients and the matched HIV-negative controls? 
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2 HIV-positive and HIV-negative Patients in 
REMoxTB 
2.1.1 Baseline Characteristics for all Randomised Patients 
In resource poor settings, where the availability of tests for HIV can be limited,  
clinicians managing TB in the community would benefit from a robust set of baseline 
characteristics that are clearly associated with TB-HIV co-infection. Patients 
presenting with these baseline characteristics would then made a priority for testing 
for HIV infection. Collaborative TB/HIV activities are listed as one of the components 
of Pillar 1 in the End TB Strategy (WHO, 2017), and targeting of those at greatest risk 
of co-infection could help the move towards universal HIV testing by introducing a 
more manageable, evidence-based goal in clinical settings that are already over-
worked. 
Almost 2000 patients were randomised onto one of the three treatment arms in 
REMoxTB and each one of them had detailed clinical and laboratory assessments 
carried out during the screening process. This section of the chapter aimed to use this 
data to compare the baseline characteristics for HIV-positive and HIV-negative 
patients across the trial prior to any treatment being administered to investigate for 
any characteristics that were significantly different between the two groups. 
2.1.2 Matched Population of HIV-positive and HIV-negative Patients 
Assigned to Standard TB Therapy 
One strategy to reduce unmeasured confounding in a non-randomised comparative 
study is to use a matched population. Cases that represent the disease-group or 
intervention of interest are assigned one or more controls who do not have the disease 
or did not receive an intervention. These controls will be similar to the cases in terms 
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of gender, age, ethnicity, and any other variables thought to be relevant. The intention 
is to reduce inherent variability between the case and control groups, and allow for a 
more unbiased estimation of disease impact or treatment effect. 
In this section, coarsened exact matching was used to take advantage of the detailed 
clinical information available for HIV positive and negative patients assigned to 
standard TB therapy in REMoxTB. This technique was employed to create a matched 
case-control sample for analysis in the chapter to attempt to reduce bias when 
estimating the impact of HIV infection on treatment toxicity and outcomes.  
2.2 Methods 
2.2.1 Baseline Characteristics for all Randomised Patients 
The baseline characteristics for all randomised patients across the three treatment 
arms in REMoxTB were compared to determine any significant differences. Patients 
were categorised according to their randomisation status and HIV status in the 
database, and patients who were not randomised were excluded from the analysis. 
Characteristics from before the initiation of treatment were collected for HIV-positive 
and HIV-negative patients, and presented in table format for visual inspection and 
comparison of proportions in each of the two patient categories. The Chi square test 
was applied to investigate for statistically significant differences in the proportion of 
patients with each of the characteristics at presentation accounting for HIV-status. 
2.2.2 Matched Population of HIV-positive and HIV-negative Patients 
Assigned to Standard TB Therapy 
Coarsened exact matching (CEM) was used to create a population of HIV positive 
cases matched to HIV negative controls. This is a monotonic imbalance-reducing 
matching method, wherein the variables to match the population were chosen prior to 
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the matching process based on clinical judgement regarding their probable 
relationship to the patients’ response to treatment over time and eventual treatment 
outcome. The method was developed by Iacus et al (Iacus, King and Porro, 2012) and 
implemented in a user written command for Stata (Newton et al., 2009). The variables 
for age, gender, ethnicity and trial site were selected as the matching variables for 
HIV-positive and HIV-negative patients allocated to the standard TB therapy arm in 
REMoxTB with the matched sample drawn from all patients randomised to this 
treatment arm in the trial. These were considered the most relevant clinical variables, 
and attempting to match on additional variables caused up to 60% of the HIV-positive 
patients being lost from the analysis population. 
CEM converted the selected variables into bins based on an automatic algorithm 
before matching HIV-positive and HIV-negative patients into strata with weights 
provided for each patient within the strata. A copy of the selected variables was made 
and coarsened according to the binning algorithm contained within the CEM program 
before one stratum was created for each unique observation of the copied dataset. 
Each observation was then placed into a stratum, and these strata were assigned to 
the original dataset. Strata that did not contain at least one HIV-positive and HIV-
negative patient were then dropped, and this final matched sample of HIV-positive and 
HIV-negative patients receiving standard TB therapy was adopted as the sample for 
analysis in the remainder of the chapter. The advantage of this process of CEM over 
one-to-one matching is that more patients can be matched using pre-defined 
coarsened variables with a specified maximum bound on the imbalance on the 
moments of each matching variable. The resulting analysis population is larger than 
that obtained from matching on the basis of exact values. 
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The test for global imbalance in the matching variables was based on the difference 
between the multidimensional histogram of the variables in the HIV-positive and HIV-
negative patients, and presented as the L1 statistic (Iacus, King and Porro, 2012). The 
covariates were initially coarsened into bins, and then the discretised variables cross-
tabulated for the case and control groups separately. The relative frequencies for the 
case and control units were recorded and the measure of imbalance given by the 
absolute difference over all the cell values. The L1 statistic indicates the measure of 
global balance between perfect global balance (L1 = 0) and complete separation 
between the matching variables (L1 = 1). 
Baseline characteristics, beyond those used to match the patients, were collected for 
the HIV-positive and HIV-negative patients in the matched sample on standard TB 
therapy. The maximum number of matching variables was chosen that allowed the 
greatest number of HIV-positive patients to be matched to HIV-negative controls. 
However, to ensure that there were no significant differences in the matched sample 
as a result, characteristics were tabulated to demonstrate the proportions according 
to HIV status. Statistical differences in the sample proportions for characteristics in 
HIV-positive and HIV-negative patients were sought using the Chi square test. 
Patients were excluded from the trial if they were taking ART at screening; however 
files in the dataset relating to concomitant medications were used to determine the 
number of patients started on ART during the trial and the timing of initiation. It should 
also be noted that over 200 HIV-positive patients were excluded at screening due to 
either CD4+ counts that were less than 250 cells/mm3 at baseline or because of ART 
use (see CONSORT diagram in REMoxTB New England Journal paper, Appendix 
One). 
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2.3 Results 
2.3.1 Baseline Characteristics for all Randomised Patients 
There were 37 of 140 (26.4%) HIV-positive patients and 349 of 1790 (19.5%) HIV-
negative patients with no cavitation seen on chest X-ray (Chi square p value 0.02). 
However, the proportion of patients with a TTP less than the median value for the total 
analysis sample was similar irrespective of HIV status: 73 of 140 (52.1%) of HIV-
positive and 841 of 1790 (47.0%) HIV-negative patient sputum samples became 
positive faster than the total sample median time at baseline (p value 0.24). 
There were 128 of 140 (92.1%) HIV-positive patients classed as “black” ethnicity and 
734 of 1790 (41.0%) HIV-negative patients; all of the black HIV-positive patients were 
enrolled at South African sites (see Table 2-1). Only 3 of 140 (2.2%) HIV-positive 
patients were Asian ethnicity, compared to 587 of 1790 (32.8%) HIV-negative patients 
belonging to this ethnic group. A higher proportion of randomised HIV-positive patients 
were female, 62 of 140 (44.3%), compared to 523 of 1790 (29.2%) of HIV-negative 
patients (p value <0.001). The median CD4+ count was 399 cells per mm3 (IQR 316 
– 526) among the HIV-positive patients. 
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 HIV-positive 
 
HIV-negative 
n 140 1790 
Gender   
 Male 78 
(55.7%) 
1267 
(70.8%) 
 Female 62 
(44.3%) 
523 
(29.2%) 
Age in Years   
 <25 20 
(14.3%) 
545 
(30.5%) 
 25 – 35 60 
(42.9%) 
546 
(30.5%) 
 >35 60 
(42.9%) 
699 
(39.0%) 
Baseline Weight   
 <40 4 
(2.9%) 
171 
(9.6%) 
 40 – 45 15 
(10.7%) 
311 
(17.4%) 
 >45 – 55 50 
(35.7%) 
716 
(40.0%) 
 >55 – 75 65 
(46.4%) 
552 
(30.8%) 
 >75 6 
(4.3%) 
40 
(2.2%) 
Ethnicity   
 Black 128 
(92.1%) 
734 
(41.0%) 
 Asian 3 
(2.2%) 
587 
(32.8%) 
 Caucasian 0 
(0.0%) 
3 
(0.2%) 
 Other 8 
(5.8%) 
8 
(5.8%) 
Smoking Status   
 Never 70 
(50.0%) 
800 
(44.7%) 
 Previous 38 
(27.1%) 
438 
(24.5%) 
 Current 32 
(22.9%) 
552 
(30.8%) 
Chest X-ray   
 Cavities 80 
(57.1%) 
1247 
(69.7%) 
 No cavities 37 
(26.4%) 
349 
(19.5%) 
MGIT TTP   
 ³ Median 67 
(47.9%) 
949 
(53.0%) 
 < Median 73 
(52.1%) 
841 
(47.0%) 
Table 2-1. Baseline characteristics of all randomised patients for REMoxTB according to HIV status. Column 
percentages included in cells for proportion of total n in for HIV-positive and HIV-negative patients belonging to 
categories of baseline characteristic 
2.3.2 Matched Population of HIV-positive and HIV-negative Patients 
Assigned to Standard TB Therapy 
Coarsened exact matching (CEM) produced a matched population of 42 HIV-positive 
cases to 220 HIV-negative controls all receiving standard TB therapy in REMoxTB. 
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The patients were allocated to 18 matching strata leaving 4 HIV-positive patients and 
374 HIV-negative patients un-matched due to an inability to fit them into one of the 
strata. The multivariate L1 statistic was 0.152 which indicated overall low global 
imbalance according to the matching variables and gives reassurance that the 
matching process worked. The univariate L1 statistic for imbalance across the matched 
population was 0.077 for age, and less than 3x10-16 for sex, ethnicity, and trial site.  
There were no significant differences identified between the HIV-positive and HIV-
negative patients in the matched sample when the Chi square test was applied to the 
proportions in the extended list of baseline characteristics. The median CD4+ cell 
count among the HIV-positive patients was 370 cells per mm3 (IQR 307 – 456). The 
proportion of patients with cavitation seen on chest X-ray at baseline was lower for 
HIV positive patients, as was seen for all patients in the trial, but this fell short of 
reaching statistical significance (p value 0.06). As was noted when all randomised 
patients were compared, the proportion of patients with a TTP less than the median 
sample time was similar with 20 of 42 (47.6%) HIV-positive and 102 of 220 (46.4%) 
HIV-negative patients falling into this category. The process of CEM addressed the 
previous large difference in ethnicity for HIV-positive and HIV-negative patients, and 
Table 2-2 demonstrates similar proportions of patients in each ethnic group (p value 
0.58). Only 10 HIV-positive patients were started on ART following randomisation into 
the trial at a median time of 180 days after first dose of trial medication. 
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 HIV-positive 
 
HIV-negative 
n 42 220 
Gender   
 Male 23 
(54.8%) 
154 
(70.0%) 
 Female 19 
(45.2%) 
66 
(30.0%) 
Age in Years   
 <25 4 
(9.5%) 
40 
(18.2%) 
 25 – 35 17 
(40.5%) 
84 
(38.2%) 
 >35 21 
(50.0%) 
96 
(43.6%) 
Baseline Weight   
 <40 2 
(4.8%) 
9 
(4.1%) 
 40 – 45 7 
(16.7%) 
39 
(17.7%) 
 >45 – 55 16 
(38.1%) 
83 
(37.7%) 
 >55 – 75 15 
(35.7%) 
83 
(37.7%) 
 >75 2 
(4.8%) 
6 
(2.7%) 
Ethnicity   
 Black 38 
(90.5%) 
186 
(84.6%) 
 Asian 2 
(4.8%) 
20 
(9.1%) 
 Other 2 
(4.8%) 
14 
(6.4%) 
Smoking Status   
 Never 18 
(42.9%) 
114 
(51.8%) 
 Previous 11 
(26.2%) 
61 
(27.7%) 
 Current 13 
(31.0%) 
45 
(20.5%) 
Chest X-ray   
 Cavities 26 
(61.9%) 
160 
(72.7%) 
 No cavities 11 
(26.2%) 
32 
(14.5%) 
MGIT TTP   
 ³ Median 22 
(52.4%) 
118 
(53.6%) 
 < Median 20 
(47.6%) 
102 
(46.4%) 
Table 2-2. Baseline characteristics of matched patients in analysis sample from REMoxTB according to HIV 
status. Column percentages included in cells for proportion of total n in for HIV-positive and HIV-negative patients 
belonging to categories of baseline characteristic 
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3 Toxicity and Adverse Events in the Matched 
Population Assigned to Standard TB Therapy 
Previous chapters have demonstrated that toxicity can take many different forms in 
the context of TB chemotherapy, and the approach to monitoring and management 
will vary depending on this. An awareness of the population-level risk and how this 
changes according to a patient’s characteristics is invaluable to the frontline clinician 
treating these patients. This information allows physicians to quickly identify those 
patients who are most likely to have a more complicated treatment period (with the 
associated negative impact on treatment outcomes demonstrated in earlier chapters), 
and ensure that they are more closely monitored and more proactively supported 
during their treatment.  
It has been demonstrated that HIV positive patients were at higher risk of toxicity in 
REMoxTB. Section 2 of this chapter investigated the baseline characteristics of ART-
naïve TB-HIV-co-infected patients with high CD4+ counts  and generated a matched 
cohort of cases and controls, and this section aimed to investigate what form toxicity 
takes in these HIV-positive patients receiving standard TB therapy and when it is most 
likely to occur in comparison to the matched controls. 
3.1 Methods 
The number of HIV-positive and HIV-negative patients who experienced ³1 grade 3 
or 4 adverse event (AE) was calculated for both the total grade 3 or 4 AEs and only 
for those that were considered related by the reporting clinician. Grade 3 or 4 AEs with 
and without recorded start dates were included when identifying these patients and 
events were collated according to System Organ Class (SOC) and Preferred Term 
(PT) for HIV-positive and HIV-negative patients.  
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The median time to the first grade 3 or 4 AE was calculated according to the patient’s 
HIV status for all grade 3 or 4 AEs and for those that were considered related-only. 
Kaplan-Meier curves were constructed using the time to first grade 3 or 4 AE among 
the HIV-positive and HIV-negative patients by calculating the difference between the 
onset date of the event and the date of first dose of standard TB therapy; the earliest 
grade 3 or 4 AE was considered the failure event with censoring at the date of last 
review for those patients who did not experience a grade 3 or 4 AE. Finally, a Cox 
proportional hazards model was used to test the association between HIV status and 
the incidence of first (total and related-only) grade 3 or 4 AE.  
3.2 Results 
A total of 20 of the 42 (47.6%) HIV-positive patients experienced ≥1 grade 3 or 4 AE, 
as opposed to 34 of the 220 (15.5%) HIV-negative patients. One or more grade 3 or 4 
AEs considered to be at least possibly related to treatment was reported by 11 of 42 
(26.2%) HIV positive patients and 14 of 220 (6.4%) HIV-negative patients. There were 
37 of 42 (88.1%) and 72 of 220 (32.7%) patients who reported one or more grade 1 or 
2 AE from among the HIV-positive and HIV-negative group, respectively. These 
proportions changed to 25 of 42 (59.5%) and 52 of 220 (23.6%) patients in the HIV-
positive and HIV-negative groups when only related grade 1 or 2 AEs were included. 
Hepatobiliary disorders accounted for the majority of the total grade 3 or 4 AEs for 
both HIV-positive and HIV-negative patients in the matched population (see Table 
3-1). Respiratory and thoracic disorders, blood and lymphatic disorders, and infections 
and infestations were among the five most common SOCs for both HIV-positive and 
HIV-negative patients.  
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 Adverse Event  
SOC  
Frequency Percent 
 
 
 
 
HIV  
Positive 
Hepatobiliary 
disorders 
12 30.00 
Respiratory and 
thoracic disorders 
7 17.50 
Blood and 
lymphatic 
disorders 
6 15.00 
Infections and 
infestations 
3 7.50 
Metabolism and 
nutrition disorders 
3 7.50 
 
 
 
 
HIV  
Negative 
Hepatobiliary 
disorders 
15 25.00 
Blood and 
lymphatic 
disorders 
13 21.67 
Respiratory and 
thoracic disorders 
10 16.67 
Infections and 
infestations 
5 8.33 
Gastrointestinal 
disorders 
4 6.67 
Table 3-1. System Organ Classes for the five most frequently reported grade 3 or 4 Adverse Events (AEs) 
reported by HIV-positive and HIV-negative patients in the matched population during enrolment in the REMoxTB 
trial. Percentage of total number of grade 3 or 4 AEs provided, but not all events are shown 
“Hepatic enzyme increased” was the most common related grade 3 or 4 adverse event 
PT for both the HIV-positive patients (3 of 18 PTs, 16.7%) and the HIV-negative (6 of 
24 PTs, 25.0%). The 5 most common PTs from related and unrelated grade 3 or 4 
AEs reported for the HIV-positive and HIV-negative patients are shown in Table 3-2. 
“Hepatic enzyme increased” was the most commonly reported PT for HIV-negative 
patients, and the five most common PTs for HIV-positive patients all had the same 
reporting frequency. 
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 Preferred Term 
 
Frequency Percentage 
 
 
 
HIV 
Positive 
Hepatic enzyme 
increased 
3 7.50 
GGT 
increased 
3 7.50 
AST 
increased 
3 
 
7.50 
Hyponatraemia 
 
3 7.50 
Respiratory  
disorder 
3 7.50 
 
 
 
HIV  
Negative 
Hepatic enzyme 
increased            
8 13.33 
Haemoglobin 
decreased 
4 6.67 
GGT  
increased 
3 5.00 
Haemoptysis 
 
3 5.00 
Prothrombin Time  
prolonged 
3 5.00 
Table 3-2. The five most common Preferred Terms used for grade 3 or 4 adverse events reported by HIV-
positive and HIV-negative patients in the REMoxTB trial. Adverse events considered to be related and those 
classed as unrelated are included, and the percentage of all Preferred Terms accounted for by each entry is 
provided although not all Terms are listed 
The hazard ratio for experiencing a grade 3 or 4 AE for HIV-positive patients was 
significantly elevated compared to HIV-negative patients at 3.25 (95% CI 1.87 – 5.66, 
p value <0.01). The hazard ratio remained significant for HIV-positive patients when 
only related grade 3 or 4 AEs were included (HR 3.77, 95% CI 1.65 – 8.60, p value 
<0.01). The median time to first grade 3 or 4 AE was 54 days (IQR 15.5 – 59.0) for 
HIV positive patients and 29.5 (IQR 9 – 119) for HIV negative patients in the analysis 
sample. When only related events were included the time to first grade 3 or 4 AE was 
56 days (IQR 29 – 57) for HIV-positive patients and 50 days (IQR 19 – 56) for HIV-
negative patients. Figure 3-1 presents Kaplan-Meier curves for the time to first grade 
3 or 4 AE according to the patient’s HIV status. 
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Figure 3-1. Kaplan-Meier curves demonstrating the time to first related or unrelated grade 3 or 4 
adverse event according to patient HIV status in the matched sample 
 
4 Longitudinal Analysis of the Matched Population 
Assigned to Standard TB therapy 
Knowledge of the expected clinical course a patient follows during treatment for a 
disease allows the treating clinician to make informed judgements regarding their care. 
This relates closely to the issue of toxicity during treatment, as a deviation from the 
expected course during therapy for a disease will prompt the treating physician to 
consider a change in therapy. In the case of TB, a change in therapy will generally 
translate into the use of less effective drugs and a longer duration of treatment. 
Patients with HIV infection suffer from a chronic disease and therefore will be less well, 
compared to HIV-negative patients with TB, but this makes an accurate quantification 
of measured parameters even more important as there is a risk that warning signs will 
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be inappropriately dismissed or that expected findings will be over-interpreted and 
treatment unnecessarily changed. 
In this fourth section of the chapter an attempt is made to illustrate the patient journey 
on standard TB therapy for largely ART-naïve HIV positive patients and how this 
compares to a group of matched HIV negative controls. Specifically, involving the 
identification of which clinical and laboratory parameters are significantly different at 
the start and end of therapy between HIV-positive and HIV-negative patients. 
4.1 Methods 
The mean values were calculated for haemoglobin result, patient weight, number of 
TB symptoms reported and alanine transferase (ALT) result at each protocol-
scheduled visit for HIV-positive and HIV-negative patients in the matched population. 
Blood samples were collected for haemoglobin at weeks 0, 2, 8, 12, and 17 routinely 
for all patients. Weight and number of TB symptoms reported was documented for 
each protocol-scheduled visit during enrolment in the trial. Serum ALT was measured 
at weeks 0, 2, 4, 8, 12, and 17 for all patients taking trial medication. The mean value 
for each variable was calculated for each scheduled visit when the data was collected 
for the HIV-positive and HIV-negative patient samples, and measurements taken at 
unscheduled visits were discarded. Four different longitudinal plots were created with 
the mean variable value plotted on the y axis and the number of weeks from the first 
dose of standard TB therapy on the x axis. 
Generalised estimation equations (GEE) were used to investigate the association 
between HIV status and the longitudinal change in haemoglobin, weight, symptom 
count, and ALT results at protocol-scheduled visits. GEEs were fit using the 
longitudinal variable of interest as the dependent variable with Gaussian distribution, 
 161 
an identifier link between dependent variable and predictor, and exchangeable 
correlation matrix. The latter rejects the assumption of independence between pairs 
of time points and instead constrains the correlations between values at paired time 
points to be equal. Weeks after first dose of treatment, a multiple of week number and 
HIV flag to test interaction, and the week number squared were also included as 
predictors in the GEE. 
The first and last haemoglobin, weight, TB symptom count, and ALT results for each 
patient in the matched population were used as dependent variables in a multivariate 
regression model with HIV status as the independent variable. Zellner’s seemingly 
unrelated regression was used to build a multivariate model testing the effect of HIV 
status on the variables of interest, chosen to allow for correlation between the error 
terms in the individual regression equations using feasible generalised least squares. 
To allow for a more appropriate comparison of variables in the model, the screening 
value and the result at week 17 were used as all variables had these time points 
routinely measured.  
4.2 Results 
Patients with HIV infection demonstrated a lower mean haemoglobin result at baseline 
and at four months of treatment with standard TB therapy compared to HIV-negative 
patients. The mean haemoglobin at the beginning of treatment was 0.89xLLN and 
1.00xLLN at week 17 in patients with HIV infection, and 0.93xLLN and 1.08xLLN at 
the same time points for HIV-negative patients. The mean haemoglobin at scheduled 
visits according to HIV status is shown in Figure 4-1. There was a significant effect of 
HIV status on the mean haemoglobin over the first 17 weeks of treatment using GEE 
with coefficient -0.05 (95% CI [-0.098] – [-0.003], p value 0.04). 
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Figure 4-1. Longitudinal plots to present the mean value of haemoglobin in HIV-positive and HIV-
negative patients taken at protocol scheduled visits in REMoxTB. Test results taken at unscheduled 
visits are not included in this graph, and haemoglobin is presented as a multiple of the lower limit of 
normal (xLLN) with the 95% confidence intervals for the mean haemoglobin illustrated as shaded 
areas 
The mean weight at baseline and at the end of the follow up period was higher for HIV-
positive rather than HIV-negative patients in the matched sample, however the 
confidence intervals were very wide (see Figure 4-2). The mean weight gain over the 
course of treatment (from baseline to week 26) was 3.16kg for patients infected with 
HIV and 4.82kg among HIV-negative patients in the matched sample. HIV-positive 
patients had a mean weight of 55.81kg at the beginning of their treatment and 62.05kg 
at the end of follow-up (week 78), and this compared to a mean weight of 53.61kg at 
baseline and 61.19kg at week 78 in HIV-negative patients. The GEE regression 
coefficient of 1.78 was not significant (95% CI -1.87 – 5.43, p value 0.34). 
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Figure 4-2. Longitudinal plots to present the mean recorded weight in HIV-positive and HIV-
negative patients collected at protocol scheduled visits in REMoxTB. Weights obtained at 
unscheduled visits are not included in this graph, and weights are presented as kilograms with 95% 
confidence intervals for the mean value as shaded areas 
Figure 4-3 shows that the mean number of TB symptoms reported reached a peak 
for both HIV-positive and HIV-negative patients between weeks 39 and 52 with 
approximately 10 symptoms reported on average per patient. There were 21 of 42 
(50.0%) HIV-positive patients reporting ≥1 TB-related symptoms at baseline with a 
mean of 5.19 symptoms reported per patient. Among the HIV-negative patients, 126 
of 220 (57.3%) reported ≥1 symptom in keeping with active TB and there was a 
mean of 4.60 symptoms recorded per patient. While the mean number of symptoms 
per patient rises to 6.00 at week 78 for the HIV-positive sample the total number of 
patients  reporting symptoms drops over time and there were only 2 of 42 (4.8%) 
patients reporting TB symptoms at that visit. When adjusting for the interaction 
between weeks after treatment and HIV status, there was no significant association 
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between HIV-positivity and the number of TB symptoms reported in a GEE model 
with a coefficient of -1.76 (95% CI -1.10 – 0.75, p value 0.71). 
 
Figure 4-3. Longitudinal plots to present the mean number of TB-related symptoms reported by 
HIV-positive and HIV-negative patients collected at protocol scheduled visits in REMoxTB. 
Symptoms collected at unscheduled visits have been excluded from the data presented in the 
graph, and 95% confidence intervals are shown in grey either side of the line 
During screening for the trial, chest pains and fever each accounted for 17 of 109 
(15.6%) symptoms reported by the HIV-positive patients, with cough and 
breathlessness the second most frequent symptoms each accounting for 16 of 109 
(14.7%) symptoms among those with HIV infection. Weight loss was 15 of 109 
(13.8%) symptoms reported in the HIV-positive group. Cough (105 of 580, 18.1%), 
fever (81 of 580, 14.0%), chest pain (79 of 580, 13.6%), weight loss (70 of 580, 
12.1%), and night sweats (65 of 580, 11.2%) were the five most common symptoms 
reported by the 220 HIV-negative patients.  
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Table 4-1 demonstrates the frequency of the reported symptoms among the 262 
patients in the analysis along with percentages based on the total number of 
symptoms reported by these patients over the course of the trial.  
TB Symptom Frequency of Reported Symptoms 
HIV-Positive 
(% of symptoms) 
HIV-Negative 
(% of symptoms) 
Cough 104 (18%) 555 (19%) 
Chest pains 84 (15%) 420 (15%) 
Shortness of 
Breath 
76 (13%) 331 (12%) 
Fever 73 (13%) 350 (12%) 
Night Sweats 76 (13%) 351 (12%) 
Weight Loss 63 (11%) 294 (10%) 
Haemoptysis 36 (6%) 137 (5%) 
Respiratory 
Abnormalities 
13 (2%) 101 (4%) 
Loss of Appetite 8 (1%) 82 (3%) 
Fatigue 10 (2%) 62 (2%) 
Other 21 (3.7%) 2692 (6%) 
Table 4-1. The ten most frequently reported TB-related symptoms in the matched analysis sample of HIV-
positive and HIV-negative patients. The number presented is the number of times a symptom was reported, and 
patients could not report a symptom more than once at a visit. Symptom count taken from all scheduled visits in 
the REMoxTB database for these patients, and unscheduled visits have been excluded. Percentages based on 
the total number of symptoms reported by these patients over the course of the trial. Percentage of all symptoms 
reported at scheduled visits accounted for by row, according to HIV status, is shown in brackets 
There were 327 symptoms reported by the 42 HIV-positive patients over the course 
of their time in the trial; cough (25.7%), weight loss (13.8%), and chest pains (13.5%) 
were the three most common symptoms. There were 1,669 symptoms reported by 
the 220 HIV-negative patients in this analysis and cough (28.3%), chest pains 
(13.8%), and breathlessness (11.3%) were the most common. Weight loss only 
accounted for 131 of the 1,669 (7.9%) symptoms reported by the HIV-negative 
patients. 
At their scheduled visits at week 8 and week 12, HIV-positive patients had a higher 
mean ALT result than those patients uninfected with HIV. The mean ALT result at 
week 8 was 1.10xULN and 0.68xULN for HIV-positive and HIV-negative patients, 
respectively. At week 12 the mean ALT was 1.25xULN for HIV-positive patients and 
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0.61xULN for HIV-negative patients and the mean ALT result at scheduled visits for 
both patient groups is presented in Figure 4-4.  There was no statistically significant 
difference when the ALT results for the two patient groups were compared at week 8 
and week 12 (p >0.40 for both). The GEE regression coefficient of 0.03 for HIV 
status against ALT result was again not statistically significant (95% CI -0.21 – 0.27, 
p value 0.79).  
 
Figure 4-4. Longitudinal plot to present the mean value of the alanine transferase result in HIV-
positive and HIV-negative patients taken at protocol scheduled visits in REMoxTB. Test results 
taken at unscheduled visits are not included in this graph, and ALT is presented as a multiple of the 
upper limit of normal (xULN) with 95% confidence intervals around the mean shown as shaded 
areas on the graph 
Multivariate regression of the above variables at week 0 and week 17 against HIV 
status as an independent variable did not demonstrate any statistically significant 
associations (see Table 4-2). While it fell short of achieving the agreed level for 
statistical significance, the regression coefficient for the relationship between HIV 
status and both the week 0 and week 17 haemoglobin confirmed a negative 
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association as seen in the above longitudinal plot and the p values were very close 
to the 5% cut-off (0.07 & 0.06). All other variables were associated with a p value 
>0.10. 
 Regression 
Coefficient 
95% CIs P value 
Haemoglobin    
 Week 0 Hb -0.05 -0.10 - 0.00 0.07 
 Week 17 Hb -0.05 -0.10 - 0.00 0.06 
Weight    
 Week 0 Wgt 2.57 -1.24 - 6.38 0.19 
 Week 17 Wgt 1.71 -1.98 - 5.40 0.36 
Symptoms    
 Week 0 Symp 0.04 -0.68 - 0.75 0.92 
 Week 17 Symp -0.59 -1.37 - 0.18 0.13 
ALT Result    
 Week 0 ALT -0.06 -0.22 - 0.10 0.45 
 Week 17 ALT 0.00 -0.22 - 0.21 0.97 
Table 4-2. Regression coefficients from a multivariate model using Zellner’s seemingly unrelated regression to 
test the effect of HIV infection on the dependent variables measured at Week 0 and Week 17. P values and 95% 
confidence intervals are provided for the model estimations 
5 Treatment Outcomes in Matched Population 
Treated with Standard TB Therapy 
Current guidance recommends an extension of treatment to 9 months in cases of TB-
HIV co-infection when the patient is not receiving ART(Nahid et al., 2016), however 
this is based predominantly on observational work and there has not been a 
systematic investigation of treatment outcomes in a prospectively recruited trial of 
these co-infected patients. A commitment to an extra three months of therapy in a 
group of patients with a greater chance of experiencing toxicity could present an 
unnecessary risk if they are as likely to achieve cure from 6 months of standard TB 
therapy. 
This final line of inquiry drew on the available microbiological culture data from 
REMoxTB to elicit differences in treatment outcomes for HIV positive patients 
receiving standard TB therapy and a group of matched HIV negative controls. The aim 
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was to again take advantage of the systematic and detailed nature of the data 
collection in the trial to provide an evidence base for making decisions about TB 
treatment duration for ART-naïve TB-HIV co-infected patients. 
5.1 Methods 
The matched sample of HIV positive and negative patients receiving standard TB 
therapy was categorised according to their recorded outcome in the original REMoxTB 
publication. The definitions for favourable, unfavourable and unassessable outcomes 
in the original REMoxTB publication can be found in the Methods chapter. Per-protocol 
(PP) and modified intention-to-treat (mITT) population criteria are also described in 
detail in the Methods chapter. The proportion of HIV-positive and HIV-negative 
patients who met the criteria for different outcomes based on each of the analysis 
populations was determined and the Chi square test employed to assess the statistical 
significance of any differences in an isolated exploratory analysis. 
The time to first sustained negative culture following randomisation was calculated for 
each patient in the matched sample. Sputum samples were collected at protocol-
specified visits and at any unscheduled visits when it was thought necessary by the 
site doctor, and these samples were cultured in Mycobacterial Growth Indicator Tube 
(MGIT) as described in the Methods chapter. In the trial database, culture results have 
an associated date of collection and time-to-positivity (TTP). The number of weeks 
from the first dose of medication to sputum sample collection was calculated for each 
patient’s culture results, and the “first sustained negative culture” was defined as the 
first culture with a subsequent negative culture collected a minimum of one week later 
with no positive cultures in between. The median time to sustained negative culture 
was calculated for HIV-positive and HIV-negative patients in the matched sample, and 
Kaplan-Meier curves were constructed for the time to first sustained negative culture 
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in both patient groups. Cox proportional hazards regression was used to obtain a 
hazard ratio for reaching a sustained negative sputum culture depending on HIV status 
in this matched sample. 
Patients were then assigned into groups based on whether they achieved a 
microbiological cure. A composite culture status at eighteen months, requiring 
negative cultures on both Lowenstein-Jensen (LJ) slopes and MGIT culture to be 
considered culture negative, was available for the majority of patients randomised into 
the trial. In the same manner as the analysis in Chapters 3 and 4, patients who were 
culture negative at eighteen months were labelled as “cured”. If a patient was lost to 
follow up, or died before eighteen months in the trial, then they were considered cured 
if they had completed their treatment and had two or more consecutive negative 
cultures (at different visits) prior to the date that they were last seen. Those patients 
who were culture positive at eighteen months, or who were lost to follow up or died 
with less than two consecutive negative cultures immediately prior, were considered 
not cured. 
5.2 Results 
Among patients receiving standard TB therapy, 29 of 42 (69.05%) HIV-positive 
patients were favourable in both the PP and mITT assessments, along with 148 of 220 
(67.27%) and 149 of 220 (67.73%) HIV-negative patients classed as favourable in the 
PP and mITT analysis, respectively. A higher proportion of matched HIV-positive 
patients were considered to have had an unfavourable outcome in both the per-
protocol (PP) and modified intention-to-treat (mITT) populations for the original trial 
analysis in REMoxTB, however higher proportions of HIV-negative patients were 
considered un-assessable (Table 5-1). 
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Per-Protocol Population 
HIV Status Favourable Unfavourable Un-assessable Total 
Positive 
(%) 
29 
(69.05) 
3 
(7.14) 
10 
(23.81) 
42 
(100.00) 
Negative 
(%) 
148 
(67.27) 
3 
(1.36) 
69 
(31.36) 
220 
(100.00) 
Modified Intention-to-Treat Population 
HIV Status Favourable Unfavourable Un-assessable Total 
Positive 
(%) 
29 
(69.05) 
4 
(9.52) 
9 
(21.43) 
42 
(100.00) 
Negative 
(%) 
149 
(67.73) 
4 
(1.82) 
67 
(30.45) 
220 
(100.00) 
Table 5-1. Patient outcomes from the matched sample of HIV-positive and HIV-negative patients. The criteria for 
favourable, unfavourable, and unassessable are those used for the per-protocol and modified intention-to-treat 
analysis in the original REMoxTB publication. Row percentages are included to provide proportions of outcomes 
based on HIV status 
 
Figure 5-1. Kaplan-Meier curves illustrating the time to first sustained (two or more 
consecutive) negative MGIT culture for HIV-positive and HIV-negative patients in the 
matched sample.  
The median time to the first sustained negative MGIT culture was 84 days (IQR 49 – 
123) for HIV-positive patients and 73 days (IQR 49.5 – 172) in HIV-negative patients 
assigned to standard TB therapy. Figure 5-1 contains the Kaplan-Meier curves for 
time to first sustained (2 or more consecutive) negative MGIT culture. No significant 
difference was detected in the time to first sustained negative culture between HIV-
positive and HIV-negative patients (logrank p value 0.60). 
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There were 4 of 42 (9.5%) of HIV-positive patients who failed to achieve 
microbiological cure as previously defined (see Section 4.1.1, Chapter 3), and 25 of 
220 (11.4%) HIV-negative patients in the matched sample (p value 0.73). Table 5-2 
contains the proportion of patients considered cured based on their HIV status. 
There were 4 of 38 (10.5%) HIV-positive and 8 of 195 (4.1%) HIV-negative patients 
who achieved microbiological cure referred to the National Treatment Program 
(NTP) at a median time of 41.5 days (IQR 19 – 53) and 130 days (IQR 93.5 – 150.5), 
respectively. “Adverse reaction/toxicity” was the reason given for withdrawal in 3 of 
the 4 (75.0%) HIV-positive patients and 3 of the 8 (37.5%) HIV-negative patients 
cured in the NTP. One HIV-positive patient was referred to the NTP after completing 
standard TB therapy in the trial for further treatment because of disease relapse; 
however, none of the HIV-negative patients were treated for relapse in this matched 
sample. 
HIV 
Status 
No 
Microbiological 
Cure 
Microbiological 
Cure 
Total 
Positive 
(%) 
4 
(9.52) 
38 
(90.48) 
42 
(100.00) 
Negative 
(%) 
25 
(11.36) 
195 
(88.64) 
220 
(100.00) 
Table 5-2. Table presenting the proportion of HIV-positive and HIV-negative patients recorded as achieving 
microbiological cure at 18 months based on culture data from the REMoxTB database. Row percentages 
provided to give proportion of HIV-positive and HIV-negative patients classified as cured, and Chi square p value 
0.73 
6 Discussion 
This chapter of the thesis investigated the incidence of toxicity in HIV-positive patients 
with high CD4+ counts and not receiving ART, and matched HIV-negative controls. All 
the results presented must be interpreted in light of the fact that they relate to these, 
presumably recently diagnosed, HIV-positive patients and are not generalisable to 
HIV-positive patients as a whole. These findings demonstrated that in a matched 
sample of ART-naïve HIV-positive patients with higher CD4+ counts there were still 
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fewer cavities on chest X-ray at presentation. Although there was no statistically 
significant difference detected in the variation of selected clinical parameters during 
treatment, the HIV-positive patients were more likely to begin and end treatment with 
a haemoglobin result below the lower limit of normal.  These HIV-positive patients 
receiving standard TB therapy in the REMoxTB trial were at greater risk of toxicity 
during treatment but not at greater risk of failing to achieve microbiological cure, when 
compared to the matched sample of HIV-negative patients receiving the same 
treatment.  
Cavitation on the chest X-rays of patients diagnosed with pulmonary TB has been 
shown to act as a marker of bacillary burden during the infection (Ong, Elkington and 
Friedland, 2014). HIV-positive patients more frequently present with pauci-bacillary 
disease and extra-pulmonary TB (Swaminathan, Padmapriyadarsini and Narendran, 
2010; Maartens, Celum and Lewin, 2014; Bell and Noursadeghi, 2017), and as such 
observational studies have demonstrated higher rates of patients presenting with 
either fewer cavities or no cavitation when compared to HIV-negative TB patients 
(Pitchenik H A, 1985; Pedro-Botet et al., 1992; Post, Wood and Pillay, 1995). The 
downregulation of CD4+ cells and macrophages seen in HIV infection impairs the 
host’s capability to contain the infection, and a consequent disruption of granuloma 
formation in the lung tissue followed by expansion of the mycobacterial population 
(Shankar et al., 2014; Hunter, 2016; Bell and Noursadeghi, 2017). This analysis 
detected a significant trend for active TB without cavitation at presentation for HIV-
positive patients when all patients were considered, but this trend was no longer 
significant when only the matched population was considered. 
Further to this point, it is noteworthy that the HIV-positive patients in both the total and 
matched samples did not differ significantly from the HIV-negative patients in the time 
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to positive result (TTP) of MGIT sputum culture at baseline. The similar TTP for these 
ART-naïve HIV-positive with higher CD4+ counts and HIV-negative patients presented 
here, along with their response to treatment, would suggest comparable burden of 
disease in both groups and argue against the accepted maxim that all HIV-positive 
patients present with less of a bacillary load. While there should be a degree of caution 
before applying these results to the wider HIV-positive population, as there is a 
spectrum of disease severity predominantly according to the CD4+ count (Ahmad 
Khan et al., 2012; Ismail and Bulgiba, 2013; Lawn et al., 2013; Pepper et al., 2015), 
some conclusions can be drawn relating to the presentation of HIV-positive patients 
with HIV disease that is not easily clinically detectable. These findings should dispel 
any complacency that a patient presenting with classical pulmonary TB is less likely 
to have HIV co-infection, and confirms the importance of testing all TB patients for HIV 
infection. This is most relevant in resource-limited settings, where constrained access 
to HIV testing can lead to a rationing for cases with the highest clinical suspicion, and 
there is a need for more evidence that will inspire direction of more funding and 
resources globally. 
Chest pains, fever, cough, and breathlessness were the four most common symptoms 
reported in the HIV-positive patients at screening. These four symptoms collectively 
made up 61% of the symptoms reported, and weight loss accounted for only 14% of 
the screening symptoms reported among the HIV-positive group. The WHO 
recommends routine screening of HIV-positive patients for active TB using a clinical 
algorithm of one or more of the following symptoms: cough, fever, weight loss, or night 
sweats (WHO 2012; WHO 2011). In a meta-analysis reviewing the individual patient-
level data of HIV-positive patients with pulmonary TB, the best-performing diagnostic 
strategy was the presence of any one of these four symptoms (Getahun et al., 2011). 
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This meta-analysis demonstrated a sensitivity of 79% and a specificity of 50% after 
including data for over 8,000 patients, and the negative predictive value was 90% at 
20% prevalence of TB among HIV-infected individuals. An issue that arises from such 
low sensitivity and specificity is that of missed diagnoses of active TB (as well as 
incorrect diagnosis of TB) among HIV-positive patients in areas with a higher 
prevalence of TB, such as South Africa. In this chapter, among the HIV-positive 
patients only cough and fevers (both daytime and night time) were reported from the 
four most common symptoms, and weight loss was a small fraction of the symptoms 
at presentation recorded in the database. If the WHO criteria were stringently applied 
to these patients in a setting with no access to other investigations, then  there could 
be a real danger of missing the diagnosis of active TB and delaying treatment as a 
result.  
The GeneXpert platform allows for the rapid identification of M tuberculosis in sputum 
(and other bodily fluids) with a sensitivity of up to 75% even in cases of sputum smear-
negative pulmonary TB (Boehme et al., 2010; Steingart et al., 2014), and this also 
provides molecular results for the rifampicin resistance profile of the organism. The 
WHO and other policy-makers now recommend GeneXpert as a first-line method for 
diagnosing active TB (WHO, 2013; Lewinsohn et al., 2017); however the infra-
structure required to support this technology has acted as a barrier to widespread 
implementation. The symptom data collected as part of REMoxTB acts as yet more 
evidence that infra-structure development to allow the use of existing, validated 
diagnostic technology in poverty-stricken areas must be a priority (Albert et al., 2016). 
Rapid identification and treatment of pulmonary TB leads to reduced time for the 
patient to act as an infectious carrier of the disease and earlier initiation of treatment 
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is associated with improved outcomes (Ormerod and Prescott, 1991; Chee et al., 
2000). 
HIV-positive patients in this sample were treated with standard TB therapy lasting six 
months, and there was no significant difference in the proportion of patients who were 
cured 18 months after randomisation. The World Health Organisation (WHO) TB 
treatment guidelines recommend that TB-HIV co-infected patients should receive at 
least the same duration of TB therapy as those patients who are not infected with HIV 
(WHO 2011). The WHO note the results of the 2010 systematic review by Khan et al 
that demonstrated lower rates of recurrence in HIV-positive patients treated for 8 or 
more months (Khan et al., 2010), however their assessment was that the data quality 
for the included studies was low and that extending treatment based on HIV status 
could be operationally challenging. The most recent guidance from the Infectious 
Diseases Society of America (IDSA) recommends extending TB treatment to 9 months 
in cases where HIV-positive patients are not taking ART to reduce the risk of treatment 
failure or relapse, and to treat with standard TB therapy for six months if a patient is 
receiving ART (Nahid et al., 2016).  
The findings in this chapter support the use of 6 months’ standard TB therapy in HIV-
positive patients, as recommended by the WHO (WHO 2011), in cases with higher 
CD4+ counts if the patient is not taking ART. The predominant concern in treating 
ART-naïve TB-HIV co-infected patients for 6 months is the risk of treatment failure or 
relapse (Nettles et al., 2004; Weiner et al., 2005; Nahid et al., 2016), however in this 
analysis there was only one case of disease relapse meriting re-treatment following 
standard TB therapy. Additionally, the HIV-positive patients who achieved a 
microbiological cure were referred to the NTP prior to completing treatment in the trial 
at a median time of 41.5 days and the most common reason was toxicity or a 
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complication during treatment. Therefore, the patients in the trial who required 
additional treatment were identified at an early stage. The WHO guidance raises the 
point of logistical challenges surrounding an extension of treatment in HIV-positive 
individuals (WHO 2011), and this data would indicate that a more appropriate method 
might be to ensure that HIV-positive patients are monitored closely during the intensive 
phase (as mentioned in previous chapters, and given that toxicity was the most 
common reason for withdrawal). Those patients who complete the intensive phase of 
treatment uneventfully could then perhaps be treated with standard TB therapy for six 
months, and this would reduce unnecessary burden on TB treatment programs that 
are already under-resourced. 
Coarsened exact matching (CEM) was adopted to address the limitations of the small 
numbers in this analysis by trying to create a case-control sub-study from the trial data. 
The analysis of small samples is fraught with danger that effect size will either be 
underestimated or overestimated due to undetected sampling bias as small numbers 
will frequently over-represent one aspect of the sample population (Lagakos, 2006; 
Chisti et al., 2015; Shann and Lange, 2015). The principle of regression to the mean 
demonstrates the effect on sample characteristics as the size of the sample increases 
and the sample mean will be brought to a place more representative of the true 
population mean. Coarsened exact matching seeks to improve the balance in the data 
between treatment and control groups (in this case the HIV infected and uninfected), 
leading to more similar empirical distributions in the two groups of the covariates used 
in the matching process. By breaking the covariates of interest down into bins, CEM 
approximately matches each HIV-positive patient with at least one HIV-negative 
control and this leads to less model dependence and reduced statistical bias when the 
two groups are compared. This does not completely remove the caveats that must be 
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applied when dealing with sample sizes as small as the HIV-positive sample in this 
analysis (Lagakos, 2006; Wang et al., 2007; Button et al., 2013), however it does allow 
for some meaningful conclusions to be drawn. The use of CEM to create the case-
control design should help to reduce the bias that will be inherent in this post-hoc 
(essentially observational) analysis of the trial data and re-inforce the significance of 
the differences noted between the two groups within the confines stated throughout 
the chapter. 
6.1 Limitations 
A further limitation to this analysis is the exclusion of HIV-positive patients with a CD4+ 
count less than 250 cells/mm3 by the trial protocol. These ART-naïve patients with HIV 
infection and high CD4+ counts represent a group that have less advanced disease, 
and this means that the rates of adverse events should be considered to represent a 
favourable scenario for patients not receiving ART. This should also be noted when 
considering the data on clinical change over time and microbiological outcomes. 
Unfortunately, this means that broader conclusions about ART-naïve TB-HIV patients 
cannot be drawn from the analysis presented here as these patients will frequently 
present to healthcare at a later stage with HIV disease that is more advanced and 
lower CD4+ counts. ART has been conclusively shown to improve TB-HIV co-infected 
patients’ outcomes, and this chapter does not disagree with the need for early ART in 
these patients despite the reassuring treatment outcomes.  
6.2 Conclusions 
This chapter concludes the investigation into toxicity during treatment for pulmonary 
TB by performing a detailed examination of the nature of adverse events experienced 
by HIV-positive patients in the REMoxTB trial, a patient group shown to be at 
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significantly greater risk of toxicity in the two previous chapters. The increased risk of 
adverse events associated with HIV infection has implications for clinical monitoring 
of these patients and confirms the need for clinicians to ensure that TB programs focus 
on this high-risk group even in cases where the CD4+ is preserved. The treatment 
outcomes among the HIV-positive and HIV-negative patients were similar with six 
months of standard TB therapy, and those patients who required longer durations of 
therapy were identified early in treatment. TB therapy is particularly toxic for HIV-
positive patients, and this would indicate that those patients performing well clinically 
do not need to be exposed to a longer duration of these hazardous drugs. The data 
presented in this chapter illustrates the wealth of information that can be gained from 
even a small number of patients prospectively recruited and systematically followed 
over the course of treatment. However the management of HIV has significantly 
changed over the past five years and the goal is now to ensure that all HIV-positive 
patients are initiated on ART much earlier, therefore limiting the generalisability of 
these findings. In future Phase III TB trials it will be critical that recruitment and 
monitoring of HIV-patients is undertaken with sufficient accuracy to translate into real 
clinical benefit for this often under-served patient population. 
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Chapter Six: Discussion 
1 Toxicity Related to Tuberculosis Treatment 
The toxicity associated with any treatment works to undermine its effectiveness, and 
this holds true with treatment-related toxicity in tuberculosis (TB) patients. There is a 
cure available for this disease, and yet it remains one of the leading causes of death 
globally (WHO, 2017). This state of affairs is clearly not wholly attributable to the 
treatment interruptions and associated increased morbidity and mortality seen with TB 
treatment-related toxicity (Saukkonen et al., 2006; Sharma et al., 2010; Shang et al., 
2011); however, toxicity is likely to be a contributing factor. 
The work presented in this thesis was intended to characterise the nature of toxicity 
related to standard treatment for drug-sensitive pulmonary TB, and the observed 
impact on treatment outcomes, based on data from the REMoxTB study. Additionally, 
the toxicity associated with the experimental, moxifloxacin-containing treatment arms 
was investigated and compared to that seen on standard TB therapy. The intentions 
were to better inform clinicians as to the true side effect profile of standard TB therapy, 
contribute to the development of monitoring programs, and help inform the current 
research agenda through a better understanding of the shortcomings of existing TB 
treatment. 
1.1 Who is at Risk of Toxicity on Standard TB Therapy? 
Female patients, those infected with the human immunodeficiency virus (HIV), and 
patients of Asian ethnicity were found to be at significantly higher risk of experiencing 
toxicity. Approximately 10% of patients taking standard TB therapy experienced one 
or more clinically significant adverse events that were thought to be related to 
 180 
treatment, with female and HIV-positive patients at significantly greater risk in Chapter 
Three. The analysis in Chapter Four demonstrated that around 6% of all patients 
experienced a clinically significant elevation of their liver enzymes while receiving 
standard TB therapy, and patients classed as Asian ethnicity were at significantly 
higher risk of hepatotoxicity. Asian ethnicity has been previously linked to increased 
risk of hepatotoxicity (Huang, 2014; P. Wang et al., 2016), thought to be contributed 
to by the high proportion of patients of slow-acetylator status among some populations 
in Asia (An et al., 2012; Chan et al., 2017), and these results reinforce the need to 
ensure that these patients are monitored closely during treatment with standard TB 
therapy. However, a significant association between female sex and toxicity related to 
standard TB therapy has only been mentioned in a small number of publications 
(Ormerod and Horsfield, 1996; Yee et al., 2003; Marra et al., 2007), and this could be 
related to the higher reported incidence of pulmonary TB among males (WHO, 2017) 
leading to smaller numbers of females with fewer events observed. While the findings 
presented here indicate a novel finding of higher risk of adverse events among 
females, it also needs to be remembered that adverse events are subject to reporting 
bias (McGauran et al., 2010). Therefore, it is not clear whether it is a matter of 
genuinely increased incidence of toxicity, or increased identification and reporting of 
adverse events. 
Interestingly, a lower baseline weight, indicators of higher bacillary load (time to 
positive Mycobacterial Growth Indicator Tube result (TTP) and cavitation on chest X-
ray) and current or previous smoking status were not significantly associated with an 
increased risk of adverse events or toxicity in a logistic regression analysis in Chapter 
Three. This is a finding that stands in contrast to previously published work where 
associations have been made between increased rates of treatment-related 
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complications and poor baseline health or higher bacillary load (Chang, Leung and 
Tam, 2004; Leung, Chan and Yew, 2004; Forget and Menzies, 2006; Mouton et al., 
2018). The enrolment of patients into the trial using strict inclusion and exclusion 
criteria lends strength to the results of analyses using the REMoxTB database by 
helping to define the patient population clearly, and therefore focussing the 
conclusions on these patient groups who were also closely monitored as part of the 
trial. These baseline findings could be related to other factors such as delay in seeking 
medical attention and generally negative aspects of the patient’s lifestyle; these could 
be the actual drivers behind the association seen in observational studies. The 
inclusion and exclusion criteria of the trial acted to select out patients who were more 
unwell at baseline and therefore the association seen in observational studies could 
have been lost.  
The HIV-positive patients in the study were enrolled with higher CD4+ counts and all, 
except for 2 patients, were not taking anti-retroviral therapy during TB treatment. 
Previous observational work has attributed varying levels of risk for adverse events 
during standard TB therapy for HIV-infected patients (Yee et al., 2003; Dworkin et al., 
2005; Lorent et al., 2011; Tesfahuneygn, Medhin and Legesse, 2015), and this work 
provides insight into a sub-group of these patients. In particular, there has been an 
association noted with hepatotoxicity on treatment which is sometimes reduced or 
increased in the context of ART (Saukkonen et al., 2006; Yimer et al., 2008; 
Pasipanodya and Gumbo, 2010; Lorent et al., 2011). While HIV-positive patients were 
at significantly higher risk of toxicity in general in this analysis (found in Chapter 
Three), the risk was attenuated when only clinically significant liver enzyme elevations 
were considered (15% vs 9% for HIV-positive and HIV-negative patients in Chapter 
Four, respectively). This is likely to have been influenced by the small numbers, 
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relative good health of the patients, and the lack of overlapping toxicity from anti-
retroviral therapy (ART). Hence, it is still noteworthy that the proportion of patients 
affected by hepatotoxicity is almost double in the HIV-positive group. 
1.2 What is the Nature and Timing of the Toxicity 
Associated with Standard TB Therapy? 
Hepatotoxicity was the most common form of treatment-related toxicity detected 
among patients receiving standard TB therapy, as seen in Chapter Three and explored 
further in Chapter Four. Toxicity affecting the liver has been identified as a common 
occurrence with standard TB therapy in earlier reports and the safety findings of the 
original clinical trials when short-course chemotherapy was developed (Fox, Ellard 
and Mitchison, 1999). The reported incidence of toxicity in the existing literature is 
wide, and ranges from approximately 5-30% (Thompson et al., 1995; Tost et al., 2005; 
Saukkonen et al., 2006; Shu et al., 2013) of treated cases but the incidence in the 
REMoxTB study was closer to the lower limit of this range. While approximately 6% of 
patients experienced clinically significant liver enzyme elevations (a three-fold or 
greater rise above the upper limit of normal), it was noteworthy that only 3% of patients 
met the criteria for true drug-induced liver injury (DILI). Several reasons could explain 
this lower incidence, compared to the apparently higher rates of toxicity seen in other 
work. First, each of these patients was prospectively followed at frequent reviews at 
protocol-scheduled assessments and therefore treatment may have been interrupted 
earlier than would normally happen in normal practice. Second, the definition of 
“hepatotoxicity” varies between these reports and could be considered an 
asymptomatic liver enzyme elevation, enzyme elevations at varying cut-off values, or 
only patients who develop symptoms that prompt liver biochemical testing. Third, 
inclusion and exclusion criteria were applied to select out a less unwell patient 
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population and therefore this incidence should be considered a minimum. Finally, this 
study involved patients recruited at different sites across the world and is more of a 
generalised estimate. Many of the published reports involve only one ethnic group and 
this may at least partly explain the discrepancy seen, bearing in mind the significant 
association seen between Asian ethnicity and hepatotoxicity in the REMoxTB study.  
The majority of all adverse events occurred in the first two months of therapy, and over 
50% of the total related adverse events reported by patients receiving standard TB 
therapy were accounted for by hepatobiliary disorders and musculoskeletal disorders 
(predominantly arthralgia). The role of pyrazinamide in standard TB therapy during the 
first two months of therapy is essential to ensure adequate treatment in six months 
(British Medical Research Council, 1974; Grosset, 1978; Association, 1982; Snider et 
al., 1984), but there is no doubt that it is also a toxic drug (Horsfall et al., 1979; Jenner 
et al., 1981; Steele and Des Prez, 1988; Schaberg, Rebhan and Lode, 1996; Jasmer 
et al., 2002; Lee et al., 2002; Yee et al., 2003). The earliest studies demonstrated the 
hepatotoxic potential of pyrazinamide and this has also been found to be both dose-
related and idiosyncratic (British Medical Research Council, 1981; Hong Kong Chest 
Service/Tuberculosis Research Centre, 1989; Jindani, Nunn and Enarson, 2004; 
Chang et al., 2007). The pattern of toxicity in this analysis would seem to reinforce 
pyrazinamide’s standing as one of the drugs in the regimen with the most pronounced 
side effect profile, and acts as a reminder that standard TB therapy continues to rely 
on drugs that are poorly tolerated and only remain in use because of a lack of viable 
alternatives. 
1.3 What is the Impact of Toxicity on Treatment Outcomes? 
Patients who experienced one or more adverse event had approximately 3-fold 
greater odds of failing to achieve a microbiological cure on standard TB therapy, for 
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both total adverse events and those assessed as being related to treatment only. 
Toxicity related to treatment is associated with higher rates of treatment failure in 
tuberculosis (Ormerod and Prescott, 1991; Pablos-Méndez et al., 1997; Chee et al., 
2000) and other infections as well (Shields et al., 2016; Danel et al., 2017), and this 
relationship is generally attributed to interruptions in treatment that occur because of 
the toxicity. However, the relationship is likely to be more complicated than this; while 
the odds ratio was higher when only related events were included, the odds were still 
significantly elevated when all events were included. Therefore, this data would seem 
to indicate that sometimes a treatment failure may be heralded by non-specific 
symptoms and findings that actually represent the failure itself in a less-defined form, 
and also that adverse events on treatment are markers of increased risk of treatment 
failure or recurrence through several potential mechanisms (including toxicity). 
The social aspect of TB disease is well-recognised: poverty and marginalisation are 
characteristic of the typical TB patient population (Lö et al., 2009; Lönnroth et al., 2010; 
Wingfield et al., 2018) and a failure to deal with the broader issues underlying the 
disease presentation can mean that even successful microbiological cures ultimately 
end in a poor outcome. Poverty is associated with increased risk of other illness, both 
infectious and non-communicable (Pickett and Wilkinson, 2015; Chetty et al., 2016; 
Canudas-Romo, 2018; Chokshi, 2018), and violence (Krug et al., 2002; Sen, 2008) 
that contribute towards a lower life expectancy among affected individuals. The 
majority of patients who died on the standard TB therapy arm in the study did so having 
completed their treatment, for reasons both related and unrelated to their pulmonary 
TB. The finding of more deaths occurring after treatment had been successfully 
completed (often with no clinically significant adverse events reported), and within 18 
months of their randomisation, should give some pause for thought. There is evidence 
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available demonstrating that simple but effective interventions that impact on both the 
risk of TB disease (Lönnroth et al., 2010; Wingfield et al., 2018) and violence (WHO 
2014) are possible, but what is required is the political will to bring about change. While 
the need for novel shorter, more effective treatment for TB is apparent the REMoxTB 
mortality data is a reminder that a holistic view of the patient and their circumstances 
is necessary to achieve a truly successful outcome following treatment. 
1.4 What is the Toxicity Profile of the Experimental 
Moxifloxacin-containing Treatment Arms? 
The intention behind investigating the experimental arms was to better understand 
what place they could potentially have in TB treatment at a time when new treatment 
options are desperately needed. The work presented in this thesis has shown that the 
experimental treatment arms were less toxic than standard TB therapy among the trial 
population in the REMoxTB study, although this must be considered in light of the fact 
that these regimens failed to demonstrate non-inferiority compared to standard TB 
therapy in terms of treatment outcomes. A question that hangs over these 
experimental regimens relates to what the optimum duration of treatment is for them; 
a less toxic treatment option that can be delivered in six months with outcomes 
comparable to standard TB therapy could still have an application in treating high-risk 
patients, for example.  
Isoniazid is used in isolation to treat latent TB infection, and because of this it is 
recognised as being a hepatotoxic drug. The rate of liver dysfunction while taking 
isoniazid preventive therapy is reported as ranging between 0.1 – 5% (Nolan, 
Goldberg and Buskin, 1999; Jasmer et al., 2002; Al-Darraji, Kamarulzaman and Altice, 
2012)and both the British and American Thoracic Societies (Ormerod et al., 1998; 
Saukkonen et al., 2006) recognise the hepatotoxic potential of the drug when advising 
 186 
on the need for treatment interruptions. As mentioned in Chapter Four (Section 8), 
after unacceptably high rates of hepatotoxicity were observed from the combination of 
rifampicin and pyrazinamide used to treat latent TB infection (Jasmer et al., 2002; 
Stout et al., 2003) the theory that isoniazid may exert some kind of protective effect 
was raised (Lee et al., 2002; Hest et al., 2004). The work presented in Chapter Four 
would disagree with this proposal and support the hepatotoxic nature of isoniazid. The 
isoniazid-containing regimens demonstrated higher rates of drug-induced liver injury 
(DILI, 3.4% on both standard TB therapy and the isoniazid arm, compared to 2.2% on 
the ethambutol arm). Furthermore, patients receiving an isoniazid-containing regimen 
also reached a clinically significant liver enzyme elevation faster than those patients 
on the ethambutol arm (18.5 vs 28 days). In cases of significant hepatotoxicity on 
standard TB therapy isoniazid should remain a potential culprit drug and its exclusion 
from liver-sparing regimens is justified by these analyses. Lastly, this also highlights 
the potential role of the ethambutol arm in the treatment of TB patients at high risk of 
hepatotoxicity, if a duration that makes the regimen more efficacious can be defined. 
Moxifloxacin has previously been shown to have a favourable safety profile in earlier 
studies that predominantly relate to its use in bacterial infections (Gillespie, 2016). 
However, it is still infrequently associated with cardiac arrhythmias (Haverkamp et al., 
2012; Mehrzad and Barza, 2015), dysglycaemia (WHO 2014), tendinopathies (van der 
Linden et al., 2002; Khaliq and Zhanel, 2003), and very rarely hypersensitivity-
mediated fulminant liver failure (Soto et al., 2002; Nori et al., 2004; Verma et al., 2009). 
In light of these accepted toxic effects, there was some uncertainty around the 
potential for an increased duration of treatment leading to an increased risk of toxicity 
when moxifloxacin was proposed as a treatment for TB. However, the number of 
patients experiencing one or more events was lower in both the isoniazid (36 patients) 
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and ethambutol (25 patients) arms compared to standard therapy (47 patients). The 
original REMoxTB publication noted that there was no increased incidence of 
fluoroquinolone-associated toxicity on the experimental arms (Gillespie et al., 2014) 
(e.g. tendinopathy, dysglycaemia, cardiac arrhythmias), and a further examination of 
the safety data relating to the trial corroborated this finding. There were also fewer 
patients with clinically significant liver enzyme elevations (ALT and/or AST ≥3xULN) 
among those receiving the experimental, moxifloxacin-containing regimens compared 
to standard TB therapy (7.0% vs 9.4%) although this must be interpreted in light of the 
similar incidence of DILI on standard TB therapy and the isoniazid arm. Overall, the 
REMoxTB database supports the role of moxifloxacin in the treatment of pulmonary 
TB, and this is an encouraging finding given the drug’s role in the treatment of both 
isoniazid-monoresistant and rifampicin-resistant TB. 
2 Applying the Results to Practice 
2.1 Patients with Pulmonary Tuberculosis 
A clear understanding of the expected toxicity associated with standard TB therapy 
will help with informed decision-making, and it is hoped it will improve adherence to 
treatment. Patients who are aware of the true frequency of adverse effects from the 
medication can be prepared for these toxicities, and if they do occur there will be less 
surprise in the context of an informed agreement to treatment. Previous work has 
shown that this has a positive impact on adherence to treatment and consequently a 
positive effect on treatment outcomes as well. Empowerment of patients with more 
knowledge about the treatment they are to receive, with a rational discussion around 
the risk to benefit ratio, is one of the goals of modern medicine and this work will 
contribute to this ongoing effort. 
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Patients taking standard TB therapy must be aware of when it is necessary to seek 
medical attention. As well as informing patients of the less serious toxicity associated 
with treatment to attempt to improve adherence, they must also be aware that some 
toxicities are a cause for concern and require intervention. The analyses presented 
here provide reassurance that many side effects from standard TB therapy are not life-
threatening; however, there were several cases of extremely high liver enzyme 
elevations with associated clinically symptoms of gastrointestinal upset and abdominal 
pain. Drug-induced hepatotoxicity can be a fatal complication and, while there were 
no confirmed deaths due to drug-induced hepatotoxicity in this study, it is critical that 
patients are aware of the symptoms of hepatotoxicity and the importance of prompt 
medical intervention.  
2.2 Clinicians Managing Pulmonary Tuberculosis 
The information in this thesis adds to the evidence base to assist clinicians in making 
informed decisions regarding the monitoring of at-risk individuals, the interpretation of 
findings and the management of toxicity. The identification of increased risk of toxicity 
among female patients, those with HIV infection, and Asian patients allows TB 
clinicians to easily target patients who are at greater risk of a complicated treatment 
course and take appropriate steps (tailored to the individual patient’s situation) to 
ensure an adequate package of care is in place. A proposed adequate care package 
would involve the direction of resources to ensure that any barriers to a patient 
attending for monitoring visits are addressed (for example housing or transport costs) 
as well as ensuring the availability of the materials and equipment (such as laboratory 
facilities). While not every patient with these baseline characteristics will experience 
clinically significant toxicity, it is hoped that an increased awareness of these patient 
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groups would result in toxicity being addressed in a timely fashion and liver toxicity is 
one of the clearest examples. 
The interpretation and appropriate response to liver function tests during treatment 
with standard TB therapy is a point of contention. The expected pattern of liver enzyme 
elevations in all patients receiving standard TB therapy, including those without any 
symptoms of hepatotoxicity, is not well defined and the official guidance from the 
American and British Thoracic Societies provides advice on treatment changes using 
liver enzyme levels that have been arbitrarily assigned (3x and 5x the upper limit of 
normal, with and without symptoms or elevated bilirubin). The data presented here 
demonstrated that the majority of patients with liver enzyme elevations of 3xULN or 
higher completed standard TB therapy and were not withdrawn from the trial. 
Additionally, only a small proportion of patients developed liver enzyme elevations 
greater than 5xULN and the practice was to re-introduce all drugs in the regimen at 
the same time in the trial.  
This would suggest that a practice of close monitoring but continuing treatment when 
liver enzyme levels are >3xULN but <5xULN would be reasonable in absence of 
concerning features, and adopting a re-introduction of the full regimen would also be 
reasonable. Furthermore, the small proportion of patients with liver enzyme elevations 
>5xULN should prompt the TB physician to think broadly and include other potential 
causes of hepatotoxicity in their differential diagnosis instead of automatically 
concluding that standard TB therapy is the underlying cause. 
2.3 Policy Makers Directing Tuberculosis Services 
Episodes of clinically significant toxicity were associated with a statistically significant 
increase in the odds of a patient failing to achieve a cure in the REMoxTB study. The 
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public health and economic implications to these findings should be given appropriate 
consideration by policy makers. Decisions regarding the allocation of resources are 
weighted by the demonstrated benefit or consequences of changing practice or failing 
to address certain issues; these results make the benefit of adequately supporting TB 
services more apparent.  
Patients who fail to be cured of their TB can either remain infectious or return to an 
infectious state, are at a higher risk of developing drug-resistant infections, and also 
are unlikely to remain fit to continue working. The first two risks are of public health 
concern as they will directly work against any efforts to curb or eradicate TB in a region, 
and the third a well-recognised economic issue associated with TB infection. Policy 
makers working in TB endemic areas are often faced with difficult decisions about 
resource management, and this helps to provide an evidence-based rationale to give 
attention to supporting TB services to not only supply treatment but also in the 
monitoring and management of complications. This thesis has indicated that the 
majority of liver enzyme elevations and cases of drug-induced liver injury occur in the 
intensive phase of treatment. The incidence of significant liver enzyme elevations in 
the intensive phase may help to guide the timing for patient monitoring and provides 
some reassurance to the clinician that patients who successfully complete the 
intensive phase of treatment are less likely to develop significant hepatotoxicity. 
However, the optimum monitoring schedule for drug-induced liver injury remains 
unclear. 
2.4 The Potential Role of the Moxifloxacin-containing 
Regimens 
The experimental treatment arms had fewer patients reporting clinically significant 
adverse events compared to the standard TB therapy arm. The main implication of 
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this finding would be the potential for the moxifloxacin-containing regimens to be 
adopted as treatment options for patients who are at elevated risk of experiencing 
adverse effects from treatment (for example, those with advanced liver disease, other 
significant pathologies, or an intolerance of isoniazid). However, the duration would 
clearly have to be extended given that four months of treatment was not non-inferior 
to standard TB therapy, and it also cannot just be assumed that six months of therapy 
with the experimental regimens would be sufficient. The inclusion and exclusion 
criteria for REMoxTB resulted in the recruitment of relatively healthy patients, and 
therefore the toxicity seen with standard TB therapy in these analyses should be seen 
as a minimum incidence. This may have also acted to close the gap in the incidence 
of toxicity on standard TB therapy and the experimental treatment arms. 
As a result, questions arise as to whether these treatment arms could potentially have 
a place in the treatment of TB for patients at greater risk of treatment-associated 
toxicity (e.g advanced liver disease, other significant chronic diseases, or intolerance 
to isoniazid or ethambutol). However, any possible benefits of using these less toxic 
regimens must be carefully balanced against their failure to achieve formal non-
inferiority compared to standard TB therapy, the uncertain optimal duration of these 
experimental arms, and that with close monitoring in a clinical trial setting less than 
10% of patients taking standard TB therapy were affected by significant toxicity. 
Therefore it should be considered that, rather than introducing the experimental arms 
as a novel treatment regimen for drug-susceptible TB, the best course of action could 
be simply working to increase the resourcing of existing TB services to allow them to 
deliver standard TB therapy in a setting that helps with early detection of adverse 
events. 
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3 Future Directions 
3.1 Development of Novel Tuberculosis Treatments 
There is a clear need for less toxic treatments for tuberculosis. In this thesis, the 
incidence of clinically significant toxicity was between 10-20% on standard TB therapy 
and there was a significant impact on treatment outcomes. In the early development 
of new TB treatment candidates there is much emphasis placed on the efficacy of a 
new regimen, and rightly so. However we must be careful to not be lulled into a false 
sense of security that a novel regimen as toxic as standard TB therapy has an 
acceptable safety profile. The comparator for these new regimens has been shown 
here to be clearly toxic, and phase II trials of new drugs should pay close attention to 
the drug safety profile. The aim is to find less toxic treatments and not just treatments 
that are as toxic but have superior efficacy to standard TB therapy. Adherence, social 
factors and the effect of other potentially toxic drugs are deciders of the effectiveness 
of a treatment in the real-world setting (Choi et al., 2014; Kirenga et al., 2014; Tiberi 
et al., 2018) and unacceptable levels of treatment-associated toxicity will undermine 
the effectiveness of any therapy. 
The majority of adverse events occurred in the first two months of therapy in 
REMoxTB, and this indicates that shortening the duration of TB therapy will not 
necessarily translate into less treatment-associated toxicity. The work presented here 
has clearly demonstrated that the majority of toxic events occurred in the intensive 
phase of treatment on all three of the treatment arms in REMoxTB, and notably there 
was no difference between patients receiving placebo (in Months 5 and 6 of treatment) 
and those patients receiving active treatment on the standard TB therapy arm. Instead, 
there should be a focus on this early stage of therapy when patients seem to be most 
vulnerable to treatment-associated toxicity and thought given to the reasons 
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underpinning this phenomenon. The role of pyrazinamide in this toxicity was raised 
previously, but the physiological state of the patient at this early stage of treatment 
should be a consideration (Makhlouf et al., 2008; Hassen Ali et al., 2013; Chen et al., 
2015). At the beginning of treatment, it is reasonable to assume that the patient is at 
their most unwell and this could leave them in a physiologically primed state for 
developing treatment-related toxicity.  
Host-directed therapies and other immune-modulating treatments could be at least 
part of the solution to this problem (Wallis and Hafner, 2015; Kolloli and Subbian, 2017; 
Tiberi et al., 2018). There is a renewed interest of late in the effect on treatment 
outcomes using therapies that up- or down-regulate certain aspects of the host 
immune system in an attempt to create the optimum immune state for combating 
active TB disease, as well as the effect of immunosuppressant agents on long term 
outcomes in pulmonary TB (Madan et al., 2013; Critchley, Orton and Pearson, 2014). 
Oxidative stress is already known to play a role in drug-related hepatotoxicity 
associated with TB therapy (W. W. Yew et al., 2018), and therefore it would seem 
reasonable to hypothesise that the immune state at the beginning of treatment with 
standard TB therapy would have a bearing on the patient’s risk of toxicity. This 
highlights the need for a broad perspective on how novel drug therapies are 
developed, with close collaboration between experts in immunology, pharmacology 
and toxicology. 
3.2 Clinical Trial Designs for Novel Tuberculosis 
Treatments 
Safety reporting is a contentious area in clinical trials, in particular the assessment of 
relatedness for an adverse event, and further work must be done to refine our 
approach to monitoring adverse events in clinical trials (Events, 2006; Mukherjee et 
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al., 2011; Pocock and Gersh, 2014; Hillman et al., 2017). In this thesis, the proportion 
of patients experiencing a clinically significant adverse event dropped from 20% to 
10%, approximately, when only events assessed as “related” to treatment (i.e. toxicity) 
were included. This could lead to quite large variation in any estimates of the side 
effect profile of a new treatment being investigated in a clinical trial. The attribution of 
relatedness, which relies almost exclusively on the judgement of the treating physician 
(constrained by soft guidance on the timing of events, effect of any re-introduction 
etc.), has already been shown as highly variable and often clearly incorrect, such as 
in situations where a patient is receiving placebo (Hillman et al., 2017).  
A more effective approach to the assessment of drug toxicity in clinical trials will have 
to balance workload for the site doctors, clear attribution of significant toxic events in 
a reproducible fashion, and regulatory requirements. The majority of adverse events 
collected in the REMoxTB study were of grade 1 or 2 severity and were considered 
unrelated to trial medication, yet each one of these thousands of events required the 
site doctors to complete the relevant paperwork with the same level of documentation 
as the more severe grade 3 or 4 adverse events. Furthermore, of the events that were 
considered related to the trial medication the majority were assessed as only “possibly” 
related.  
The result is a collection of recorded events that add little meaningful knowledge to 
the safety profile of a drug but consume a lot of the site doctor’s time and effort. One 
recommendation following on from the work presented here could be a system 
whereby only clinically significant events are reported, and relatedness is attributed as 
either “probably” or “definitely” based on a checklist of agreed criteria. A reproducible 
relatedness score could be applied (in a similar manner to the RUCAM scoring system 
(Regev et al., 2014; Danan and Teschke, 2018), but made significantly more brief) 
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using five to six criteria and the relatedness score deciding the relatedness 
assessment. The need to convince regulatory authorities on any proposed changes 
places a burden on the clinical trial community to ensure that any new approach to 
safety data collection is carefully thought out, involving experienced trial physicians, 
statisticians and trial managers, and the benefit to participants, site doctors, and the 
conduct of the trial is made very clear. 
4 Final Remarks 
The need for new TB treatment options is indisputable: the current standard TB 
therapy is lengthy, toxic and achieves cure rates below what is needed to end the 
global epidemic. While there are many drugs in the development pipeline it is unlikely 
that a novel therapy will be in widespread use any time soon. Therefore, it is critical 
that we maximise our ability to address the epidemic using the treatment we already 
have at our disposal. This thesis has sought to contribute to this by adding to our 
understanding of the toxicity profile of standard TB therapy, especially relating to 
hepatotoxicity (the most common form of toxicity) and the HIV-positive patient 
population (a patient group at elevated risk of toxicity).  
Close monitoring for liver dysfunction among female patients, those infected with HIV, 
and those of Asian ethnicity should be considered during the first two months of 
therapy. By providing a thorough analysis of prospectively gathered data from a large, 
randomised patient sample receiving standard TB therapy this work can help provide 
the robust evidence needed to guide individual clinicians and policy-makers. The 
identification of at-risk patient groups, the most common toxicity, and the time window 
when toxicity is most likely means that simple plans with clear monitoring schedules 
can be drawn up and reasonably accurate estimates can be made as to the necessary 
resources. The demonstration of a significant impact of the rates of treatment failure 
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will add to the motivation to take seriously the need to address the management of 
toxic side effects from treatment. 
Overcoming the global tuberculosis epidemic will require a multi-faceted approach that 
involves a combination of better diagnostics, better treatments, and better 
infrastructure to reach the goals laid out in the End TB strategy. This is an exciting 
time to be involved in TB research, with more progress made over the past decade 
than the preceding four decades combined, and it is encouraging to see the global 
effort to combat this disease. The work presented here will hopefully inform our 
progress in developing TB treatment by providing detail on the current state of TB 
therapy, the priorities for future research, and some insight into considerations for the 
development and trialling on new therapeutics. 
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Appendix Two: Tuberculosis Drug 
Dosing in the REMoxTB Study, the 
Roussel-Uclaf Causality 
Assessment Method, and the 
Child-Pugh Score 
Drug Name Daily Dosing 
Moxifloxacin 400mg 
Rifampicin  
 <45 kg 450mg 
 >45 kg 600mg 
Isoniazid 300mg 
Pyrazinamide  
 <40 kg 25mg/kg (rounded to nearest 500mg) 
 40 - 55 kg 1000mg 
 >55 – 75 kg 1500mg 
 >75 kg 2000mg 
Ethambutol  
 <40 kg 15mg/kg (rounded to nearest 100mg) 
 40 - 55 kg 800mg 
 >55 – 75 kg 1200mg 
 >75 kg 1600mg 
Table 1: Daily dosing of TB medications for patients randomised into REMoxTB 
based on weight at screening. Isoniazid and moxifloxacin were both given at fixed 
doses irrespective of weight 
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Criteria Score 
Time to onset of the reaction  
 Highly suggestive +3 
 Suggestive +2 
 Compatible +1 
 Inconclusive 0 
Course of the reaction  
 Highly suggestive +3 
 Suggestive +2 
 Compatible +1 
 Against the role of the drug -2 
 Inconclusive or unavailable 0 
Risk factor(s) for drug reaction  
 Presence +1 to +2 
 Absence 0 
Concomitant drugs  
 Time to onset incompatible 0 
 Time to onset compatible, but unknown 
reaction 
-1 
 Time to onset compatible and known 
reaction 
-2 
 Role proved in this case -3 
 None or no information available 0 
Non-drug related causes  
 Ruled out +2 
 Possible or not investigated +1 to -2 
 Probable -3 
Previous information on the drug  
 Reaction unknown 0 
 Reaction published but unlabelled +1 
 Reaction labelled in product 
characteristics 
+2 
Response to readministration  
 Positive +3 
 Compatible +1 
 Negative -2 
 Not available or uninterpretable 0 
Table 2: The Roussel-Uclaf Causality Assessment Method (RUCAM) for 
causality assessment of adverse drug reactions 
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Measure 1 point 2 points 3 points 
Total bilirubin, 
μmol/L (mg/dL) <34 (<2) 34–50 (2–3) >50 (>3) 
Serum albumin, 
g/dL >3.5 2.8–3.5 <2.8 
Prothrombin 
time, 
prolongation (s) 
<4.0 4.0–6.0 > 6.0 
Ascites None 
Mild (or 
suppressed with 
medication) 
Moderate to 
severe (or 
refractory) 
Hepatic 
encephalopathy None Grade I–II Grade III–IV 
Table 3: Child-Pugh scoring system for grading the prognosis of chronic liver 
disease. Class A: 5-6 points (85% 2 year survival); Class B: 7-9 points (57% 2 year 
survival); Class C: 10-15 points (35% 2 year survival)
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